Mitch Report
Antony Kaspi & Mark Ziemann
date generated: 2024-11-01
Background
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Input profiles
Here is the first few lines of the input profile.
| x | |
|---|---|
| 5_8S_rRNA | 0.1666742 |
| A1BG | -1.0533748 |
| A1BG-AS1 | -0.2260162 |
| A1CF | 1.1773907 |
| A2M | 1.7931937 |
| A2M-AS1 | 0.7455551 |
Here are some metrics about the input data profile:
| Profile metrics | |
|---|---|
| num_genesets | 2725 |
| num_genes_in_profile | 21253 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 8700 |
| num_profile_genes_not_in_sets | 12553 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Input genesets
Here are some metrics about the gene sets used:
GMT file of genesets:| Gene sets metrics | |
|---|---|
| num_genesets | 2725 |
| num_genesets_excluded | 1198 |
| num_genesets_included | 1527 |
Differential pathway expression
Interactive enrichment scatterplot
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
Results table
Top N= 50 gene sets| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| CD163 mediating an anti-inflammatory response | 8 | 1.91e-05 | 0.873 | 3.50e-04 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | 6 | 5.54e-04 | 0.814 | 6.26e-03 |
| Response to metal ions | 6 | 1.03e-03 | 0.774 | 1.03e-02 |
| Inhibition of Signaling by Overexpressed EGFR | 5 | 3.54e-03 | 0.753 | 2.70e-02 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | 5 | 3.54e-03 | 0.753 | 2.70e-02 |
| Formation of xylulose-5-phosphate | 5 | 5.28e-03 | -0.720 | 3.59e-02 |
| NFE2L2 regulates pentose phosphate pathway genes | 8 | 5.94e-04 | 0.701 | 6.60e-03 |
| G2/M DNA replication checkpoint | 5 | 7.40e-03 | 0.692 | 4.49e-02 |
| Formation of a pool of free 40S subunits | 100 | 1.71e-32 | -0.686 | 5.47e-30 |
| Peptide chain elongation | 88 | 1.39e-28 | -0.683 | 2.22e-26 |
| Eukaryotic Translation Elongation | 93 | 3.95e-29 | -0.671 | 6.89e-27 |
| Selenocysteine synthesis | 92 | 2.01e-28 | -0.666 | 2.98e-26 |
| Viral mRNA Translation | 88 | 1.31e-26 | -0.658 | 1.48e-24 |
| SARS-CoV-1 modulates host translation machinery | 36 | 9.12e-12 | -0.656 | 3.73e-10 |
| EGFR interacts with phospholipase C-gamma | 6 | 5.49e-03 | 0.655 | 3.64e-02 |
| Eukaryotic Translation Termination | 92 | 1.70e-27 | -0.655 | 2.34e-25 |
| Formation of the ternary complex, and subsequently, the 43S complex | 51 | 1.77e-15 | -0.644 | 1.03e-13 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 110 | 2.14e-31 | -0.642 | 4.56e-29 |
| Acetylcholine binding and downstream events | 5 | 1.32e-02 | 0.640 | 6.64e-02 |
| Postsynaptic nicotinic acetylcholine receptors | 5 | 1.32e-02 | 0.640 | 6.64e-02 |
| rRNA modification in the mitochondrion | 8 | 1.74e-03 | -0.639 | 1.56e-02 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 94 | 1.16e-26 | -0.637 | 1.40e-24 |
| Synthesis of diphthamide-EEF2 | 8 | 1.81e-03 | -0.637 | 1.59e-02 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 111 | 1.55e-30 | -0.630 | 2.97e-28 |
| Cap-dependent Translation Initiation | 118 | 5.65e-32 | -0.626 | 1.36e-29 |
| Eukaryotic Translation Initiation | 118 | 5.65e-32 | -0.626 | 1.36e-29 |
| Erythrocytes take up oxygen and release carbon dioxide | 7 | 4.92e-03 | 0.614 | 3.48e-02 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 59 | 1.91e-15 | -0.598 | 1.08e-13 |
| Translation initiation complex formation | 58 | 5.79e-15 | -0.592 | 3.18e-13 |
| Relaxin receptors | 5 | 2.20e-02 | 0.591 | 9.21e-02 |
| Regulation of NFE2L2 gene expression | 8 | 3.85e-03 | 0.590 | 2.87e-02 |
| STAT5 activation downstream of FLT3 ITD mutants | 9 | 2.17e-03 | 0.590 | 1.81e-02 |
| RUNX1 regulates transcription of genes involved in BCR signaling | 6 | 1.23e-02 | 0.590 | 6.42e-02 |
| Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA | 5 | 2.28e-02 | -0.588 | 9.39e-02 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 100 | 3.25e-24 | -0.587 | 2.83e-22 |
| Defective GALNT3 causes HFTC | 8 | 4.30e-03 | 0.583 | 3.17e-02 |
| Fructose metabolism | 7 | 7.78e-03 | -0.581 | 4.63e-02 |
| Ribosomal scanning and start codon recognition | 58 | 2.39e-14 | -0.579 | 1.28e-12 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | 15 | 1.05e-04 | 0.578 | 1.61e-03 |
| Beta oxidation of hexanoyl-CoA to butanoyl-CoA | 5 | 2.55e-02 | -0.577 | 1.01e-01 |
| Butyrophilin (BTN) family interactions | 10 | 1.64e-03 | -0.575 | 1.50e-02 |
| POLB-Dependent Long Patch Base Excision Repair | 8 | 5.05e-03 | -0.572 | 3.51e-02 |
| Mitochondrial translation initiation | 90 | 1.09e-20 | -0.568 | 8.24e-19 |
| Ethanol oxidation | 6 | 1.60e-02 | -0.568 | 7.65e-02 |
| Type I hemidesmosome assembly | 8 | 5.60e-03 | 0.566 | 3.67e-02 |
| SRP-dependent cotranslational protein targeting to membrane | 111 | 7.74e-25 | -0.565 | 7.08e-23 |
| RHOT1 GTPase cycle | 5 | 2.98e-02 | 0.561 | 1.14e-01 |
| Mitochondrial translation elongation | 90 | 4.25e-20 | -0.559 | 3.02e-18 |
| Synthesis of wybutosine at G37 of tRNA(Phe) | 6 | 1.83e-02 | -0.556 | 8.17e-02 |
| GAB1 signalosome | 14 | 3.15e-04 | 0.556 | 4.04e-03 |
Results (complete table)
Click HERE to show results for all gene sets
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| CD163 mediating an anti-inflammatory response | 8 | 1.91e-05 | 0.873000 | 3.50e-04 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | 6 | 5.54e-04 | 0.814000 | 6.26e-03 |
| Response to metal ions | 6 | 1.03e-03 | 0.774000 | 1.03e-02 |
| Inhibition of Signaling by Overexpressed EGFR | 5 | 3.54e-03 | 0.753000 | 2.70e-02 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | 5 | 3.54e-03 | 0.753000 | 2.70e-02 |
| Formation of xylulose-5-phosphate | 5 | 5.28e-03 | -0.720000 | 3.59e-02 |
| NFE2L2 regulates pentose phosphate pathway genes | 8 | 5.94e-04 | 0.701000 | 6.60e-03 |
| G2/M DNA replication checkpoint | 5 | 7.40e-03 | 0.692000 | 4.49e-02 |
| Formation of a pool of free 40S subunits | 100 | 1.71e-32 | -0.686000 | 5.47e-30 |
| Peptide chain elongation | 88 | 1.39e-28 | -0.683000 | 2.22e-26 |
| Eukaryotic Translation Elongation | 93 | 3.95e-29 | -0.671000 | 6.89e-27 |
| Selenocysteine synthesis | 92 | 2.01e-28 | -0.666000 | 2.98e-26 |
| Viral mRNA Translation | 88 | 1.31e-26 | -0.658000 | 1.48e-24 |
| SARS-CoV-1 modulates host translation machinery | 36 | 9.12e-12 | -0.656000 | 3.73e-10 |
| EGFR interacts with phospholipase C-gamma | 6 | 5.49e-03 | 0.655000 | 3.64e-02 |
| Eukaryotic Translation Termination | 92 | 1.70e-27 | -0.655000 | 2.34e-25 |
| Formation of the ternary complex, and subsequently, the 43S complex | 51 | 1.77e-15 | -0.644000 | 1.03e-13 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 110 | 2.14e-31 | -0.642000 | 4.56e-29 |
| Acetylcholine binding and downstream events | 5 | 1.32e-02 | 0.640000 | 6.64e-02 |
| Postsynaptic nicotinic acetylcholine receptors | 5 | 1.32e-02 | 0.640000 | 6.64e-02 |
| rRNA modification in the mitochondrion | 8 | 1.74e-03 | -0.639000 | 1.56e-02 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 94 | 1.16e-26 | -0.637000 | 1.40e-24 |
| Synthesis of diphthamide-EEF2 | 8 | 1.81e-03 | -0.637000 | 1.59e-02 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 111 | 1.55e-30 | -0.630000 | 2.97e-28 |
| Cap-dependent Translation Initiation | 118 | 5.65e-32 | -0.626000 | 1.36e-29 |
| Eukaryotic Translation Initiation | 118 | 5.65e-32 | -0.626000 | 1.36e-29 |
| Erythrocytes take up oxygen and release carbon dioxide | 7 | 4.92e-03 | 0.614000 | 3.48e-02 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 59 | 1.91e-15 | -0.598000 | 1.08e-13 |
| Translation initiation complex formation | 58 | 5.79e-15 | -0.592000 | 3.18e-13 |
| Relaxin receptors | 5 | 2.20e-02 | 0.591000 | 9.21e-02 |
| Regulation of NFE2L2 gene expression | 8 | 3.85e-03 | 0.590000 | 2.87e-02 |
| STAT5 activation downstream of FLT3 ITD mutants | 9 | 2.17e-03 | 0.590000 | 1.81e-02 |
| RUNX1 regulates transcription of genes involved in BCR signaling | 6 | 1.23e-02 | 0.590000 | 6.42e-02 |
| Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA | 5 | 2.28e-02 | -0.588000 | 9.39e-02 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 100 | 3.25e-24 | -0.587000 | 2.83e-22 |
| Defective GALNT3 causes HFTC | 8 | 4.30e-03 | 0.583000 | 3.17e-02 |
| Fructose metabolism | 7 | 7.78e-03 | -0.581000 | 4.63e-02 |
| Ribosomal scanning and start codon recognition | 58 | 2.39e-14 | -0.579000 | 1.28e-12 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | 15 | 1.05e-04 | 0.578000 | 1.61e-03 |
| Beta oxidation of hexanoyl-CoA to butanoyl-CoA | 5 | 2.55e-02 | -0.577000 | 1.01e-01 |
| Butyrophilin (BTN) family interactions | 10 | 1.64e-03 | -0.575000 | 1.50e-02 |
| POLB-Dependent Long Patch Base Excision Repair | 8 | 5.05e-03 | -0.572000 | 3.51e-02 |
| Mitochondrial translation initiation | 90 | 1.09e-20 | -0.568000 | 8.24e-19 |
| Ethanol oxidation | 6 | 1.60e-02 | -0.568000 | 7.65e-02 |
| Type I hemidesmosome assembly | 8 | 5.60e-03 | 0.566000 | 3.67e-02 |
| SRP-dependent cotranslational protein targeting to membrane | 111 | 7.74e-25 | -0.565000 | 7.08e-23 |
| RHOT1 GTPase cycle | 5 | 2.98e-02 | 0.561000 | 1.14e-01 |
| Mitochondrial translation elongation | 90 | 4.25e-20 | -0.559000 | 3.02e-18 |
| Synthesis of wybutosine at G37 of tRNA(Phe) | 6 | 1.83e-02 | -0.556000 | 8.17e-02 |
| GAB1 signalosome | 14 | 3.15e-04 | 0.556000 | 4.04e-03 |
| Selenoamino acid metabolism | 115 | 6.38e-25 | -0.556000 | 6.13e-23 |
| SARS-CoV-2 modulates host translation machinery | 49 | 2.33e-11 | -0.552000 | 8.60e-10 |
| Regulation of gene expression by Hypoxia-inducible Factor | 8 | 6.92e-03 | 0.551000 | 4.32e-02 |
| Mitochondrial translation termination | 90 | 1.65e-19 | -0.551000 | 1.13e-17 |
| Mitochondrial translation | 96 | 1.12e-20 | -0.550000 | 8.24e-19 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 114 | 1.39e-23 | -0.542000 | 1.11e-21 |
| Nonsense-Mediated Decay (NMD) | 114 | 1.39e-23 | -0.542000 | 1.11e-21 |
| GRB2 events in EGFR signaling | 10 | 3.11e-03 | 0.540000 | 2.43e-02 |
| NFE2L2 regulating tumorigenic genes | 11 | 2.09e-03 | 0.536000 | 1.76e-02 |
| Defects in biotin (Btn) metabolism | 8 | 9.03e-03 | -0.533000 | 5.13e-02 |
| APOBEC3G mediated resistance to HIV-1 infection | 5 | 3.96e-02 | -0.531000 | 1.39e-01 |
| Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA | 6 | 2.51e-02 | -0.528000 | 9.95e-02 |
| Phenylalanine metabolism | 5 | 4.18e-02 | -0.526000 | 1.45e-01 |
| Major pathway of rRNA processing in the nucleolus and cytosol | 179 | 9.60e-34 | -0.524000 | 3.69e-31 |
| rRNA processing in the nucleus and cytosol | 189 | 3.75e-35 | -0.521000 | 2.40e-32 |
| Influenza Viral RNA Transcription and Replication | 135 | 2.07e-25 | -0.519000 | 2.21e-23 |
| Biosynthesis of Lipoxins (LX) | 6 | 2.82e-02 | 0.517000 | 1.09e-01 |
| Vitamin B1 (thiamin) metabolism | 5 | 4.59e-02 | -0.515000 | 1.56e-01 |
| Propionyl-CoA catabolism | 5 | 4.63e-02 | -0.515000 | 1.56e-01 |
| Beta oxidation of octanoyl-CoA to hexanoyl-CoA | 5 | 4.91e-02 | -0.508000 | 1.62e-01 |
| Synthesis of UDP-N-acetyl-glucosamine | 8 | 1.30e-02 | -0.507000 | 6.59e-02 |
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | 6 | 3.17e-02 | 0.506000 | 1.19e-01 |
| Netrin mediated repulsion signals | 5 | 5.04e-02 | 0.505000 | 1.64e-01 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | 7 | 2.10e-02 | -0.504000 | 8.95e-02 |
| Methionine salvage pathway | 6 | 3.26e-02 | -0.504000 | 1.22e-01 |
| RHO GTPases activate IQGAPs | 25 | 1.38e-05 | 0.502000 | 2.80e-04 |
| Termination of O-glycan biosynthesis | 15 | 7.89e-04 | 0.501000 | 8.28e-03 |
| Translation | 293 | 9.11e-49 | -0.497000 | 1.75e-45 |
| Signaling by FLT3 ITD and TKD mutants | 15 | 9.51e-04 | 0.493000 | 9.71e-03 |
| Interaction between L1 and Ankyrins | 26 | 1.50e-05 | 0.490000 | 2.91e-04 |
| Eicosanoids | 6 | 3.80e-02 | 0.489000 | 1.36e-01 |
| rRNA processing | 213 | 9.90e-35 | -0.488000 | 4.76e-32 |
| EGFR Transactivation by Gastrin | 7 | 2.55e-02 | 0.488000 | 1.01e-01 |
| Scavenging by Class F Receptors | 5 | 5.94e-02 | 0.487000 | 1.82e-01 |
| Fructose catabolism | 5 | 5.97e-02 | -0.486000 | 1.82e-01 |
| MET activates PI3K/AKT signaling | 5 | 5.99e-02 | 0.486000 | 1.82e-01 |
| Defective HLCS causes multiple carboxylase deficiency | 7 | 2.61e-02 | -0.486000 | 1.02e-01 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 5.46e-03 | -0.484000 | 3.63e-02 |
| Influenza Infection | 154 | 4.71e-25 | -0.482000 | 4.76e-23 |
| Sulfide oxidation to sulfate | 5 | 6.26e-02 | -0.481000 | 1.87e-01 |
| SHC1 events in EGFR signaling | 11 | 6.05e-03 | 0.478000 | 3.89e-02 |
| Complex III assembly | 23 | 7.30e-05 | -0.478000 | 1.13e-03 |
| N-Glycan antennae elongation | 12 | 4.57e-03 | 0.473000 | 3.27e-02 |
| Signal attenuation | 9 | 1.42e-02 | 0.472000 | 6.99e-02 |
| NFE2L2 regulating MDR associated enzymes | 8 | 2.10e-02 | 0.471000 | 8.95e-02 |
| Processing of SMDT1 | 15 | 1.61e-03 | -0.470000 | 1.49e-02 |
| Sodium/Proton exchangers | 7 | 3.32e-02 | 0.465000 | 1.23e-01 |
| SLBP independent Processing of Histone Pre-mRNAs | 10 | 1.11e-02 | -0.464000 | 5.95e-02 |
| PI3K/AKT activation | 8 | 2.43e-02 | 0.460000 | 9.81e-02 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | 7 | 3.53e-02 | 0.459000 | 1.30e-01 |
| RUNX3 regulates WNT signaling | 8 | 2.48e-02 | 0.458000 | 9.90e-02 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | 7 | 3.65e-02 | 0.456000 | 1.33e-01 |
| Axonal growth inhibition (RHOA activation) | 7 | 3.70e-02 | 0.455000 | 1.34e-01 |
| p75NTR regulates axonogenesis | 7 | 3.70e-02 | 0.455000 | 1.34e-01 |
| mRNA decay by 3’ to 5’ exoribonuclease | 13 | 4.52e-03 | -0.455000 | 3.25e-02 |
| Defective C1GALT1C1 causes TNPS | 9 | 1.82e-02 | 0.455000 | 8.17e-02 |
| Mitochondrial protein import | 63 | 4.56e-10 | -0.454000 | 1.65e-08 |
| Maturation of protein 3a 9683673 | 9 | 1.84e-02 | 0.454000 | 8.17e-02 |
| Maturation of protein 3a 9694719 | 9 | 1.84e-02 | 0.454000 | 8.17e-02 |
| Olfactory Signaling Pathway | 54 | 9.22e-09 | 0.452000 | 3.11e-07 |
| Displacement of DNA glycosylase by APEX1 | 9 | 1.90e-02 | -0.452000 | 8.33e-02 |
| mitochondrial fatty acid beta-oxidation of unsaturated fatty acids | 6 | 5.55e-02 | -0.452000 | 1.75e-01 |
| Signaling by RNF43 mutants | 7 | 3.95e-02 | 0.449000 | 1.39e-01 |
| Translocation of ZAP-70 to Immunological synapse | 24 | 1.40e-04 | -0.449000 | 2.05e-03 |
| Common Pathway of Fibrin Clot Formation | 13 | 5.08e-03 | 0.449000 | 3.51e-02 |
| Diseases of branched-chain amino acid catabolism | 13 | 5.10e-03 | -0.449000 | 3.51e-02 |
| Mitotic Telophase/Cytokinesis | 13 | 5.16e-03 | 0.448000 | 3.53e-02 |
| G2 Phase | 5 | 8.30e-02 | 0.448000 | 2.26e-01 |
| Expression and translocation of olfactory receptors | 49 | 6.23e-08 | 0.447000 | 1.84e-06 |
| RHO GTPases activate KTN1 | 11 | 1.07e-02 | 0.444000 | 5.85e-02 |
| Defective GALNT12 causes CRCS1 | 8 | 3.00e-02 | 0.443000 | 1.14e-01 |
| Regulation of IFNA/IFNB signaling | 12 | 8.20e-03 | 0.441000 | 4.82e-02 |
| SOS-mediated signalling | 7 | 4.44e-02 | 0.439000 | 1.52e-01 |
| Platelet sensitization by LDL | 16 | 2.50e-03 | 0.436000 | 2.05e-02 |
| Translesion synthesis by POLI | 17 | 1.86e-03 | -0.436000 | 1.60e-02 |
| Phosphate bond hydrolysis by NUDT proteins | 7 | 4.60e-02 | -0.435000 | 1.56e-01 |
| Biotin transport and metabolism | 11 | 1.24e-02 | -0.435000 | 6.42e-02 |
| Phosphorylation of Emi1 | 6 | 6.51e-02 | 0.435000 | 1.91e-01 |
| Induction of Cell-Cell Fusion | 8 | 3.59e-02 | 0.428000 | 1.31e-01 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | 16 | 3.09e-03 | 0.427000 | 2.42e-02 |
| ChREBP activates metabolic gene expression | 7 | 5.13e-02 | 0.425000 | 1.66e-01 |
| Synthesis of glycosylphosphatidylinositol (GPI) | 18 | 1.81e-03 | -0.425000 | 1.59e-02 |
| Integration of provirus | 9 | 2.80e-02 | -0.423000 | 1.08e-01 |
| rRNA modification in the nucleus and cytosol | 59 | 2.38e-08 | -0.420000 | 7.74e-07 |
| DNA replication initiation | 8 | 3.97e-02 | -0.420000 | 1.39e-01 |
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | 5 | 1.06e-01 | 0.418000 | 2.66e-01 |
| Signaling by LTK in cancer | 7 | 5.62e-02 | 0.417000 | 1.75e-01 |
| Linoleic acid (LA) metabolism | 7 | 5.63e-02 | 0.417000 | 1.76e-01 |
| Digestion | 5 | 1.07e-01 | 0.416000 | 2.68e-01 |
| Purine ribonucleoside monophosphate biosynthesis | 9 | 3.12e-02 | -0.415000 | 1.17e-01 |
| Telomere C-strand synthesis initiation | 13 | 1.01e-02 | -0.412000 | 5.60e-02 |
| Reduction of cytosolic Ca++ levels | 9 | 3.31e-02 | 0.410000 | 1.23e-01 |
| Formation of the nephric duct | 8 | 4.59e-02 | 0.408000 | 1.56e-01 |
| Translesion synthesis by REV1 | 16 | 5.12e-03 | -0.404000 | 3.52e-02 |
| Beta oxidation of butanoyl-CoA to acetyl-CoA | 5 | 1.18e-01 | -0.404000 | 2.86e-01 |
| Erythrocytes take up carbon dioxide and release oxygen | 11 | 2.07e-02 | 0.403000 | 8.88e-02 |
| O2/CO2 exchange in erythrocytes | 11 | 2.07e-02 | 0.403000 | 8.88e-02 |
| NOTCH3 Intracellular Domain Regulates Transcription | 20 | 1.92e-03 | 0.401000 | 1.64e-02 |
| Regulation of expression of SLITs and ROBOs | 149 | 3.61e-17 | -0.400000 | 2.31e-15 |
| Signaling by Leptin | 10 | 2.90e-02 | 0.399000 | 1.11e-01 |
| Interleukin-10 signaling | 36 | 3.48e-05 | 0.399000 | 5.86e-04 |
| EGFR downregulation | 26 | 4.35e-04 | 0.399000 | 5.22e-03 |
| Phase 4 - resting membrane potential | 9 | 3.88e-02 | 0.398000 | 1.38e-01 |
| Role of ABL in ROBO-SLIT signaling | 6 | 9.17e-02 | 0.398000 | 2.44e-01 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | 12 | 1.72e-02 | 0.397000 | 7.91e-02 |
| Transport of connexons to the plasma membrane | 12 | 1.72e-02 | 0.397000 | 7.91e-02 |
| Fatty acids | 6 | 9.22e-02 | 0.397000 | 2.44e-01 |
| Mitochondrial calcium ion transport | 22 | 1.31e-03 | -0.396000 | 1.25e-02 |
| Early Phase of HIV Life Cycle | 14 | 1.05e-02 | -0.395000 | 5.76e-02 |
| SUMO is transferred from E1 to E2 (UBE2I, UBC9) | 7 | 7.08e-02 | -0.394000 | 2.03e-01 |
| Cohesin Loading onto Chromatin | 10 | 3.27e-02 | 0.390000 | 1.22e-01 |
| Gap junction assembly | 16 | 6.99e-03 | 0.389000 | 4.35e-02 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 1.16e-02 | 0.389000 | 6.20e-02 |
| Cellular response to starvation | 148 | 2.93e-16 | -0.389000 | 1.76e-14 |
| Kidney development | 16 | 7.06e-03 | 0.389000 | 4.38e-02 |
| RNA Polymerase III Chain Elongation | 18 | 4.44e-03 | -0.387000 | 3.24e-02 |
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | 25 | 8.35e-04 | 0.386000 | 8.67e-03 |
| CREB3 factors activate genes | 6 | 1.03e-01 | -0.385000 | 2.61e-01 |
| Signaling by FLT3 fusion proteins | 18 | 4.72e-03 | 0.385000 | 3.35e-02 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 6.11e-03 | -0.384000 | 3.90e-02 |
| RUNX3 regulates CDKN1A transcription | 7 | 7.95e-02 | -0.383000 | 2.18e-01 |
| Protein repair | 6 | 1.05e-01 | 0.383000 | 2.65e-01 |
| Regulation of IFNG signaling | 14 | 1.36e-02 | 0.381000 | 6.79e-02 |
| GDP-fucose biosynthesis | 6 | 1.07e-01 | -0.380000 | 2.68e-01 |
| Protein lipoylation | 10 | 3.76e-02 | -0.380000 | 1.35e-01 |
| Translesion Synthesis by POLH | 18 | 5.30e-03 | -0.380000 | 3.59e-02 |
| PCNA-Dependent Long Patch Base Excision Repair | 21 | 2.64e-03 | -0.379000 | 2.12e-02 |
| CHL1 interactions | 8 | 6.42e-02 | 0.378000 | 1.90e-01 |
| tRNA modification in the mitochondrion | 9 | 4.98e-02 | -0.378000 | 1.63e-01 |
| Resolution of Abasic Sites (AP sites) | 38 | 5.79e-05 | -0.377000 | 9.20e-04 |
| Translesion synthesis by POLK | 17 | 7.21e-03 | -0.376000 | 4.43e-02 |
| Platelet Adhesion to exposed collagen | 14 | 1.52e-02 | 0.375000 | 7.34e-02 |
| Malate-aspartate shuttle | 8 | 6.69e-02 | -0.374000 | 1.95e-01 |
| Activation of Matrix Metalloproteinases | 20 | 3.79e-03 | 0.374000 | 2.85e-02 |
| O-linked glycosylation of mucins | 46 | 1.15e-05 | 0.374000 | 2.38e-04 |
| Alpha-oxidation of phytanate | 6 | 1.13e-01 | -0.373000 | 2.78e-01 |
| Tight junction interactions | 17 | 7.79e-03 | -0.373000 | 4.63e-02 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 25 | 1.28e-03 | -0.372000 | 1.22e-02 |
| Caspase activation via Dependence Receptors in the absence of ligand | 9 | 5.37e-02 | 0.371000 | 1.71e-01 |
| Pexophagy | 10 | 4.25e-02 | -0.370000 | 1.47e-01 |
| Vitamin C (ascorbate) metabolism | 8 | 7.04e-02 | 0.369000 | 2.03e-01 |
| Platelet calcium homeostasis | 22 | 2.71e-03 | 0.369000 | 2.17e-02 |
| Maturation of spike protein 9683686 | 5 | 1.53e-01 | -0.369000 | 3.33e-01 |
| Regulation of innate immune responses to cytosolic DNA | 14 | 1.70e-02 | -0.368000 | 7.91e-02 |
| Heme degradation | 10 | 4.39e-02 | 0.368000 | 1.51e-01 |
| Defective LFNG causes SCDO3 | 5 | 1.55e-01 | 0.367000 | 3.36e-01 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | 5 | 1.55e-01 | -0.367000 | 3.36e-01 |
| Maple Syrup Urine Disease | 5 | 1.55e-01 | -0.367000 | 3.36e-01 |
| Telomere C-strand (Lagging Strand) Synthesis | 34 | 2.21e-04 | -0.366000 | 3.03e-03 |
| Inactivation of CDC42 and RAC1 | 7 | 9.36e-02 | 0.366000 | 2.46e-01 |
| Free fatty acids regulate insulin secretion | 10 | 4.64e-02 | 0.364000 | 1.56e-01 |
| Cation-coupled Chloride cotransporters | 6 | 1.23e-01 | 0.363000 | 2.96e-01 |
| Signaling by PDGFRA extracellular domain mutants | 12 | 2.94e-02 | 0.363000 | 1.13e-01 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 2.94e-02 | 0.363000 | 1.13e-01 |
| Signaling by EGFR | 47 | 1.69e-05 | 0.363000 | 3.21e-04 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | 8 | 7.63e-02 | 0.362000 | 2.12e-01 |
| Tandem pore domain potassium channels | 5 | 1.61e-01 | 0.362000 | 3.42e-01 |
| Alternative complement activation | 5 | 1.62e-01 | -0.362000 | 3.42e-01 |
| Processing and activation of SUMO | 10 | 4.79e-02 | -0.361000 | 1.59e-01 |
| RUNX1 regulates expression of components of tight junctions | 5 | 1.62e-01 | 0.361000 | 3.43e-01 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 1.16e-03 | -0.361000 | 1.13e-02 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | 8 | 7.76e-02 | 0.360000 | 2.15e-01 |
| Signaling by Erythropoietin | 24 | 2.45e-03 | 0.357000 | 2.03e-02 |
| STAT5 Activation | 7 | 1.03e-01 | 0.356000 | 2.61e-01 |
| Attachment and Entry 9694614 | 13 | 2.64e-02 | 0.356000 | 1.03e-01 |
| Polymerase switching on the C-strand of the telomere | 26 | 1.71e-03 | -0.355000 | 1.55e-02 |
| Protein methylation | 15 | 1.72e-02 | -0.355000 | 7.91e-02 |
| mRNA Splicing - Minor Pathway | 50 | 1.38e-05 | -0.355000 | 2.80e-04 |
| Class I peroxisomal membrane protein import | 20 | 6.09e-03 | -0.354000 | 3.90e-02 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 1.22e-03 | -0.353000 | 1.18e-02 |
| Interleukin-4 and Interleukin-13 signaling | 89 | 8.57e-09 | 0.353000 | 2.94e-07 |
| Formation of the beta-catenin:TCF transactivating complex | 44 | 5.15e-05 | 0.353000 | 8.31e-04 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | 5 | 1.72e-01 | 0.352000 | 3.55e-01 |
| HDMs demethylate histones | 22 | 4.27e-03 | 0.352000 | 3.17e-02 |
| ARMS-mediated activation | 6 | 1.36e-01 | 0.351000 | 3.12e-01 |
| Lagging Strand Synthesis | 20 | 6.57e-03 | -0.351000 | 4.15e-02 |
| Prostanoid ligand receptors | 8 | 8.61e-02 | 0.350000 | 2.33e-01 |
| KSRP (KHSRP) binds and destabilizes mRNA | 17 | 1.24e-02 | -0.350000 | 6.42e-02 |
| BBSome-mediated cargo-targeting to cilium | 23 | 3.69e-03 | -0.350000 | 2.79e-02 |
| Uptake and function of diphtheria toxin | 6 | 1.38e-01 | 0.349000 | 3.13e-01 |
| Complex I biogenesis | 66 | 9.51e-07 | -0.349000 | 2.40e-05 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580 K2555) Translocation Mutant | 6 | 1.39e-01 | 0.348000 | 3.13e-01 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580 K2555) Translocation Mutant | 6 | 1.39e-01 | 0.348000 | 3.13e-01 |
| RUNX1 regulates transcription of genes involved in WNT signaling | 5 | 1.78e-01 | 0.348000 | 3.63e-01 |
| tRNA processing in the nucleus | 59 | 3.86e-06 | -0.348000 | 8.94e-05 |
| Glycosphingolipid biosynthesis | 16 | 1.62e-02 | 0.347000 | 7.72e-02 |
| Gamma-carboxylation, transport, and amino-terminal cleavage of proteins | 7 | 1.12e-01 | 0.347000 | 2.76e-01 |
| Interactions of Vpr with host cellular proteins | 37 | 2.65e-04 | -0.346000 | 3.49e-03 |
| Regulation of HMOX1 expression and activity | 5 | 1.80e-01 | 0.346000 | 3.65e-01 |
| Estrogen biosynthesis | 5 | 1.81e-01 | 0.345000 | 3.67e-01 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 4.74e-02 | 0.345000 | 1.58e-01 |
| Recycling of bile acids and salts | 8 | 9.15e-02 | 0.345000 | 2.43e-01 |
| Biosynthesis of E-series 18(S)-resolvins | 5 | 1.83e-01 | 0.344000 | 3.68e-01 |
| Establishment of Sister Chromatid Cohesion | 11 | 4.84e-02 | 0.344000 | 1.60e-01 |
| Kinesins | 51 | 2.20e-05 | 0.343000 | 3.98e-04 |
| Arachidonate production from DAG | 5 | 1.84e-01 | -0.343000 | 3.71e-01 |
| Antimicrobial peptides | 33 | 6.62e-04 | 0.342000 | 7.27e-03 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | 6 | 1.47e-01 | -0.342000 | 3.25e-01 |
| Biosynthesis of EPA-derived SPMs | 6 | 1.47e-01 | 0.342000 | 3.25e-01 |
| PKA activation | 15 | 2.19e-02 | 0.342000 | 9.19e-02 |
| Elevation of cytosolic Ca2+ levels | 13 | 3.35e-02 | 0.341000 | 1.24e-01 |
| Downregulation of ERBB2:ERBB3 signaling | 12 | 4.13e-02 | -0.340000 | 1.44e-01 |
| Sulfur amino acid metabolism | 22 | 5.77e-03 | -0.340000 | 3.74e-02 |
| Other semaphorin interactions | 16 | 1.90e-02 | 0.339000 | 8.33e-02 |
| Uptake and function of anthrax toxins | 10 | 6.37e-02 | 0.339000 | 1.89e-01 |
| Respiratory electron transport | 149 | 1.03e-12 | -0.338000 | 4.71e-11 |
| Regulation of RUNX1 Expression and Activity | 18 | 1.31e-02 | 0.338000 | 6.62e-02 |
| Maturation of TCA enzymes and regulation of TCA cycle | 20 | 8.96e-03 | -0.338000 | 5.13e-02 |
| Keratan sulfate biosynthesis | 19 | 1.10e-02 | 0.337000 | 5.95e-02 |
| Cytosolic iron-sulfur cluster assembly | 13 | 3.57e-02 | -0.336000 | 1.30e-01 |
| Degradation of cysteine and homocysteine | 12 | 4.42e-02 | -0.335000 | 1.52e-01 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 74 | 6.20e-07 | 0.335000 | 1.61e-05 |
| Polo-like kinase mediated events | 16 | 2.05e-02 | 0.335000 | 8.80e-02 |
| Nucleotide biosynthesis | 12 | 4.50e-02 | -0.334000 | 1.54e-01 |
| Metabolism of non-coding RNA | 53 | 2.58e-05 | -0.334000 | 4.51e-04 |
| snRNP Assembly | 53 | 2.58e-05 | -0.334000 | 4.51e-04 |
| Proton-coupled monocarboxylate transport | 6 | 1.56e-01 | 0.334000 | 3.37e-01 |
| RHO GTPases Activate NADPH Oxidases | 21 | 8.09e-03 | 0.334000 | 4.77e-02 |
| Termination of translesion DNA synthesis | 32 | 1.12e-03 | -0.333000 | 1.10e-02 |
| 2-LTR circle formation | 7 | 1.28e-01 | -0.332000 | 3.02e-01 |
| Interleukin-6 signaling | 10 | 6.90e-02 | 0.332000 | 2.00e-01 |
| Ubiquinol biosynthesis | 13 | 3.87e-02 | -0.331000 | 1.38e-01 |
| Interleukin-7 signaling | 21 | 8.64e-03 | 0.331000 | 4.98e-02 |
| Modulation by Mtb of host immune system | 7 | 1.30e-01 | -0.331000 | 3.05e-01 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | 6 | 1.61e-01 | 0.330000 | 3.42e-01 |
| Growth hormone receptor signaling | 20 | 1.05e-02 | 0.330000 | 5.76e-02 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 13 | 3.91e-02 | 0.330000 | 1.38e-01 |
| Triglyceride catabolism | 15 | 2.69e-02 | 0.330000 | 1.05e-01 |
| Laminin interactions | 25 | 4.44e-03 | 0.329000 | 3.24e-02 |
| NPAS4 regulates expression of target genes | 16 | 2.31e-02 | 0.328000 | 9.47e-02 |
| Collagen degradation | 41 | 2.80e-04 | 0.328000 | 3.63e-03 |
| Nephrin family interactions | 19 | 1.34e-02 | 0.328000 | 6.70e-02 |
| Activated NTRK2 signals through FRS2 and FRS3 | 8 | 1.08e-01 | 0.328000 | 2.70e-01 |
| ALK mutants bind TKIs | 11 | 6.00e-02 | 0.328000 | 1.82e-01 |
| Anchoring fibril formation | 7 | 1.34e-01 | 0.327000 | 3.11e-01 |
| Signaling by ALK | 24 | 5.61e-03 | 0.327000 | 3.67e-02 |
| Retinoid metabolism and transport | 23 | 6.76e-03 | 0.326000 | 4.24e-02 |
| Mitochondrial Fatty Acid Beta-Oxidation | 36 | 7.35e-04 | -0.325000 | 7.92e-03 |
| Serine biosynthesis | 8 | 1.12e-01 | 0.325000 | 2.75e-01 |
| Repression of WNT target genes | 14 | 3.55e-02 | 0.325000 | 1.30e-01 |
| RNA Polymerase III Transcription Termination | 22 | 8.52e-03 | -0.324000 | 4.96e-02 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 5.09e-03 | -0.324000 | 3.51e-02 |
| Defective binding of VWF variant to GPIb:IX:V | 5 | 2.11e-01 | 0.323000 | 4.03e-01 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | 5 | 2.11e-01 | 0.323000 | 4.03e-01 |
| N-glycan antennae elongation in the medial/trans-Golgi | 20 | 1.23e-02 | 0.323000 | 6.42e-02 |
| Mitochondrial protein degradation | 96 | 4.79e-08 | -0.322000 | 1.44e-06 |
| Recycling of eIF2:GDP | 8 | 1.15e-01 | -0.322000 | 2.80e-01 |
| Gastrin-CREB signalling pathway via PKC and MAPK | 14 | 3.73e-02 | 0.321000 | 1.34e-01 |
| Hydrolysis of LPC | 8 | 1.15e-01 | 0.321000 | 2.81e-01 |
| Interleukin-21 signaling | 9 | 9.58e-02 | 0.321000 | 2.50e-01 |
| Scavenging by Class A Receptors | 10 | 7.94e-02 | 0.320000 | 2.18e-01 |
| Plasma lipoprotein assembly | 10 | 7.96e-02 | 0.320000 | 2.18e-01 |
| Chemokine receptors bind chemokines | 39 | 5.48e-04 | 0.320000 | 6.23e-03 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 2.27e-02 | 0.319000 | 9.39e-02 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 2.27e-02 | 0.319000 | 9.39e-02 |
| Mitochondrial iron-sulfur cluster biogenesis | 13 | 4.63e-02 | -0.319000 | 1.56e-01 |
| Post-transcriptional silencing by small RNAs | 7 | 1.45e-01 | 0.318000 | 3.22e-01 |
| Mitochondrial Uncoupling | 6 | 1.79e-01 | -0.317000 | 3.65e-01 |
| Vpr-mediated nuclear import of PICs | 34 | 1.40e-03 | -0.317000 | 1.31e-02 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | 6 | 1.80e-01 | 0.316000 | 3.65e-01 |
| Gap junction trafficking | 27 | 4.67e-03 | 0.315000 | 3.34e-02 |
| Prolonged ERK activation events | 13 | 4.98e-02 | 0.314000 | 1.63e-01 |
| Post-translational protein phosphorylation | 67 | 8.73e-06 | 0.314000 | 1.84e-04 |
| Endosomal/Vacuolar pathway | 11 | 7.18e-02 | -0.313000 | 2.05e-01 |
| Inwardly rectifying K+ channels | 22 | 1.11e-02 | 0.313000 | 5.95e-02 |
| Abacavir ADME | 5 | 2.26e-01 | 0.313000 | 4.18e-01 |
| NOTCH2 intracellular domain regulates transcription | 11 | 7.27e-02 | 0.313000 | 2.06e-01 |
| Protein localization | 157 | 1.83e-11 | -0.311000 | 7.16e-10 |
| G0 and Early G1 | 27 | 5.36e-03 | 0.310000 | 3.60e-02 |
| Organic cation transport | 8 | 1.31e-01 | 0.308000 | 3.07e-01 |
| Organic cation/anion/zwitterion transport | 8 | 1.31e-01 | 0.308000 | 3.07e-01 |
| Transcriptional Regulation by NPAS4 | 27 | 5.55e-03 | 0.308000 | 3.66e-02 |
| MET activates RAP1 and RAC1 | 10 | 9.14e-02 | 0.308000 | 2.43e-01 |
| SHC-related events triggered by IGF1R | 7 | 1.58e-01 | 0.308000 | 3.39e-01 |
| Interleukin-37 signaling | 19 | 2.01e-02 | 0.308000 | 8.69e-02 |
| ADP signalling through P2Y purinoceptor 1 | 21 | 1.46e-02 | 0.308000 | 7.14e-02 |
| Transcriptional regulation of granulopoiesis | 44 | 4.13e-04 | 0.308000 | 4.99e-03 |
| Plasma lipoprotein remodeling | 18 | 2.44e-02 | 0.306000 | 9.83e-02 |
| Interleukin receptor SHC signaling | 23 | 1.11e-02 | 0.306000 | 5.98e-02 |
| Erythropoietin activates RAS | 13 | 5.65e-02 | 0.305000 | 1.76e-01 |
| RHO GTPases activate PAKs | 20 | 1.83e-02 | 0.305000 | 8.17e-02 |
| Miscellaneous substrates | 7 | 1.65e-01 | 0.303000 | 3.47e-01 |
| NS1 Mediated Effects on Host Pathways | 40 | 9.03e-04 | -0.303000 | 9.33e-03 |
| Digestion and absorption | 7 | 1.65e-01 | 0.303000 | 3.47e-01 |
| Aspirin ADME | 13 | 5.92e-02 | 0.302000 | 1.82e-01 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 76 | 5.27e-06 | -0.302000 | 1.16e-04 |
| Formation of ATP by chemiosmotic coupling | 20 | 1.96e-02 | -0.302000 | 8.48e-02 |
| RAS signaling downstream of NF1 loss-of-function variants | 7 | 1.68e-01 | 0.301000 | 3.50e-01 |
| tRNA modification in the nucleus and cytosol | 43 | 6.43e-04 | -0.301000 | 7.10e-03 |
| ATF6 (ATF6-alpha) activates chaperone genes | 10 | 9.97e-02 | 0.301000 | 2.58e-01 |
| PI3K events in ERBB4 signaling | 6 | 2.03e-01 | 0.300000 | 3.97e-01 |
| Fibronectin matrix formation | 6 | 2.04e-01 | 0.299000 | 3.98e-01 |
| tRNA processing | 128 | 5.15e-09 | -0.299000 | 1.80e-07 |
| Gap junction trafficking and regulation | 29 | 5.37e-03 | 0.299000 | 3.60e-02 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 14 | 5.34e-02 | 0.298000 | 1.70e-01 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 48 | 3.58e-04 | 0.298000 | 4.49e-03 |
| RUNX1 regulates estrogen receptor mediated transcription | 6 | 2.08e-01 | 0.297000 | 4.01e-01 |
| Signalling to ERKs | 32 | 3.70e-03 | 0.296000 | 2.79e-02 |
| mRNA Editing | 8 | 1.47e-01 | 0.296000 | 3.25e-01 |
| Processive synthesis on the lagging strand | 15 | 4.70e-02 | -0.296000 | 1.58e-01 |
| RHOC GTPase cycle | 71 | 1.61e-05 | 0.296000 | 3.10e-04 |
| mitochondrial fatty acid beta-oxidation of saturated fatty acids | 11 | 8.94e-02 | -0.296000 | 2.40e-01 |
| RORA activates gene expression | 18 | 3.01e-02 | 0.295000 | 1.14e-01 |
| Regulation of beta-cell development | 21 | 1.96e-02 | 0.294000 | 8.48e-02 |
| Frs2-mediated activation | 11 | 9.49e-02 | 0.291000 | 2.49e-01 |
| Complex IV assembly | 45 | 7.38e-04 | -0.291000 | 7.92e-03 |
| Mitochondrial tRNA aminoacylation | 21 | 2.13e-02 | -0.290000 | 9.01e-02 |
| L1CAM interactions | 100 | 5.46e-07 | 0.290000 | 1.48e-05 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 11 | 9.61e-02 | -0.290000 | 2.50e-01 |
| Branched-chain amino acid catabolism | 21 | 2.19e-02 | -0.289000 | 9.19e-02 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 13 | 7.15e-02 | 0.289000 | 2.04e-01 |
| Interleukin-20 family signaling | 17 | 3.94e-02 | 0.289000 | 1.39e-01 |
| Generation of second messenger molecules | 38 | 2.10e-03 | -0.288000 | 1.76e-02 |
| Dectin-2 family | 18 | 3.48e-02 | 0.287000 | 1.28e-01 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | 23 | 1.71e-02 | 0.287000 | 7.91e-02 |
| DNA methylation | 18 | 3.49e-02 | 0.287000 | 1.28e-01 |
| Downstream signal transduction | 27 | 9.85e-03 | 0.287000 | 5.53e-02 |
| Condensation of Prometaphase Chromosomes | 11 | 9.98e-02 | 0.287000 | 2.58e-01 |
| mRNA Splicing | 211 | 7.64e-13 | -0.286000 | 3.67e-11 |
| Transport of Ribonucleoproteins into the Host Nucleus | 32 | 5.09e-03 | -0.286000 | 3.51e-02 |
| Regulation of gene expression in beta cells | 7 | 1.90e-01 | 0.286000 | 3.80e-01 |
| Sema4D induced cell migration and growth-cone collapse | 19 | 3.10e-02 | 0.286000 | 1.17e-01 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 13 | 7.58e-02 | 0.284000 | 2.11e-01 |
| Specification of primordial germ cells | 6 | 2.28e-01 | 0.284000 | 4.21e-01 |
| Formation of TC-NER Pre-Incision Complex | 51 | 4.53e-04 | -0.284000 | 5.41e-03 |
| Dual Incision in GG-NER | 41 | 1.66e-03 | -0.284000 | 1.52e-02 |
| Attenuation phase | 22 | 2.12e-02 | 0.284000 | 9.01e-02 |
| Phase 0 - rapid depolarisation | 23 | 1.86e-02 | 0.283000 | 8.25e-02 |
| RNA Polymerase I Transcription Termination | 30 | 7.26e-03 | -0.283000 | 4.43e-02 |
| DNA Damage Recognition in GG-NER | 38 | 2.55e-03 | -0.283000 | 2.07e-02 |
| mRNA Splicing - Major Pathway | 203 | 3.70e-12 | -0.283000 | 1.58e-10 |
| InlA-mediated entry of Listeria monocytogenes into host cells | 9 | 1.42e-01 | -0.282000 | 3.18e-01 |
| Signaling by ROBO receptors | 189 | 2.14e-11 | -0.282000 | 8.22e-10 |
| Nectin/Necl trans heterodimerization | 5 | 2.74e-01 | 0.282000 | 4.76e-01 |
| FGFR1b ligand binding and activation | 5 | 2.76e-01 | -0.281000 | 4.76e-01 |
| TNFR1-mediated ceramide production | 6 | 2.33e-01 | -0.281000 | 4.26e-01 |
| Signalling to RAS | 19 | 3.39e-02 | 0.281000 | 1.25e-01 |
| RHO GTPases Activate ROCKs | 18 | 3.91e-02 | 0.281000 | 1.38e-01 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | 7 | 1.98e-01 | 0.281000 | 3.91e-01 |
| Pre-NOTCH Processing in Golgi | 18 | 3.93e-02 | 0.281000 | 1.39e-01 |
| SARS-CoV-2 modulates autophagy | 11 | 1.07e-01 | -0.281000 | 2.68e-01 |
| Regulation of CDH19 Expression and Function | 5 | 2.78e-01 | 0.280000 | 4.76e-01 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 13 | 8.05e-02 | 0.280000 | 2.20e-01 |
| Leading Strand Synthesis | 14 | 7.04e-02 | -0.279000 | 2.03e-01 |
| Polymerase switching | 14 | 7.04e-02 | -0.279000 | 2.03e-01 |
| Regulation of NPAS4 gene expression | 11 | 1.09e-01 | 0.279000 | 2.71e-01 |
| PD-1 signaling | 28 | 1.05e-02 | -0.279000 | 5.76e-02 |
| Peptide ligand-binding receptors | 100 | 1.51e-06 | 0.278000 | 3.59e-05 |
| Phosphorylation of CD3 and TCR zeta chains | 27 | 1.24e-02 | -0.278000 | 6.42e-02 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 1.11e-01 | 0.277000 | 2.75e-01 |
| Glucagon signaling in metabolic regulation | 26 | 1.45e-02 | 0.277000 | 7.10e-02 |
| Transport of nucleotide sugars | 9 | 1.50e-01 | -0.277000 | 3.30e-01 |
| Insulin receptor recycling | 24 | 1.88e-02 | 0.277000 | 8.31e-02 |
| Metabolism of RNA | 717 | 1.30e-36 | -0.277000 | 1.25e-33 |
| SUMOylation of transcription factors | 16 | 5.57e-02 | -0.276000 | 1.75e-01 |
| Factors involved in megakaryocyte development and platelet production | 128 | 7.10e-08 | 0.276000 | 2.04e-06 |
| Signaling by SCF-KIT | 40 | 2.56e-03 | 0.276000 | 2.07e-02 |
| Aerobic respiration and respiratory electron transport | 245 | 1.09e-13 | -0.275000 | 5.36e-12 |
| Acyl chain remodelling of PG | 11 | 1.14e-01 | 0.275000 | 2.79e-01 |
| Signal amplification | 28 | 1.17e-02 | 0.275000 | 6.21e-02 |
| Signaling by FGFR4 in disease | 11 | 1.15e-01 | 0.275000 | 2.80e-01 |
| p38MAPK events | 13 | 8.66e-02 | 0.275000 | 2.34e-01 |
| Formation of Incision Complex in GG-NER | 43 | 1.88e-03 | -0.274000 | 1.61e-02 |
| Myogenesis | 20 | 3.39e-02 | 0.274000 | 1.25e-01 |
| Neurofascin interactions | 5 | 2.89e-01 | 0.274000 | 4.88e-01 |
| Assembly of active LPL and LIPC lipase complexes | 10 | 1.35e-01 | 0.273000 | 3.12e-01 |
| GABA receptor activation | 35 | 5.32e-03 | 0.272000 | 3.59e-02 |
| Formation of Fibrin Clot (Clotting Cascade) | 26 | 1.63e-02 | 0.272000 | 7.73e-02 |
| Gain-of-function MRAS complexes activate RAF signaling | 8 | 1.83e-01 | 0.272000 | 3.68e-01 |
| SHOC2 M1731 mutant abolishes MRAS complex function | 8 | 1.83e-01 | 0.272000 | 3.68e-01 |
| Signaling by MRAS-complex mutants | 8 | 1.83e-01 | 0.272000 | 3.68e-01 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | 44 | 1.81e-03 | 0.272000 | 1.59e-02 |
| Recognition of DNA damage by PCNA-containing replication complex | 30 | 1.01e-02 | -0.271000 | 5.60e-02 |
| NFE2L2 regulating ER-stress associated genes | 5 | 2.95e-01 | 0.271000 | 4.94e-01 |
| The activation of arylsulfatases | 10 | 1.38e-01 | -0.271000 | 3.13e-01 |
| COPI-independent Golgi-to-ER retrograde traffic | 45 | 1.69e-03 | 0.271000 | 1.54e-02 |
| Global Genome Nucleotide Excision Repair (GG-NER) | 84 | 1.82e-05 | -0.271000 | 3.39e-04 |
| Cargo concentration in the ER | 31 | 9.15e-03 | 0.270000 | 5.19e-02 |
| RHO GTPases Activate WASPs and WAVEs | 35 | 5.67e-03 | 0.270000 | 3.69e-02 |
| Smooth Muscle Contraction | 34 | 6.43e-03 | 0.270000 | 4.08e-02 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 2.50e-02 | -0.270000 | 9.95e-02 |
| RUNX3 regulates p14-ARF | 10 | 1.41e-01 | 0.269000 | 3.17e-01 |
| PTK6 promotes HIF1A stabilization | 6 | 2.55e-01 | 0.268000 | 4.55e-01 |
| Regulation of TP53 Activity through Methylation | 19 | 4.29e-02 | -0.268000 | 1.48e-01 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 5.82e-04 | 0.268000 | 6.53e-03 |
| Nucleotide Excision Repair | 108 | 1.51e-06 | -0.268000 | 3.59e-05 |
| Activation of gene expression by SREBF (SREBP) | 42 | 2.75e-03 | 0.267000 | 2.18e-02 |
| FLT3 signaling in disease | 27 | 1.64e-02 | 0.267000 | 7.76e-02 |
| Sema4D in semaphorin signaling | 22 | 3.04e-02 | 0.267000 | 1.15e-01 |
| Regulation of KIT signaling | 15 | 7.42e-02 | 0.266000 | 2.09e-01 |
| Interleukin-15 signaling | 14 | 8.49e-02 | 0.266000 | 2.30e-01 |
| CS/DS degradation | 9 | 1.68e-01 | -0.266000 | 3.50e-01 |
| Branched-chain ketoacid dehydrogenase kinase deficiency | 5 | 3.04e-01 | -0.265000 | 5.04e-01 |
| Depolymerization of the Nuclear Lamina | 15 | 7.52e-02 | 0.265000 | 2.11e-01 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 4.04e-02 | -0.265000 | 1.41e-01 |
| Pyrimidine catabolism | 9 | 1.70e-01 | 0.264000 | 3.52e-01 |
| ROBO receptors bind AKAP5 | 7 | 2.26e-01 | 0.264000 | 4.18e-01 |
| Viral Messenger RNA Synthesis | 44 | 2.46e-03 | -0.264000 | 2.03e-02 |
| RNA Polymerase I Transcription Initiation | 47 | 1.77e-03 | -0.264000 | 1.58e-02 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 6.00e-02 | -0.264000 | 1.82e-01 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 9 | 1.71e-01 | 0.263000 | 3.53e-01 |
| Defective EXT2 causes exostoses 2 | 9 | 1.71e-01 | 0.263000 | 3.53e-01 |
| Removal of the Flap Intermediate | 14 | 8.80e-02 | -0.263000 | 2.37e-01 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 22 | 3.26e-02 | -0.263000 | 1.22e-01 |
| HDL remodeling | 6 | 2.64e-01 | 0.263000 | 4.64e-01 |
| SUMOylation of ubiquitinylation proteins | 39 | 4.48e-03 | -0.263000 | 3.25e-02 |
| RNA Polymerase II Transcription Termination | 66 | 2.32e-04 | -0.262000 | 3.14e-03 |
| Processing of Capped Intronless Pre-mRNA | 29 | 1.46e-02 | -0.262000 | 7.14e-02 |
| Dual incision in TC-NER | 63 | 3.24e-04 | -0.262000 | 4.12e-03 |
| TYSND1 cleaves peroxisomal proteins | 7 | 2.31e-01 | -0.261000 | 4.25e-01 |
| Signaling by PDGF | 48 | 1.74e-03 | 0.261000 | 1.56e-02 |
| PKA activation in glucagon signalling | 14 | 9.09e-02 | 0.261000 | 2.43e-01 |
| PI-3K cascade:FGFR3 | 10 | 1.54e-01 | 0.261000 | 3.34e-01 |
| VxPx cargo-targeting to cilium | 19 | 4.93e-02 | 0.261000 | 1.62e-01 |
| Semaphorin interactions | 56 | 7.58e-04 | 0.260000 | 8.06e-03 |
| PINK1-PRKN Mediated Mitophagy | 31 | 1.24e-02 | -0.260000 | 6.42e-02 |
| Fanconi Anemia Pathway | 36 | 7.18e-03 | -0.259000 | 4.43e-02 |
| Processing of Capped Intron-Containing Pre-mRNA | 279 | 1.09e-13 | -0.258000 | 5.36e-12 |
| Activation of GABAB receptors | 29 | 1.63e-02 | 0.258000 | 7.73e-02 |
| GABA B receptor activation | 29 | 1.63e-02 | 0.258000 | 7.73e-02 |
| Interactions of Rev with host cellular proteins | 37 | 6.69e-03 | -0.258000 | 4.22e-02 |
| Activation of G protein gated Potassium channels | 18 | 5.86e-02 | 0.257000 | 1.81e-01 |
| G protein gated Potassium channels | 18 | 5.86e-02 | 0.257000 | 1.81e-01 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 18 | 5.86e-02 | 0.257000 | 1.81e-01 |
| Adenylate cyclase inhibitory pathway | 11 | 1.39e-01 | 0.257000 | 3.13e-01 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 38 | 6.06e-03 | -0.257000 | 3.89e-02 |
| Voltage gated Potassium channels | 26 | 2.32e-02 | 0.257000 | 9.47e-02 |
| Long-term potentiation | 14 | 9.59e-02 | -0.257000 | 2.50e-01 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 7.71e-03 | 0.257000 | 4.61e-02 |
| RHOB GTPase cycle | 64 | 3.87e-04 | 0.256000 | 4.76e-03 |
| SARS-CoV-1-host interactions | 94 | 1.72e-05 | -0.256000 | 3.24e-04 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | 6 | 2.77e-01 | 0.256000 | 4.76e-01 |
| RUNX3 regulates NOTCH signaling | 14 | 9.68e-02 | 0.256000 | 2.51e-01 |
| Platelet homeostasis | 69 | 2.34e-04 | 0.256000 | 3.14e-03 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 32 | 1.22e-02 | 0.256000 | 6.41e-02 |
| Signal regulatory protein family interactions | 13 | 1.10e-01 | 0.256000 | 2.73e-01 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 62 | 4.98e-04 | -0.256000 | 5.85e-03 |
| Regulation of insulin secretion | 62 | 5.00e-04 | 0.256000 | 5.85e-03 |
| Signaling by CSF1 (M-CSF) in myeloid cells | 30 | 1.56e-02 | 0.255000 | 7.50e-02 |
| Transport of the SLBP Dependant Mature mRNA | 36 | 8.09e-03 | -0.255000 | 4.77e-02 |
| DARPP-32 events | 22 | 3.86e-02 | 0.255000 | 1.38e-01 |
| Negative regulation of MET activity | 18 | 6.13e-02 | 0.255000 | 1.85e-01 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | 72 | 1.86e-04 | -0.255000 | 2.58e-03 |
| Cellular response to mitochondrial stress | 9 | 1.86e-01 | -0.255000 | 3.73e-01 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 50 | 1.83e-03 | 0.255000 | 1.59e-02 |
| Miro GTPase Cycle | 8 | 2.13e-01 | 0.254000 | 4.06e-01 |
| Activation of the AP-1 family of transcription factors | 10 | 1.65e-01 | 0.254000 | 3.47e-01 |
| Nuclear import of Rev protein | 34 | 1.04e-02 | -0.254000 | 5.75e-02 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 4.94e-02 | -0.254000 | 1.62e-01 |
| Regulation of CDH11 function | 9 | 1.89e-01 | 0.253000 | 3.78e-01 |
| Synthesis of 15-eicosatetraenoic acid derivatives | 6 | 2.83e-01 | -0.253000 | 4.82e-01 |
| Constitutive Signaling by EGFRvIII | 14 | 1.02e-01 | 0.253000 | 2.60e-01 |
| Signaling by EGFRvIII in Cancer | 14 | 1.02e-01 | 0.253000 | 2.60e-01 |
| Signaling by LTK | 10 | 1.67e-01 | 0.253000 | 3.49e-01 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 10 | 1.67e-01 | 0.252000 | 3.50e-01 |
| NEP/NS2 Interacts with the Cellular Export Machinery | 32 | 1.39e-02 | -0.251000 | 6.92e-02 |
| Signaling by EGFR in Cancer | 22 | 4.15e-02 | 0.251000 | 1.44e-01 |
| RHOF GTPase cycle | 38 | 7.40e-03 | 0.251000 | 4.49e-02 |
| Respiratory syncytial virus (RSV) attachment and entry | 17 | 7.43e-02 | 0.250000 | 2.09e-01 |
| Presynaptic depolarization and calcium channel opening | 8 | 2.21e-01 | -0.250000 | 4.14e-01 |
| Activation of RAS in B cells | 5 | 3.34e-01 | 0.250000 | 5.34e-01 |
| MECP2 regulates neuronal receptors and channels | 13 | 1.19e-01 | 0.250000 | 2.88e-01 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 1.35e-01 | 0.249000 | 3.12e-01 |
| alpha-linolenic acid (ALA) metabolism | 12 | 1.35e-01 | 0.249000 | 3.12e-01 |
| Degradation of the extracellular matrix | 92 | 3.68e-05 | 0.249000 | 6.15e-04 |
| Phosphate bond hydrolysis by NTPDase proteins | 6 | 2.91e-01 | -0.249000 | 4.90e-01 |
| Sema3A PAK dependent Axon repulsion | 15 | 9.53e-02 | 0.249000 | 2.49e-01 |
| Activated NTRK2 signals through RAS | 6 | 2.92e-01 | 0.249000 | 4.90e-01 |
| Activated NTRK3 signals through RAS | 6 | 2.92e-01 | 0.249000 | 4.90e-01 |
| Dissolution of Fibrin Clot | 12 | 1.36e-01 | 0.248000 | 3.12e-01 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 20 | 5.47e-02 | 0.248000 | 1.73e-01 |
| FBXW7 Mutants and NOTCH1 in Cancer | 5 | 3.37e-01 | 0.248000 | 5.35e-01 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | 5 | 3.37e-01 | 0.248000 | 5.35e-01 |
| Postmitotic nuclear pore complex (NPC) reformation | 27 | 2.57e-02 | -0.248000 | 1.01e-01 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | 7 | 2.56e-01 | 0.248000 | 4.56e-01 |
| Citric acid cycle (TCA cycle) | 34 | 1.25e-02 | -0.247000 | 6.43e-02 |
| Formation of the cornified envelope | 33 | 1.40e-02 | 0.247000 | 6.93e-02 |
| Metabolism of Angiotensinogen to Angiotensins | 12 | 1.39e-01 | 0.247000 | 3.13e-01 |
| Replacement of protamines by nucleosomes in the male pronucleus | 12 | 1.39e-01 | 0.247000 | 3.13e-01 |
| Gamma-carboxylation of protein precursors | 6 | 2.96e-01 | 0.246000 | 4.95e-01 |
| DNA Damage Bypass | 47 | 3.53e-03 | -0.246000 | 2.70e-02 |
| Rev-mediated nuclear export of HIV RNA | 35 | 1.19e-02 | -0.246000 | 6.26e-02 |
| Signaling by PDGFR in disease | 19 | 6.38e-02 | 0.246000 | 1.89e-01 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | 9 | 2.03e-01 | 0.245000 | 3.97e-01 |
| RUNX3 regulates BCL2L11 (BIM) transcription | 5 | 3.43e-01 | -0.245000 | 5.40e-01 |
| Anti-inflammatory response favouring Leishmania parasite infection | 131 | 1.27e-06 | 0.245000 | 3.12e-05 |
| Leishmania parasite growth and survival | 131 | 1.27e-06 | 0.245000 | 3.12e-05 |
| Acyl chain remodelling of PC | 19 | 6.44e-02 | 0.245000 | 1.90e-01 |
| RHO GTPases activate CIT | 18 | 7.21e-02 | 0.245000 | 2.05e-01 |
| Interleukin-9 signaling | 8 | 2.31e-01 | 0.244000 | 4.25e-01 |
| Defects in vitamin and cofactor metabolism | 21 | 5.35e-02 | -0.243000 | 1.70e-01 |
| Protein hydroxylation | 17 | 8.30e-02 | -0.243000 | 2.26e-01 |
| Transport of the SLBP independent Mature mRNA | 35 | 1.29e-02 | -0.243000 | 6.57e-02 |
| Na+/Cl- dependent neurotransmitter transporters | 7 | 2.67e-01 | 0.242000 | 4.67e-01 |
| Regulation of PTEN mRNA translation | 12 | 1.47e-01 | 0.242000 | 3.25e-01 |
| Nuclear events mediated by NFE2L2 | 81 | 1.73e-04 | 0.241000 | 2.44e-03 |
| VEGFA-VEGFR2 Pathway | 93 | 5.76e-05 | 0.241000 | 9.20e-04 |
| Export of Viral Ribonucleoproteins from Nucleus | 33 | 1.65e-02 | -0.241000 | 7.76e-02 |
| Cristae formation | 33 | 1.66e-02 | -0.241000 | 7.79e-02 |
| PI-3K cascade:FGFR4 | 11 | 1.67e-01 | 0.241000 | 3.49e-01 |
| Netrin-1 signaling | 34 | 1.51e-02 | 0.241000 | 7.32e-02 |
| SUMO is conjugated to E1 (UBA2:SAE1) | 5 | 3.52e-01 | -0.240000 | 5.49e-01 |
| G beta:gamma signalling through BTK | 15 | 1.07e-01 | 0.240000 | 2.68e-01 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 83 | 1.68e-04 | 0.239000 | 2.39e-03 |
| ATF6 (ATF6-alpha) activates chaperones | 12 | 1.52e-01 | 0.239000 | 3.33e-01 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 12 | 1.53e-01 | 0.238000 | 3.33e-01 |
| MAPK3 (ERK1) activation | 9 | 2.16e-01 | 0.238000 | 4.10e-01 |
| activated TAK1 mediates p38 MAPK activation | 23 | 4.81e-02 | 0.238000 | 1.60e-01 |
| SUMOylation of SUMOylation proteins | 35 | 1.48e-02 | -0.238000 | 7.20e-02 |
| MET activates RAS signaling | 10 | 1.93e-01 | 0.238000 | 3.83e-01 |
| NRIF signals cell death from the nucleus | 15 | 1.11e-01 | -0.238000 | 2.74e-01 |
| Regulation of actin dynamics for phagocytic cup formation | 123 | 5.27e-06 | 0.238000 | 1.16e-04 |
| RNA Polymerase III Transcription Initiation | 36 | 1.38e-02 | -0.237000 | 6.86e-02 |
| Metabolism of amino acids and derivatives | 304 | 1.21e-12 | -0.237000 | 5.41e-11 |
| Potassium Channels | 62 | 1.26e-03 | 0.237000 | 1.21e-02 |
| CD22 mediated BCR regulation | 58 | 1.81e-03 | 0.237000 | 1.59e-02 |
| mRNA 3’-end processing | 57 | 2.02e-03 | -0.236000 | 1.71e-02 |
| Integration of energy metabolism | 87 | 1.45e-04 | 0.236000 | 2.09e-03 |
| Cardiac conduction | 88 | 1.33e-04 | 0.236000 | 1.96e-03 |
| STAT3 nuclear events downstream of ALK signaling | 11 | 1.77e-01 | 0.235000 | 3.62e-01 |
| Regulation of TP53 Activity through Association with Co-factors | 11 | 1.78e-01 | -0.235000 | 3.63e-01 |
| RHOJ GTPase cycle | 49 | 4.52e-03 | 0.234000 | 3.25e-02 |
| Toxicity of botulinum toxin type D (botD) | 5 | 3.64e-01 | -0.234000 | 5.60e-01 |
| Toxicity of botulinum toxin type F (botF) | 5 | 3.64e-01 | -0.234000 | 5.60e-01 |
| DNA strand elongation | 32 | 2.19e-02 | -0.234000 | 9.19e-02 |
| Binding and Uptake of Ligands by Scavenger Receptors | 90 | 1.25e-04 | 0.234000 | 1.86e-03 |
| G-protein activation | 19 | 7.77e-02 | 0.234000 | 2.15e-01 |
| Defects of platelet adhesion to exposed collagen | 6 | 3.23e-01 | 0.233000 | 5.24e-01 |
| Rap1 signalling | 14 | 1.31e-01 | 0.233000 | 3.07e-01 |
| Adherens junctions interactions | 37 | 1.42e-02 | 0.233000 | 6.99e-02 |
| Thromboxane signalling through TP receptor | 20 | 7.13e-02 | 0.233000 | 2.04e-01 |
| RHOG GTPase cycle | 70 | 7.59e-04 | 0.233000 | 8.06e-03 |
| COPI-dependent Golgi-to-ER retrograde traffic | 90 | 1.43e-04 | 0.232000 | 2.08e-03 |
| GP1b-IX-V activation signalling | 10 | 2.05e-01 | 0.232000 | 3.98e-01 |
| Metabolism of fat-soluble vitamins | 26 | 4.10e-02 | 0.231000 | 1.43e-01 |
| Acyl chain remodelling of PI | 10 | 2.05e-01 | 0.231000 | 3.98e-01 |
| Nephron development | 5 | 3.71e-01 | 0.231000 | 5.69e-01 |
| Regulation of Expression and Function of Type II Classical Cadherins | 23 | 5.53e-02 | 0.231000 | 1.75e-01 |
| Regulation of Homotypic Cell-Cell Adhesion | 23 | 5.53e-02 | 0.231000 | 1.75e-01 |
| Golgi-to-ER retrograde transport | 123 | 1.02e-05 | 0.230000 | 2.13e-04 |
| ADP signalling through P2Y purinoceptor 12 | 18 | 9.14e-02 | 0.230000 | 2.43e-01 |
| Neutrophil degranulation | 456 | 4.36e-17 | 0.229000 | 2.70e-15 |
| Ca2+ pathway | 57 | 2.74e-03 | 0.229000 | 2.18e-02 |
| Triglyceride metabolism | 24 | 5.23e-02 | 0.229000 | 1.69e-01 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | 11 | 1.89e-01 | -0.229000 | 3.79e-01 |
| TGFBR3 regulates TGF-beta signaling | 8 | 2.63e-01 | -0.229000 | 4.62e-01 |
| Recycling pathway of L1 | 40 | 1.25e-02 | 0.228000 | 6.43e-02 |
| FCGR3A-mediated phagocytosis | 121 | 1.44e-05 | 0.228000 | 2.83e-04 |
| Leishmania phagocytosis | 121 | 1.44e-05 | 0.228000 | 2.83e-04 |
| Parasite infection | 121 | 1.44e-05 | 0.228000 | 2.83e-04 |
| Vasopressin regulates renal water homeostasis via Aquaporins | 34 | 2.14e-02 | 0.228000 | 9.03e-02 |
| AMPK inhibits chREBP transcriptional activation activity | 6 | 3.34e-01 | -0.228000 | 5.34e-01 |
| Organic anion transporters | 7 | 2.97e-01 | -0.227000 | 4.97e-01 |
| ROS and RNS production in phagocytes | 30 | 3.12e-02 | 0.227000 | 1.17e-01 |
| PKA-mediated phosphorylation of CREB | 17 | 1.05e-01 | 0.227000 | 2.65e-01 |
| Beta-catenin phosphorylation cascade | 17 | 1.05e-01 | 0.227000 | 2.65e-01 |
| Constitutive Signaling by Overexpressed ERBB2 | 11 | 1.92e-01 | 0.227000 | 3.83e-01 |
| Base Excision Repair | 56 | 3.30e-03 | -0.227000 | 2.54e-02 |
| ADORA2B mediated anti-inflammatory cytokines production | 35 | 2.02e-02 | 0.227000 | 8.70e-02 |
| Scavenging of heme from plasma | 70 | 1.04e-03 | 0.227000 | 1.04e-02 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 77 | 5.92e-04 | 0.226000 | 6.60e-03 |
| Defective factor IX causes hemophilia B | 6 | 3.37e-01 | 0.226000 | 5.35e-01 |
| Formation of axial mesoderm | 6 | 3.37e-01 | 0.226000 | 5.35e-01 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | 6 | 3.37e-01 | 0.226000 | 5.35e-01 |
| Suppression of apoptosis | 7 | 3.00e-01 | 0.226000 | 5.00e-01 |
| RET signaling | 32 | 2.69e-02 | 0.226000 | 1.05e-01 |
| Formation of the Early Elongation Complex | 33 | 2.47e-02 | -0.226000 | 9.90e-02 |
| Formation of the HIV-1 Early Elongation Complex | 33 | 2.47e-02 | -0.226000 | 9.90e-02 |
| Keratinization | 34 | 2.28e-02 | 0.226000 | 9.39e-02 |
| Pre-NOTCH Transcription and Translation | 47 | 7.55e-03 | 0.225000 | 4.56e-02 |
| Fcgamma receptor (FCGR) dependent phagocytosis | 147 | 2.43e-06 | 0.225000 | 5.68e-05 |
| MAP2K and MAPK activation | 36 | 1.94e-02 | 0.225000 | 8.47e-02 |
| Transferrin endocytosis and recycling | 26 | 4.72e-02 | 0.225000 | 1.58e-01 |
| SHC1 events in ERBB4 signaling | 10 | 2.19e-01 | 0.225000 | 4.12e-01 |
| Cellular responses to mechanical stimuli | 83 | 4.03e-04 | 0.225000 | 4.90e-03 |
| Response of endothelial cells to shear stress | 83 | 4.03e-04 | 0.225000 | 4.90e-03 |
| Sialic acid metabolism | 27 | 4.35e-02 | 0.224000 | 1.50e-01 |
| RA biosynthesis pathway | 13 | 1.63e-01 | -0.224000 | 3.44e-01 |
| Initiation of Nuclear Envelope (NE) Reformation | 19 | 9.22e-02 | 0.223000 | 2.44e-01 |
| Interleukin-2 family signaling | 38 | 1.74e-02 | 0.223000 | 7.91e-02 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 4.13e-02 | -0.223000 | 1.44e-01 |
| Erythropoietin activates STAT5 | 6 | 3.45e-01 | 0.223000 | 5.42e-01 |
| Zygotic genome activation (ZGA) | 5 | 3.89e-01 | 0.223000 | 5.84e-01 |
| Transport of Mature Transcript to Cytoplasm | 81 | 5.36e-04 | -0.223000 | 6.17e-03 |
| Insulin processing | 19 | 9.43e-02 | 0.222000 | 2.48e-01 |
| FGFR2 mutant receptor activation | 23 | 6.58e-02 | -0.222000 | 1.92e-01 |
| Muscle contraction | 142 | 5.18e-06 | 0.222000 | 1.16e-04 |
| Release of apoptotic factors from the mitochondria | 6 | 3.48e-01 | -0.221000 | 5.45e-01 |
| ATF4 activates genes in response to endoplasmic reticulum stress | 25 | 5.54e-02 | -0.221000 | 1.75e-01 |
| rRNA processing in the mitochondrion | 24 | 6.09e-02 | -0.221000 | 1.84e-01 |
| Chondroitin sulfate biosynthesis | 12 | 1.86e-01 | 0.220000 | 3.73e-01 |
| VEGF binds to VEGFR leading to receptor dimerization | 5 | 3.94e-01 | 0.220000 | 5.88e-01 |
| VEGF ligand-receptor interactions | 5 | 3.94e-01 | 0.220000 | 5.88e-01 |
| FCERI mediated Ca+2 mobilization | 92 | 2.69e-04 | 0.220000 | 3.51e-03 |
| Leishmania infection | 210 | 4.13e-08 | 0.220000 | 1.26e-06 |
| Parasitic Infection Pathways | 210 | 4.13e-08 | 0.220000 | 1.26e-06 |
| Trafficking of GluR2-containing AMPA receptors | 11 | 2.08e-01 | 0.219000 | 4.01e-01 |
| Synthesis of PIPs at the plasma membrane | 52 | 6.23e-03 | 0.219000 | 3.96e-02 |
| MAPK1 (ERK2) activation | 8 | 2.83e-01 | 0.219000 | 4.82e-01 |
| Signaling by WNT in cancer | 30 | 3.79e-02 | 0.219000 | 1.36e-01 |
| Molecules associated with elastic fibres | 26 | 5.34e-02 | 0.219000 | 1.70e-01 |
| GPVI-mediated activation cascade | 31 | 3.57e-02 | 0.218000 | 1.30e-01 |
| Hemostasis | 553 | 1.83e-18 | 0.218000 | 1.21e-16 |
| Class A/1 (Rhodopsin-like receptors) | 176 | 6.19e-07 | 0.218000 | 1.61e-05 |
| Signaling by high-kinase activity BRAF mutants | 33 | 3.07e-02 | 0.217000 | 1.16e-01 |
| RNA Polymerase III Abortive And Retractive Initiation | 40 | 1.74e-02 | -0.217000 | 7.91e-02 |
| RNA Polymerase III Transcription | 40 | 1.74e-02 | -0.217000 | 7.91e-02 |
| SUMOylation of RNA binding proteins | 47 | 9.96e-03 | -0.217000 | 5.58e-02 |
| FRS-mediated FGFR3 signaling | 12 | 1.94e-01 | 0.216000 | 3.85e-01 |
| Adenylate cyclase activating pathway | 8 | 2.89e-01 | 0.216000 | 4.88e-01 |
| G alpha (z) signalling events | 36 | 2.47e-02 | 0.216000 | 9.90e-02 |
| Signaling by cytosolic FGFR1 fusion mutants | 18 | 1.13e-01 | 0.216000 | 2.77e-01 |
| Aquaporin-mediated transport | 38 | 2.13e-02 | 0.216000 | 9.03e-02 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | 14 | 1.62e-01 | -0.216000 | 3.43e-01 |
| Synthesis, secretion, and deacylation of Ghrelin | 11 | 2.16e-01 | -0.215000 | 4.10e-01 |
| Activation of AMPK downstream of NMDARs | 20 | 9.59e-02 | 0.215000 | 2.50e-01 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 1.97e-01 | 0.215000 | 3.89e-01 |
| Extracellular matrix organization | 213 | 6.75e-08 | 0.215000 | 1.96e-06 |
| Biosynthesis of specialized proresolving mediators (SPMs) | 15 | 1.50e-01 | 0.214000 | 3.31e-01 |
| Synthesis of PE | 12 | 1.99e-01 | -0.214000 | 3.91e-01 |
| Cyclin A/B1/B2 associated events during G2/M transition | 25 | 6.40e-02 | 0.214000 | 1.89e-01 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | 29 | 4.61e-02 | 0.214000 | 1.56e-01 |
| Signaling by VEGF | 100 | 2.23e-04 | 0.214000 | 3.03e-03 |
| FCGR3A-mediated IL10 synthesis | 99 | 2.53e-04 | 0.213000 | 3.35e-03 |
| Signaling by ALK fusions and activated point mutants | 89 | 5.25e-04 | 0.213000 | 6.08e-03 |
| Signaling by ALK in cancer | 89 | 5.25e-04 | 0.213000 | 6.08e-03 |
| Keratan sulfate/keratin metabolism | 27 | 5.59e-02 | 0.213000 | 1.75e-01 |
| Downstream signaling of activated FGFR3 | 17 | 1.30e-01 | 0.212000 | 3.05e-01 |
| Signaling by ERBB2 ECD mutants | 15 | 1.55e-01 | 0.212000 | 3.36e-01 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | 42 | 1.75e-02 | -0.212000 | 7.91e-02 |
| HIV Transcription Elongation | 42 | 1.75e-02 | -0.212000 | 7.91e-02 |
| Tat-mediated elongation of the HIV-1 transcript | 42 | 1.75e-02 | -0.212000 | 7.91e-02 |
| Loss of Function of SMAD2/3 in Cancer | 7 | 3.32e-01 | -0.212000 | 5.31e-01 |
| Mitophagy | 38 | 2.40e-02 | -0.212000 | 9.74e-02 |
| EPHB-mediated forward signaling | 38 | 2.43e-02 | 0.211000 | 9.81e-02 |
| FGFR1 ligand binding and activation | 10 | 2.48e-01 | -0.211000 | 4.47e-01 |
| RAC2 GTPase cycle | 85 | 7.73e-04 | 0.211000 | 8.16e-03 |
| Signaling by FGFR3 in disease | 14 | 1.72e-01 | 0.211000 | 3.54e-01 |
| Molybdenum cofactor biosynthesis | 6 | 3.72e-01 | -0.210000 | 5.69e-01 |
| GPER1 signaling | 38 | 2.48e-02 | 0.210000 | 9.90e-02 |
| Sodium/Calcium exchangers | 9 | 2.75e-01 | 0.210000 | 4.76e-01 |
| Synthesis of Dolichyl-phosphate | 6 | 3.74e-01 | 0.210000 | 5.71e-01 |
| RHO GTPases Activate Rhotekin and Rhophilins | 8 | 3.06e-01 | -0.209000 | 5.07e-01 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 21 | 9.76e-02 | 0.209000 | 2.53e-01 |
| RNA Polymerase I Promoter Opening | 17 | 1.36e-01 | 0.209000 | 3.12e-01 |
| Signaling by NTRK3 (TRKC) | 15 | 1.61e-01 | 0.209000 | 3.42e-01 |
| Methylation | 13 | 1.94e-01 | -0.208000 | 3.85e-01 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 43 | 1.84e-02 | -0.208000 | 8.17e-02 |
| SARS-CoV-2-host interactions | 181 | 1.45e-06 | -0.208000 | 3.52e-05 |
| FCERI mediated MAPK activation | 93 | 5.43e-04 | 0.207000 | 6.21e-03 |
| Response to elevated platelet cytosolic Ca2+ | 108 | 1.97e-04 | 0.207000 | 2.72e-03 |
| RHOA GTPase cycle | 138 | 2.62e-05 | 0.207000 | 4.53e-04 |
| Constitutive Signaling by Aberrant PI3K in Cancer | 57 | 6.83e-03 | 0.207000 | 4.27e-02 |
| Regulation of signaling by CBL | 22 | 9.27e-02 | 0.207000 | 2.45e-01 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | 60 | 5.57e-03 | 0.207000 | 3.67e-02 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | 85 | 9.94e-04 | 0.207000 | 9.99e-03 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | 85 | 9.94e-04 | 0.207000 | 9.99e-03 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | 85 | 9.94e-04 | 0.207000 | 9.99e-03 |
| SHC1 events in ERBB2 signaling | 17 | 1.41e-01 | 0.206000 | 3.17e-01 |
| Maturation of spike protein 9694548 | 35 | 3.49e-02 | 0.206000 | 1.28e-01 |
| Apoptotic factor-mediated response | 19 | 1.21e-01 | -0.205000 | 2.91e-01 |
| Cell surface interactions at the vascular wall | 170 | 3.95e-06 | 0.205000 | 9.03e-05 |
| Gap junction degradation | 11 | 2.39e-01 | 0.205000 | 4.36e-01 |
| Signaling by ERBB2 in Cancer | 21 | 1.04e-01 | 0.205000 | 2.63e-01 |
| Signaling by Interleukins | 387 | 4.38e-12 | 0.205000 | 1.83e-10 |
| Pausing and recovery of Tat-mediated HIV elongation | 30 | 5.27e-02 | -0.204000 | 1.69e-01 |
| Tat-mediated HIV elongation arrest and recovery | 30 | 5.27e-02 | -0.204000 | 1.69e-01 |
| Interleukin-2 signaling | 11 | 2.41e-01 | 0.204000 | 4.39e-01 |
| Regulated proteolysis of p75NTR | 11 | 2.42e-01 | 0.204000 | 4.41e-01 |
| Gluconeogenesis | 19 | 1.24e-01 | 0.204000 | 2.96e-01 |
| HS-GAG biosynthesis | 19 | 1.24e-01 | 0.204000 | 2.96e-01 |
| Diseases of hemostasis | 13 | 2.04e-01 | 0.203000 | 3.98e-01 |
| FRS-mediated FGFR4 signaling | 13 | 2.05e-01 | 0.203000 | 3.98e-01 |
| Downstream signaling of activated FGFR4 | 18 | 1.36e-01 | 0.203000 | 3.12e-01 |
| G1/S-Specific Transcription | 29 | 5.88e-02 | 0.203000 | 1.81e-01 |
| Classical antibody-mediated complement activation | 69 | 3.61e-03 | 0.203000 | 2.74e-02 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 84 | 1.37e-03 | 0.202000 | 1.29e-02 |
| Hyaluronan uptake and degradation | 12 | 2.26e-01 | 0.202000 | 4.18e-01 |
| Regulation of CDH11 Expression and Function | 22 | 1.01e-01 | 0.202000 | 2.60e-01 |
| Platelet degranulation | 104 | 3.85e-04 | 0.201000 | 4.76e-03 |
| NOTCH4 Intracellular Domain Regulates Transcription | 17 | 1.51e-01 | 0.201000 | 3.31e-01 |
| Synthesis of IP2, IP, and Ins in the cytosol | 13 | 2.10e-01 | 0.201000 | 4.03e-01 |
| Regulation of CDH11 mRNA translation by microRNAs | 8 | 3.27e-01 | 0.200000 | 5.27e-01 |
| Regulation of NPAS4 mRNA translation | 8 | 3.27e-01 | 0.200000 | 5.27e-01 |
| RHO GTPases activate PKNs | 46 | 1.89e-02 | 0.200000 | 8.31e-02 |
| Thrombin signalling through proteinase activated receptors (PARs) | 27 | 7.25e-02 | 0.200000 | 2.06e-01 |
| Formation of the active cofactor, UDP-glucuronate | 5 | 4.40e-01 | 0.200000 | 6.31e-01 |
| Sphingolipid catabolism | 11 | 2.54e-01 | 0.199000 | 4.54e-01 |
| Integrin cell surface interactions | 64 | 6.03e-03 | 0.198000 | 3.89e-02 |
| Formation of HIV elongation complex in the absence of HIV Tat | 44 | 2.27e-02 | -0.198000 | 9.39e-02 |
| Signal transduction by L1 | 20 | 1.24e-01 | 0.198000 | 2.96e-01 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 32 | 5.27e-02 | -0.198000 | 1.69e-01 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | 32 | 5.27e-02 | -0.198000 | 1.69e-01 |
| Tie2 Signaling | 16 | 1.71e-01 | 0.198000 | 3.53e-01 |
| Platelet activation, signaling and aggregation | 219 | 4.59e-07 | 0.198000 | 1.26e-05 |
| Intrinsic Pathway of Fibrin Clot Formation | 15 | 1.86e-01 | 0.197000 | 3.73e-01 |
| FCGR activation | 76 | 2.93e-03 | 0.197000 | 2.31e-02 |
| FLT3 signaling by CBL mutants | 7 | 3.67e-01 | -0.197000 | 5.64e-01 |
| PI-3K cascade:FGFR2 | 13 | 2.19e-01 | 0.197000 | 4.12e-01 |
| Transport of Mature mRNA Derived from an Intronless Transcript | 42 | 2.76e-02 | -0.197000 | 1.07e-01 |
| Circadian Clock | 67 | 5.42e-03 | 0.196000 | 3.62e-02 |
| RHOD GTPase cycle | 49 | 1.75e-02 | 0.196000 | 7.91e-02 |
| PIWI-interacting RNA (piRNA) biogenesis | 23 | 1.03e-01 | -0.196000 | 2.63e-01 |
| Uptake and actions of bacterial toxins | 27 | 7.83e-02 | 0.196000 | 2.17e-01 |
| Deadenylation-dependent mRNA decay | 50 | 1.67e-02 | -0.196000 | 7.81e-02 |
| FLT3 Signaling | 38 | 3.71e-02 | 0.195000 | 1.34e-01 |
| Diseases of DNA repair | 50 | 1.71e-02 | -0.195000 | 7.91e-02 |
| mRNA Capping | 29 | 6.93e-02 | -0.195000 | 2.01e-01 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | 10 | 2.87e-01 | -0.194000 | 4.85e-01 |
| Pre-NOTCH Expression and Processing | 63 | 7.63e-03 | 0.194000 | 4.60e-02 |
| FGFR2 alternative splicing | 25 | 9.31e-02 | -0.194000 | 2.46e-01 |
| Diseases associated with surfactant metabolism | 5 | 4.53e-01 | 0.194000 | 6.43e-01 |
| Glycine degradation | 7 | 3.75e-01 | 0.194000 | 5.72e-01 |
| SUMOylation of chromatin organization proteins | 57 | 1.14e-02 | -0.194000 | 6.13e-02 |
| RAB GEFs exchange GTP for GDP on RABs | 89 | 1.61e-03 | 0.193000 | 1.49e-02 |
| GRB2 events in ERBB2 signaling | 11 | 2.67e-01 | 0.193000 | 4.67e-01 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 1.26e-01 | -0.193000 | 3.00e-01 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 1.26e-01 | -0.193000 | 3.00e-01 |
| Regulation of Complement cascade | 96 | 1.14e-03 | 0.192000 | 1.13e-02 |
| Removal of the Flap Intermediate from the C-strand | 17 | 1.71e-01 | -0.192000 | 3.53e-01 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 2.50e-01 | -0.192000 | 4.48e-01 |
| Neurotransmitter clearance | 6 | 4.16e-01 | -0.192000 | 6.12e-01 |
| Interleukin-6 family signaling | 18 | 1.60e-01 | 0.191000 | 3.41e-01 |
| Reversible hydration of carbon dioxide | 8 | 3.49e-01 | 0.191000 | 5.46e-01 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | 52 | 1.72e-02 | -0.191000 | 7.91e-02 |
| MET promotes cell motility | 32 | 6.22e-02 | 0.190000 | 1.87e-01 |
| Unblocking of NMDA receptors, glutamate binding and activation | 12 | 2.54e-01 | -0.190000 | 4.54e-01 |
| Glutathione synthesis and recycling | 10 | 2.98e-01 | 0.190000 | 4.97e-01 |
| Glycosphingolipid transport | 7 | 3.84e-01 | -0.190000 | 5.79e-01 |
| Transport of bile salts and organic acids, metal ions and amine compounds | 51 | 1.91e-02 | 0.190000 | 8.35e-02 |
| Processing of Intronless Pre-mRNAs | 20 | 1.42e-01 | -0.190000 | 3.18e-01 |
| Phenylalanine and tyrosine metabolism | 9 | 3.25e-01 | -0.190000 | 5.26e-01 |
| HDL assembly | 6 | 4.22e-01 | 0.189000 | 6.17e-01 |
| Negative regulators of DDX58/IFIH1 signaling | 34 | 5.61e-02 | -0.189000 | 1.75e-01 |
| SUMO is proteolytically processed | 6 | 4.22e-01 | -0.189000 | 6.17e-01 |
| tRNA Aminoacylation | 42 | 3.40e-02 | -0.189000 | 1.25e-01 |
| Zinc influx into cells by the SLC39 gene family | 9 | 3.26e-01 | 0.189000 | 5.27e-01 |
| Extension of Telomeres | 51 | 1.95e-02 | -0.189000 | 8.48e-02 |
| Negative regulation of the PI3K/AKT network | 91 | 1.86e-03 | 0.189000 | 1.60e-02 |
| Coenzyme A biosynthesis | 7 | 3.88e-01 | -0.188000 | 5.83e-01 |
| Disorders of Developmental Biology | 12 | 2.58e-01 | 0.188000 | 4.57e-01 |
| Disorders of Nervous System Development | 12 | 2.58e-01 | 0.188000 | 4.57e-01 |
| Loss of function of MECP2 in Rett syndrome | 12 | 2.58e-01 | 0.188000 | 4.57e-01 |
| Pervasive developmental disorders | 12 | 2.58e-01 | 0.188000 | 4.57e-01 |
| KEAP1-NFE2L2 pathway | 106 | 8.06e-04 | 0.188000 | 8.41e-03 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | 15 | 2.07e-01 | 0.188000 | 3.99e-01 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | 24 | 1.10e-01 | 0.188000 | 2.73e-01 |
| Transcriptional Regulation by MECP2 | 47 | 2.57e-02 | 0.188000 | 1.01e-01 |
| Phase 2 - plateau phase | 12 | 2.60e-01 | 0.188000 | 4.59e-01 |
| Estrogen-dependent gene expression | 96 | 1.48e-03 | 0.188000 | 1.38e-02 |
| MET receptor recycling | 9 | 3.30e-01 | 0.188000 | 5.30e-01 |
| Transport to the Golgi and subsequent modification | 170 | 2.47e-05 | 0.187000 | 4.39e-04 |
| Signaling by Insulin receptor | 63 | 1.01e-02 | 0.187000 | 5.60e-02 |
| Signaling by FGFR2 IIIa TM | 18 | 1.69e-01 | -0.187000 | 3.52e-01 |
| GPCR ligand binding | 241 | 5.63e-07 | 0.187000 | 1.50e-05 |
| APC-Cdc20 mediated degradation of Nek2A | 26 | 9.99e-02 | -0.186000 | 2.58e-01 |
| Regulation of NF-kappa B signaling | 18 | 1.71e-01 | -0.186000 | 3.53e-01 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | 8 | 3.62e-01 | 0.186000 | 5.58e-01 |
| HIV elongation arrest and recovery | 32 | 6.82e-02 | -0.186000 | 1.98e-01 |
| Pausing and recovery of HIV elongation | 32 | 6.82e-02 | -0.186000 | 1.98e-01 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | 19 | 1.60e-01 | 0.186000 | 3.41e-01 |
| Trafficking of AMPA receptors | 19 | 1.60e-01 | 0.186000 | 3.41e-01 |
| Activation of NOXA and translocation to mitochondria | 5 | 4.71e-01 | -0.186000 | 6.60e-01 |
| RHOT2 GTPase cycle | 7 | 3.96e-01 | 0.185000 | 5.89e-01 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 18 | 1.74e-01 | 0.185000 | 3.57e-01 |
| RAC1 GTPase cycle | 170 | 3.17e-05 | 0.185000 | 5.43e-04 |
| Hyaluronan metabolism | 15 | 2.15e-01 | 0.185000 | 4.09e-01 |
| Signaling by ERBB2 KD Mutants | 20 | 1.53e-01 | 0.185000 | 3.33e-01 |
| Interleukin-18 signaling | 6 | 4.36e-01 | 0.184000 | 6.29e-01 |
| G alpha (12/13) signalling events | 68 | 8.97e-03 | 0.183000 | 5.13e-02 |
| Transcriptional regulation by RUNX1 | 170 | 3.84e-05 | 0.183000 | 6.36e-04 |
| RND3 GTPase cycle | 35 | 6.13e-02 | 0.183000 | 1.85e-01 |
| Regulation of MITF-M-dependent genes involved in apoptosis | 16 | 2.06e-01 | 0.182000 | 3.99e-01 |
| Post-chaperonin tubulin folding pathway | 18 | 1.80e-01 | 0.182000 | 3.66e-01 |
| Signaling by FGFR1 in disease | 32 | 7.42e-02 | 0.182000 | 2.09e-01 |
| CTNNB1 S33 mutants aren’t phosphorylated | 15 | 2.22e-01 | 0.182000 | 4.14e-01 |
| CTNNB1 S37 mutants aren’t phosphorylated | 15 | 2.22e-01 | 0.182000 | 4.14e-01 |
| CTNNB1 S45 mutants aren’t phosphorylated | 15 | 2.22e-01 | 0.182000 | 4.14e-01 |
| CTNNB1 T41 mutants aren’t phosphorylated | 15 | 2.22e-01 | 0.182000 | 4.14e-01 |
| Signaling by CTNNB1 phospho-site mutants | 15 | 2.22e-01 | 0.182000 | 4.14e-01 |
| Signaling by GSK3beta mutants | 15 | 2.22e-01 | 0.182000 | 4.14e-01 |
| Platelet Aggregation (Plug Formation) | 28 | 9.53e-02 | 0.182000 | 2.49e-01 |
| Glucuronidation | 8 | 3.73e-01 | 0.182000 | 5.69e-01 |
| O-linked glycosylation | 81 | 4.71e-03 | 0.182000 | 3.35e-02 |
| Processive synthesis on the C-strand of the telomere | 19 | 1.71e-01 | -0.181000 | 3.53e-01 |
| Nef Mediated CD8 Down-regulation | 7 | 4.07e-01 | 0.181000 | 6.02e-01 |
| Metalloprotease DUBs | 20 | 1.61e-01 | 0.181000 | 3.42e-01 |
| Elastic fibre formation | 33 | 7.24e-02 | 0.181000 | 2.06e-01 |
| ER to Golgi Anterograde Transport | 145 | 1.80e-04 | 0.180000 | 2.52e-03 |
| FGFR1 mutant receptor activation | 25 | 1.19e-01 | 0.180000 | 2.88e-01 |
| DNA Damage Reversal | 8 | 3.78e-01 | -0.180000 | 5.74e-01 |
| IRF3-mediated induction of type I IFN | 12 | 2.80e-01 | -0.180000 | 4.78e-01 |
| FGFR2c ligand binding and activation | 5 | 4.86e-01 | 0.180000 | 6.74e-01 |
| Activation of RAC1 downstream of NMDARs | 7 | 4.11e-01 | 0.180000 | 6.07e-01 |
| Ca-dependent events | 29 | 9.45e-02 | 0.179000 | 2.48e-01 |
| Sensory Perception | 188 | 2.30e-05 | 0.179000 | 4.13e-04 |
| FGFR3 ligand binding and activation | 5 | 4.88e-01 | 0.179000 | 6.75e-01 |
| FGFR3c ligand binding and activation | 5 | 4.88e-01 | 0.179000 | 6.75e-01 |
| PECAM1 interactions | 12 | 2.83e-01 | 0.179000 | 4.82e-01 |
| Formation of annular gap junctions | 10 | 3.28e-01 | 0.179000 | 5.28e-01 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | 28 | 1.02e-01 | 0.178000 | 2.61e-01 |
| Synthesis of PI | 5 | 4.90e-01 | 0.178000 | 6.76e-01 |
| Downstream signaling of activated FGFR2 | 20 | 1.68e-01 | 0.178000 | 3.50e-01 |
| APC truncation mutants have impaired AXIN binding | 14 | 2.49e-01 | 0.178000 | 4.47e-01 |
| AXIN missense mutants destabilize the destruction complex | 14 | 2.49e-01 | 0.178000 | 4.47e-01 |
| Signaling by AMER1 mutants | 14 | 2.49e-01 | 0.178000 | 4.47e-01 |
| Signaling by APC mutants | 14 | 2.49e-01 | 0.178000 | 4.47e-01 |
| Signaling by AXIN mutants | 14 | 2.49e-01 | 0.178000 | 4.47e-01 |
| Truncations of AMER1 destabilize the destruction complex | 14 | 2.49e-01 | 0.178000 | 4.47e-01 |
| RHO GTPase Effectors | 257 | 8.96e-07 | 0.178000 | 2.30e-05 |
| Cholesterol biosynthesis | 26 | 1.16e-01 | 0.178000 | 2.82e-01 |
| APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 1.31e-01 | -0.178000 | 3.07e-01 |
| RHOQ GTPase cycle | 54 | 2.40e-02 | 0.178000 | 9.74e-02 |
| COPI-mediated anterograde transport | 92 | 3.26e-03 | 0.177000 | 2.54e-02 |
| CDC42 GTPase cycle | 139 | 3.06e-04 | 0.177000 | 3.94e-03 |
| FGFR2 ligand binding and activation | 9 | 3.57e-01 | -0.177000 | 5.54e-01 |
| PI3K/AKT Signaling in Cancer | 83 | 5.33e-03 | 0.177000 | 3.59e-02 |
| Opioid Signalling | 74 | 8.56e-03 | 0.177000 | 4.97e-02 |
| G alpha (q) signalling events | 139 | 3.26e-04 | 0.177000 | 4.12e-03 |
| Role of phospholipids in phagocytosis | 88 | 4.34e-03 | 0.176000 | 3.20e-02 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | 59 | 1.95e-02 | 0.176000 | 8.48e-02 |
| Signaling by MET | 67 | 1.29e-02 | 0.176000 | 6.57e-02 |
| Prolactin receptor signaling | 11 | 3.13e-01 | -0.176000 | 5.15e-01 |
| HSF1-dependent transactivation | 28 | 1.08e-01 | 0.175000 | 2.69e-01 |
| ESR-mediated signaling | 157 | 1.53e-04 | 0.175000 | 2.20e-03 |
| RIP-mediated NFkB activation via ZBP1 | 17 | 2.12e-01 | 0.175000 | 4.05e-01 |
| Creation of C4 and C2 activators | 71 | 1.09e-02 | 0.175000 | 5.92e-02 |
| Formation of apoptosome | 11 | 3.16e-01 | -0.175000 | 5.17e-01 |
| Regulation of the apoptosome activity | 11 | 3.16e-01 | -0.175000 | 5.17e-01 |
| Downstream signaling of activated FGFR1 | 22 | 1.57e-01 | 0.174000 | 3.38e-01 |
| Regulation of BACH1 activity | 11 | 3.17e-01 | -0.174000 | 5.18e-01 |
| Non-integrin membrane-ECM interactions | 46 | 4.11e-02 | 0.174000 | 1.43e-01 |
| Sema4D mediated inhibition of cell attachment and migration | 7 | 4.26e-01 | 0.174000 | 6.21e-01 |
| Signaling by NOTCH3 | 42 | 5.21e-02 | 0.173000 | 1.69e-01 |
| TCF dependent signaling in response to WNT | 151 | 2.40e-04 | 0.173000 | 3.20e-03 |
| MicroRNA (miRNA) biogenesis | 24 | 1.43e-01 | -0.173000 | 3.19e-01 |
| Peroxisomal protein import | 58 | 2.32e-02 | -0.172000 | 9.47e-02 |
| G alpha (i) signalling events | 196 | 3.30e-05 | 0.172000 | 5.60e-04 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | 10 | 3.48e-01 | 0.171000 | 5.45e-01 |
| Nucleotide-like (purinergic) receptors | 14 | 2.67e-01 | 0.171000 | 4.67e-01 |
| Fc epsilon receptor (FCERI) signaling | 179 | 8.05e-05 | 0.171000 | 1.24e-03 |
| Creatine metabolism | 7 | 4.34e-01 | 0.171000 | 6.29e-01 |
| CRMPs in Sema3A signaling | 13 | 2.86e-01 | 0.171000 | 4.84e-01 |
| G alpha (s) signalling events | 93 | 4.45e-03 | 0.171000 | 3.24e-02 |
| Defective B3GAT3 causes JDSSDHD | 10 | 3.52e-01 | 0.170000 | 5.49e-01 |
| Nuclear events stimulated by ALK signaling in cancer | 33 | 9.09e-02 | 0.170000 | 2.43e-01 |
| FRS-mediated FGFR2 signaling | 15 | 2.54e-01 | 0.170000 | 4.54e-01 |
| EPH-Ephrin signaling | 79 | 9.02e-03 | 0.170000 | 5.13e-02 |
| ISG15 antiviral mechanism | 72 | 1.27e-02 | -0.170000 | 6.51e-02 |
| Glycerophospholipid catabolism | 6 | 4.72e-01 | -0.170000 | 6.60e-01 |
| Signaling by RAF1 mutants | 36 | 7.86e-02 | 0.169000 | 2.17e-01 |
| Syndecan interactions | 23 | 1.60e-01 | 0.169000 | 3.41e-01 |
| Translation of Replicase and Assembly of the Replication Transcription Complex 9694676 | 13 | 2.91e-01 | -0.169000 | 4.90e-01 |
| Signaling by the B Cell Receptor (BCR) | 150 | 3.66e-04 | 0.169000 | 4.56e-03 |
| Collagen chain trimerization | 26 | 1.37e-01 | 0.169000 | 3.13e-01 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | 6 | 4.76e-01 | -0.168000 | 6.62e-01 |
| TGFBR1 KD Mutants in Cancer | 6 | 4.76e-01 | -0.168000 | 6.62e-01 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | 41 | 6.25e-02 | -0.168000 | 1.87e-01 |
| Diseases of DNA Double-Strand Break Repair | 41 | 6.25e-02 | -0.168000 | 1.87e-01 |
| Condensation of Prophase Chromosomes | 27 | 1.31e-01 | 0.168000 | 3.07e-01 |
| COPII-mediated vesicle transport | 67 | 1.75e-02 | 0.168000 | 7.91e-02 |
| Cell-Cell communication | 108 | 2.60e-03 | 0.168000 | 2.10e-02 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 2.79e-01 | -0.167000 | 4.77e-01 |
| p75NTR recruits signalling complexes | 12 | 3.16e-01 | -0.167000 | 5.18e-01 |
| PI3K events in ERBB2 signaling | 11 | 3.38e-01 | 0.167000 | 5.35e-01 |
| PP2A-mediated dephosphorylation of key metabolic factors | 7 | 4.45e-01 | 0.167000 | 6.36e-01 |
| Metabolism of cofactors | 25 | 1.49e-01 | -0.167000 | 3.28e-01 |
| PDH complex synthesizes acetyl-CoA from PYR | 5 | 5.18e-01 | -0.167000 | 7.00e-01 |
| Signaling by TGF-beta Receptor Complex in Cancer | 8 | 4.14e-01 | -0.167000 | 6.11e-01 |
| RUNX2 regulates bone development | 21 | 1.89e-01 | 0.166000 | 3.79e-01 |
| ZBP1(DAI) mediated induction of type I IFNs | 20 | 2.00e-01 | 0.165000 | 3.94e-01 |
| Signaling by CSF3 (G-CSF) | 29 | 1.24e-01 | 0.165000 | 2.96e-01 |
| Late SARS-CoV-2 Infection Events | 63 | 2.40e-02 | 0.164000 | 9.74e-02 |
| Fatty acyl-CoA biosynthesis | 35 | 9.27e-02 | 0.164000 | 2.45e-01 |
| Detoxification of Reactive Oxygen Species | 30 | 1.20e-01 | 0.164000 | 2.88e-01 |
| Reelin signalling pathway | 5 | 5.25e-01 | 0.164000 | 7.06e-01 |
| Homologous DNA Pairing and Strand Exchange | 43 | 6.38e-02 | -0.163000 | 1.89e-01 |
| Tryptophan catabolism | 12 | 3.28e-01 | -0.163000 | 5.28e-01 |
| NR1H2 and NR1H3-mediated signaling | 38 | 8.24e-02 | 0.163000 | 2.25e-01 |
| MAPK family signaling cascades | 259 | 6.62e-06 | 0.163000 | 1.41e-04 |
| Blood group systems biosynthesis | 16 | 2.60e-01 | -0.163000 | 4.59e-01 |
| Activation of the pre-replicative complex | 32 | 1.12e-01 | -0.162000 | 2.75e-01 |
| Stimuli-sensing channels | 78 | 1.31e-02 | 0.162000 | 6.62e-02 |
| Heme signaling | 45 | 5.96e-02 | 0.162000 | 1.82e-01 |
| Ion homeostasis | 40 | 7.57e-02 | 0.162000 | 2.11e-01 |
| RHOU GTPase cycle | 40 | 7.66e-02 | 0.162000 | 2.13e-01 |
| TP53 Regulates Transcription of DNA Repair Genes | 61 | 2.89e-02 | -0.162000 | 1.11e-01 |
| Extra-nuclear estrogen signaling | 65 | 2.41e-02 | 0.162000 | 9.78e-02 |
| Vesicle-mediated transport | 663 | 1.40e-12 | 0.161000 | 6.11e-11 |
| Cell-extracellular matrix interactions | 15 | 2.80e-01 | 0.161000 | 4.78e-01 |
| Signaling by MST1 | 5 | 5.33e-01 | -0.161000 | 7.12e-01 |
| Biosynthesis of maresins | 5 | 5.33e-01 | 0.161000 | 7.12e-01 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | 9 | 4.03e-01 | 0.161000 | 5.97e-01 |
| IkBA variant leads to EDA-ID | 7 | 4.61e-01 | 0.161000 | 6.51e-01 |
| Metabolism of amine-derived hormones | 10 | 3.78e-01 | 0.161000 | 5.74e-01 |
| MyD88 deficiency (TLR2/4) | 14 | 2.98e-01 | 0.161000 | 4.97e-01 |
| Transcription of E2F targets under negative control by DREAM complex | 19 | 2.28e-01 | 0.160000 | 4.21e-01 |
| Signaling by Rho GTPases | 603 | 2.19e-11 | 0.160000 | 8.27e-10 |
| IRE1alpha activates chaperones | 46 | 6.20e-02 | 0.159000 | 1.87e-01 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 13 | 3.21e-01 | 0.159000 | 5.22e-01 |
| G-protein mediated events | 43 | 7.12e-02 | 0.159000 | 2.04e-01 |
| Aryl hydrocarbon receptor signalling | 6 | 5.00e-01 | -0.159000 | 6.84e-01 |
| Ion channel transport | 136 | 1.37e-03 | 0.159000 | 1.29e-02 |
| Signaling by ERBB2 TMD/JMD mutants | 17 | 2.57e-01 | 0.159000 | 4.57e-01 |
| Signaling by Rho GTPases, Miro GTPases and RHOBTB3 | 619 | 1.65e-11 | 0.159000 | 6.61e-10 |
| Interleukin-35 Signalling | 12 | 3.42e-01 | 0.158000 | 5.40e-01 |
| FCERI mediated NF-kB activation | 129 | 1.93e-03 | 0.158000 | 1.64e-02 |
| MAPK1/MAPK3 signaling | 227 | 4.20e-05 | 0.158000 | 6.89e-04 |
| N-glycan trimming and elongation in the cis-Golgi | 5 | 5.43e-01 | -0.157000 | 7.19e-01 |
| Defective RIPK1-mediated regulated necrosis | 7 | 4.71e-01 | -0.157000 | 6.60e-01 |
| Neurotransmitter receptors and postsynaptic signal transmission | 132 | 1.83e-03 | 0.157000 | 1.59e-02 |
| Myoclonic epilepsy of Lafora | 8 | 4.42e-01 | -0.157000 | 6.34e-01 |
| p130Cas linkage to MAPK signaling for integrins | 11 | 3.67e-01 | 0.157000 | 5.64e-01 |
| Presynaptic phase of homologous DNA pairing and strand exchange | 40 | 8.56e-02 | -0.157000 | 2.32e-01 |
| Signaling by GPCR | 441 | 1.61e-08 | 0.157000 | 5.34e-07 |
| AKT phosphorylates targets in the cytosol | 14 | 3.10e-01 | 0.157000 | 5.11e-01 |
| HDR through Homologous Recombination (HRR) | 68 | 2.56e-02 | -0.157000 | 1.01e-01 |
| HIV Life Cycle | 144 | 1.20e-03 | -0.156000 | 1.16e-02 |
| MITF-M-dependent gene expression | 81 | 1.52e-02 | 0.156000 | 7.34e-02 |
| SUMOylation of DNA damage response and repair proteins | 77 | 1.80e-02 | -0.156000 | 8.12e-02 |
| Synthesis of very long-chain fatty acyl-CoAs | 22 | 2.06e-01 | 0.156000 | 3.99e-01 |
| GPCR downstream signalling | 396 | 1.19e-07 | 0.155000 | 3.31e-06 |
| Gastrulation | 73 | 2.21e-02 | 0.155000 | 9.21e-02 |
| Cytochrome P450 - arranged by substrate type | 33 | 1.24e-01 | 0.155000 | 2.96e-01 |
| Interleukin-12 signaling | 44 | 7.57e-02 | 0.155000 | 2.11e-01 |
| DNA Repair | 288 | 6.40e-06 | -0.155000 | 1.38e-04 |
| Ion transport by P-type ATPases | 41 | 8.71e-02 | 0.154000 | 2.35e-01 |
| Downregulation of ERBB4 signaling | 8 | 4.51e-01 | -0.154000 | 6.42e-01 |
| RHO GTPase cycle | 408 | 1.00e-07 | 0.154000 | 2.83e-06 |
| Signaling by Receptor Tyrosine Kinases | 443 | 3.38e-08 | 0.153000 | 1.06e-06 |
| RNA Pol II CTD phosphorylation and interaction with CE | 27 | 1.69e-01 | -0.153000 | 3.52e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 27 | 1.69e-01 | -0.153000 | 3.52e-01 |
| Formation of the Editosome | 6 | 5.17e-01 | 0.153000 | 7.00e-01 |
| mRNA Editing: C to U Conversion | 6 | 5.17e-01 | 0.153000 | 7.00e-01 |
| Complement cascade | 100 | 8.31e-03 | 0.153000 | 4.86e-02 |
| Drug-mediated inhibition of CDK4/CDK6 activity | 5 | 5.55e-01 | 0.153000 | 7.29e-01 |
| Nuclear Pore Complex (NPC) Disassembly | 36 | 1.13e-01 | -0.153000 | 2.78e-01 |
| Transcriptional regulation of pluripotent stem cells | 18 | 2.63e-01 | 0.153000 | 4.62e-01 |
| PERK regulates gene expression | 30 | 1.48e-01 | -0.153000 | 3.27e-01 |
| NrCAM interactions | 6 | 5.18e-01 | -0.153000 | 7.00e-01 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | 5 | 5.56e-01 | -0.152000 | 7.29e-01 |
| Transcriptional Regulation by E2F6 | 34 | 1.27e-01 | -0.151000 | 3.00e-01 |
| Pentose phosphate pathway | 13 | 3.45e-01 | 0.151000 | 5.42e-01 |
| Apoptotic cleavage of cellular proteins | 35 | 1.22e-01 | 0.151000 | 2.92e-01 |
| RAF/MAP kinase cascade | 222 | 1.07e-04 | 0.151000 | 1.61e-03 |
| Signaling by WNT | 237 | 6.39e-05 | 0.151000 | 9.99e-04 |
| Serotonin Neurotransmitter Release Cycle | 15 | 3.13e-01 | 0.150000 | 5.15e-01 |
| PLC beta mediated events | 39 | 1.04e-01 | 0.150000 | 2.65e-01 |
| RAC3 GTPase cycle | 86 | 1.61e-02 | 0.150000 | 7.70e-02 |
| Synthesis of pyrophosphates in the cytosol | 8 | 4.62e-01 | -0.150000 | 6.51e-01 |
| Formation of tubulin folding intermediates by CCT/TriC | 21 | 2.34e-01 | 0.150000 | 4.29e-01 |
| Nuclear Receptor transcription pathway | 38 | 1.10e-01 | 0.150000 | 2.73e-01 |
| Physiological factors | 9 | 4.36e-01 | 0.150000 | 6.29e-01 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | 7 | 4.93e-01 | 0.150000 | 6.78e-01 |
| Peptide hormone metabolism | 53 | 6.03e-02 | 0.149000 | 1.83e-01 |
| Class B/2 (Secretin family receptors) | 54 | 5.82e-02 | 0.149000 | 1.80e-01 |
| NRAGE signals death through JNK | 52 | 6.39e-02 | 0.149000 | 1.89e-01 |
| VEGFR2 mediated cell proliferation | 18 | 2.75e-01 | 0.148000 | 4.76e-01 |
| Cytochrome c-mediated apoptotic response | 13 | 3.55e-01 | -0.148000 | 5.52e-01 |
| Assembly of collagen fibrils and other multimeric structures | 41 | 1.01e-01 | 0.148000 | 2.60e-01 |
| P2Y receptors | 10 | 4.19e-01 | 0.148000 | 6.15e-01 |
| Cellular response to chemical stress | 178 | 7.08e-04 | 0.147000 | 7.73e-03 |
| Rab regulation of trafficking | 122 | 5.04e-03 | 0.147000 | 3.51e-02 |
| SARS-CoV-1 Infection | 137 | 2.98e-03 | -0.147000 | 2.35e-02 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 13 | 3.60e-01 | -0.147000 | 5.56e-01 |
| WNT mediated activation of DVL | 8 | 4.72e-01 | 0.147000 | 6.60e-01 |
| Metabolism of ingested SeMet, Sec, MeSec into H2Se | 7 | 5.02e-01 | -0.147000 | 6.85e-01 |
| SHC-mediated cascade:FGFR3 | 10 | 4.22e-01 | 0.147000 | 6.17e-01 |
| TGFBR3 expression | 20 | 2.57e-01 | 0.146000 | 4.57e-01 |
| Membrane Trafficking | 575 | 2.11e-09 | 0.146000 | 7.49e-08 |
| Acyl chain remodelling of PS | 14 | 3.44e-01 | 0.146000 | 5.42e-01 |
| Activation of SMO | 14 | 3.44e-01 | 0.146000 | 5.42e-01 |
| G beta:gamma signalling through CDC42 | 17 | 2.98e-01 | 0.146000 | 4.97e-01 |
| Neuronal System | 262 | 4.87e-05 | 0.146000 | 7.93e-04 |
| Signaling by NTRK2 (TRKB) | 20 | 2.63e-01 | 0.145000 | 4.62e-01 |
| TICAM1, RIP1-mediated IKK complex recruitment | 19 | 2.75e-01 | 0.145000 | 4.76e-01 |
| Signaling by NTRKs | 116 | 7.25e-03 | 0.144000 | 4.43e-02 |
| Signal Transduction | 2034 | 8.48e-27 | 0.144000 | 1.09e-24 |
| Interleukin-1 family signaling | 127 | 5.07e-03 | 0.144000 | 3.51e-02 |
| Glycogen breakdown (glycogenolysis) | 12 | 3.89e-01 | 0.144000 | 5.84e-01 |
| HS-GAG degradation | 18 | 2.91e-01 | -0.144000 | 4.90e-01 |
| Activation of caspases through apoptosome-mediated cleavage | 6 | 5.42e-01 | 0.144000 | 7.19e-01 |
| Innate Immune System | 966 | 4.25e-14 | 0.144000 | 2.21e-12 |
| Interleukin-12 family signaling | 53 | 7.07e-02 | 0.144000 | 2.03e-01 |
| Initial triggering of complement | 79 | 2.75e-02 | 0.143000 | 1.07e-01 |
| Chromosome Maintenance | 102 | 1.23e-02 | -0.143000 | 6.42e-02 |
| Glycosaminoglycan metabolism | 95 | 1.58e-02 | 0.143000 | 7.57e-02 |
| CD28 dependent PI3K/Akt signaling | 22 | 2.46e-01 | -0.143000 | 4.45e-01 |
| TP53 Regulates Transcription of Cell Cycle Genes | 47 | 9.00e-02 | 0.143000 | 2.41e-01 |
| eNOS activation | 10 | 4.37e-01 | -0.142000 | 6.30e-01 |
| Regulation of PTEN localization | 9 | 4.61e-01 | 0.142000 | 6.51e-01 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | 191 | 7.29e-04 | 0.142000 | 7.91e-03 |
| Signaling by ERBB4 | 45 | 1.01e-01 | 0.142000 | 2.59e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 3.59e-01 | -0.141000 | 5.56e-01 |
| Cytoprotection by HMOX1 | 53 | 7.49e-02 | 0.141000 | 2.10e-01 |
| Interconversion of nucleotide di- and triphosphates | 27 | 2.04e-01 | -0.141000 | 3.98e-01 |
| Attachment of GPI anchor to uPAR | 7 | 5.18e-01 | 0.141000 | 7.00e-01 |
| Somitogenesis | 41 | 1.19e-01 | 0.141000 | 2.87e-01 |
| PPARA activates gene expression | 105 | 1.27e-02 | 0.141000 | 6.51e-02 |
| Phosphorylation of the APC/C | 20 | 2.77e-01 | -0.140000 | 4.76e-01 |
| CaM pathway | 27 | 2.07e-01 | 0.140000 | 3.99e-01 |
| Calmodulin induced events | 27 | 2.07e-01 | 0.140000 | 3.99e-01 |
| FGFR2b ligand binding and activation | 6 | 5.53e-01 | -0.140000 | 7.29e-01 |
| Beta-catenin independent WNT signaling | 124 | 7.23e-03 | 0.140000 | 4.43e-02 |
| EPHA-mediated growth cone collapse | 21 | 2.68e-01 | 0.140000 | 4.68e-01 |
| Collagen formation | 63 | 5.59e-02 | 0.139000 | 1.75e-01 |
| FGFR1c ligand binding and activation | 8 | 4.95e-01 | -0.139000 | 6.79e-01 |
| MET activates PTK2 signaling | 21 | 2.70e-01 | 0.139000 | 4.70e-01 |
| Insulin receptor signalling cascade | 40 | 1.28e-01 | 0.139000 | 3.03e-01 |
| RHOBTB GTPase Cycle | 35 | 1.56e-01 | 0.139000 | 3.37e-01 |
| Signaling by FGFR3 | 32 | 1.75e-01 | 0.139000 | 3.59e-01 |
| Activation of ATR in response to replication stress | 37 | 1.45e-01 | -0.138000 | 3.22e-01 |
| Negative regulation of FLT3 | 15 | 3.54e-01 | 0.138000 | 5.52e-01 |
| Synthesis of PIPs at the Golgi membrane | 16 | 3.39e-01 | -0.138000 | 5.37e-01 |
| Diseases associated with N-glycosylation of proteins | 20 | 2.85e-01 | -0.138000 | 4.83e-01 |
| CaMK IV-mediated phosphorylation of CREB | 8 | 5.00e-01 | -0.138000 | 6.84e-01 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 38 | 1.42e-01 | 0.138000 | 3.17e-01 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 16 | 3.40e-01 | -0.138000 | 5.38e-01 |
| RNA Polymerase I Promoter Clearance | 64 | 5.72e-02 | -0.137000 | 1.77e-01 |
| RNA Polymerase I Transcription | 64 | 5.72e-02 | -0.137000 | 1.77e-01 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 62 | 6.15e-02 | 0.137000 | 1.85e-01 |
| SHC-mediated cascade:FGFR4 | 11 | 4.31e-01 | 0.137000 | 6.26e-01 |
| Uptake of dietary cobalamins into enterocytes | 5 | 5.96e-01 | 0.137000 | 7.55e-01 |
| XBP1(S) activates chaperone genes | 44 | 1.16e-01 | 0.137000 | 2.82e-01 |
| Telomere Maintenance | 78 | 3.70e-02 | -0.137000 | 1.34e-01 |
| IRAK4 deficiency (TLR2/4) | 15 | 3.60e-01 | 0.137000 | 5.56e-01 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | 69 | 5.00e-02 | 0.136000 | 1.63e-01 |
| Mucopolysaccharidoses | 11 | 4.34e-01 | -0.136000 | 6.29e-01 |
| MASTL Facilitates Mitotic Progression | 10 | 4.55e-01 | 0.136000 | 6.45e-01 |
| Nef and signal transduction | 8 | 5.05e-01 | 0.136000 | 6.88e-01 |
| Transcriptional regulation of white adipocyte differentiation | 77 | 3.89e-02 | 0.136000 | 1.38e-01 |
| Heme biosynthesis | 13 | 3.96e-01 | -0.136000 | 5.89e-01 |
| Transcription of the HIV genome | 67 | 5.46e-02 | -0.136000 | 1.73e-01 |
| Peroxisomal lipid metabolism | 27 | 2.24e-01 | -0.135000 | 4.16e-01 |
| Striated Muscle Contraction | 25 | 2.42e-01 | 0.135000 | 4.41e-01 |
| Defective B4GALT7 causes EDS, progeroid type | 10 | 4.60e-01 | 0.135000 | 6.50e-01 |
| Late Phase of HIV Life Cycle | 131 | 7.68e-03 | -0.135000 | 4.61e-02 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 36 | 1.62e-01 | 0.135000 | 3.43e-01 |
| Glycosphingolipid catabolism | 31 | 1.95e-01 | -0.134000 | 3.86e-01 |
| Synthesis of 12-eicosatetraenoic acid derivatives | 6 | 5.69e-01 | -0.134000 | 7.36e-01 |
| Synthesis of PIPs at the ER membrane | 5 | 6.04e-01 | -0.134000 | 7.60e-01 |
| TGF-beta receptor signaling activates SMADs | 45 | 1.21e-01 | 0.134000 | 2.91e-01 |
| Metabolism of steroids | 120 | 1.15e-02 | 0.134000 | 6.15e-02 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | 11 | 4.45e-01 | -0.133000 | 6.36e-01 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 16 | 3.57e-01 | 0.133000 | 5.54e-01 |
| Degradation of beta-catenin by the destruction complex | 72 | 5.11e-02 | 0.133000 | 1.66e-01 |
| Signaling by Nuclear Receptors | 210 | 9.09e-04 | 0.133000 | 9.34e-03 |
| Regulation of MECP2 expression and activity | 28 | 2.26e-01 | 0.132000 | 4.18e-01 |
| Lysine catabolism | 10 | 4.70e-01 | 0.132000 | 6.59e-01 |
| Signaling by MAPK mutants | 6 | 5.77e-01 | -0.132000 | 7.42e-01 |
| Integrin signaling | 22 | 2.86e-01 | 0.131000 | 4.84e-01 |
| FOXO-mediated transcription of cell death genes | 16 | 3.64e-01 | 0.131000 | 5.60e-01 |
| Signaling by NTRK1 (TRKA) | 102 | 2.22e-02 | 0.131000 | 9.25e-02 |
| Formation of paraxial mesoderm | 52 | 1.02e-01 | 0.131000 | 2.61e-01 |
| Transmission across Chemical Synapses | 179 | 2.52e-03 | 0.131000 | 2.06e-02 |
| PI5P Regulates TP53 Acetylation | 8 | 5.22e-01 | 0.131000 | 7.03e-01 |
| DNA Damage/Telomere Stress Induced Senescence | 42 | 1.43e-01 | 0.131000 | 3.19e-01 |
| tRNA processing in the mitochondrion | 24 | 2.68e-01 | -0.131000 | 4.68e-01 |
| Transport of vitamins, nucleosides, and related molecules | 31 | 2.09e-01 | -0.130000 | 4.02e-01 |
| Interferon alpha/beta signaling | 63 | 7.37e-02 | -0.130000 | 2.08e-01 |
| CLEC7A/inflammasome pathway | 6 | 5.81e-01 | 0.130000 | 7.44e-01 |
| Formation of WDR5-containing histone-modifying complexes | 42 | 1.46e-01 | -0.130000 | 3.23e-01 |
| Toll Like Receptor 4 (TLR4) Cascade | 138 | 8.67e-03 | 0.129000 | 4.98e-02 |
| Phospholipase C-mediated cascade: FGFR1 | 8 | 5.27e-01 | -0.129000 | 7.07e-01 |
| Thyroxine biosynthesis | 5 | 6.17e-01 | -0.129000 | 7.67e-01 |
| Activation of Ca-permeable Kainate Receptor | 8 | 5.28e-01 | 0.129000 | 7.07e-01 |
| Ionotropic activity of kainate receptors | 8 | 5.28e-01 | 0.129000 | 7.07e-01 |
| Interleukin-27 signaling | 11 | 4.61e-01 | 0.128000 | 6.51e-01 |
| RAB geranylgeranylation | 62 | 8.07e-02 | 0.128000 | 2.21e-01 |
| Signaling by TGFB family members | 137 | 9.76e-03 | 0.128000 | 5.50e-02 |
| DAG and IP3 signaling | 33 | 2.04e-01 | 0.128000 | 3.98e-01 |
| HIV Transcription Initiation | 45 | 1.38e-01 | -0.128000 | 3.13e-01 |
| RNA Polymerase II HIV Promoter Escape | 45 | 1.38e-01 | -0.128000 | 3.13e-01 |
| RNA Polymerase II Promoter Escape | 45 | 1.38e-01 | -0.128000 | 3.13e-01 |
| RNA Polymerase II Transcription Initiation | 45 | 1.38e-01 | -0.128000 | 3.13e-01 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | 45 | 1.38e-01 | -0.128000 | 3.13e-01 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 45 | 1.38e-01 | -0.128000 | 3.13e-01 |
| Adrenaline,noradrenaline inhibits insulin secretion | 24 | 2.79e-01 | 0.128000 | 4.77e-01 |
| Regulation of lipid metabolism by PPARalpha | 107 | 2.27e-02 | 0.128000 | 9.39e-02 |
| SUMOylation of DNA replication proteins | 46 | 1.35e-01 | -0.127000 | 3.12e-01 |
| ABC transporter disorders | 59 | 9.04e-02 | 0.127000 | 2.42e-01 |
| p75NTR negatively regulates cell cycle via SC1 | 5 | 6.22e-01 | 0.127000 | 7.67e-01 |
| Deadenylation of mRNA | 22 | 3.02e-01 | -0.127000 | 5.01e-01 |
| Prostacyclin signalling through prostacyclin receptor | 16 | 3.79e-01 | 0.127000 | 5.74e-01 |
| Maternal to zygotic transition (MZT) | 71 | 6.43e-02 | 0.127000 | 1.90e-01 |
| Activation of the TFAP2 (AP-2) family of transcription factors | 7 | 5.61e-01 | 0.127000 | 7.31e-01 |
| Apoptotic cleavage of cell adhesion proteins | 8 | 5.34e-01 | 0.127000 | 7.13e-01 |
| Regulation of FOXO transcriptional activity by acetylation | 10 | 4.88e-01 | 0.127000 | 6.75e-01 |
| Plasma lipoprotein assembly, remodeling, and clearance | 56 | 1.01e-01 | 0.127000 | 2.60e-01 |
| Synthesis of Ketone Bodies | 6 | 5.92e-01 | -0.127000 | 7.52e-01 |
| IRS-related events triggered by IGF1R | 36 | 1.90e-01 | 0.126000 | 3.80e-01 |
| Diseases associated with O-glycosylation of proteins | 46 | 1.39e-01 | 0.126000 | 3.13e-01 |
| Signaling by NOTCH | 173 | 4.25e-03 | 0.126000 | 3.16e-02 |
| MAPK6/MAPK4 signaling | 69 | 7.06e-02 | 0.126000 | 2.03e-01 |
| Translation of Structural Proteins 9694635 | 55 | 1.06e-01 | 0.126000 | 2.67e-01 |
| ERBB2 Activates PTK6 Signaling | 8 | 5.38e-01 | 0.126000 | 7.14e-01 |
| DAP12 interactions | 39 | 1.76e-01 | 0.125000 | 3.60e-01 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 32 | 2.21e-01 | 0.125000 | 4.14e-01 |
| Diseases of signal transduction by growth factor receptors and second messengers | 399 | 1.88e-05 | 0.125000 | 3.47e-04 |
| Oxidative Stress Induced Senescence | 77 | 5.94e-02 | 0.124000 | 1.82e-01 |
| Activation of kainate receptors upon glutamate binding | 25 | 2.82e-01 | 0.124000 | 4.81e-01 |
| Post-translational modification: synthesis of GPI-anchored proteins | 57 | 1.06e-01 | -0.124000 | 2.66e-01 |
| TLR3-mediated TICAM1-dependent programmed cell death | 6 | 6.00e-01 | 0.124000 | 7.58e-01 |
| Bacterial Infection Pathways | 65 | 8.47e-02 | 0.124000 | 2.30e-01 |
| Potential therapeutics for SARS | 148 | 9.43e-03 | 0.124000 | 5.33e-02 |
| Loss of Function of TGFBR1 in Cancer | 7 | 5.74e-01 | -0.123000 | 7.41e-01 |
| G beta:gamma signalling through PLC beta | 17 | 3.84e-01 | 0.122000 | 5.79e-01 |
| Presynaptic function of Kainate receptors | 17 | 3.84e-01 | 0.122000 | 5.79e-01 |
| Transcriptional regulation by small RNAs | 61 | 1.00e-01 | -0.122000 | 2.58e-01 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | 7 | 5.78e-01 | 0.122000 | 7.42e-01 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | 50 | 1.38e-01 | 0.121000 | 3.13e-01 |
| Purine catabolism | 16 | 4.02e-01 | -0.121000 | 5.96e-01 |
| Surfactant metabolism | 20 | 3.49e-01 | 0.121000 | 5.46e-01 |
| Arachidonate metabolism | 42 | 1.76e-01 | 0.121000 | 3.60e-01 |
| HDR through Single Strand Annealing (SSA) | 37 | 2.04e-01 | -0.121000 | 3.98e-01 |
| WNT5A-dependent internalization of FZD4 | 13 | 4.52e-01 | 0.120000 | 6.43e-01 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | 7 | 5.81e-01 | 0.120000 | 7.44e-01 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | 9 | 5.34e-01 | 0.120000 | 7.13e-01 |
| Cross-presentation of soluble exogenous antigens (endosomes) | 35 | 2.21e-01 | 0.120000 | 4.14e-01 |
| ECM proteoglycans | 45 | 1.65e-01 | 0.120000 | 3.47e-01 |
| Signaling by BMP | 23 | 3.21e-01 | 0.119000 | 5.23e-01 |
| Diseases of carbohydrate metabolism | 29 | 2.66e-01 | -0.119000 | 4.66e-01 |
| DCC mediated attractive signaling | 13 | 4.56e-01 | 0.119000 | 6.46e-01 |
| IGF1R signaling cascade | 37 | 2.10e-01 | 0.119000 | 4.03e-01 |
| Cell junction organization | 77 | 7.16e-02 | 0.119000 | 2.04e-01 |
| DAP12 signaling | 28 | 2.80e-01 | 0.118000 | 4.78e-01 |
| Response of EIF2AK1 (HRI) to heme deficiency | 14 | 4.45e-01 | 0.118000 | 6.36e-01 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | 16 | 4.17e-01 | -0.117000 | 6.13e-01 |
| Toll-like Receptor Cascades | 162 | 1.01e-02 | 0.117000 | 5.60e-02 |
| Host Interactions of HIV factors | 118 | 2.81e-02 | -0.117000 | 1.08e-01 |
| Dermatan sulfate biosynthesis | 6 | 6.21e-01 | 0.117000 | 7.67e-01 |
| Intracellular signaling by second messengers | 264 | 1.15e-03 | 0.116000 | 1.13e-02 |
| Glucagon-type ligand receptors | 19 | 3.82e-01 | 0.116000 | 5.77e-01 |
| RNA Polymerase I Promoter Escape | 45 | 1.80e-01 | -0.116000 | 3.65e-01 |
| STING mediated induction of host immune responses | 15 | 4.38e-01 | -0.116000 | 6.30e-01 |
| Synthesis of 5-eicosatetraenoic acids | 7 | 5.96e-01 | -0.116000 | 7.55e-01 |
| The phototransduction cascade | 26 | 3.08e-01 | -0.116000 | 5.09e-01 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 27 | 2.99e-01 | 0.115000 | 4.98e-01 |
| FOXO-mediated transcription | 57 | 1.32e-01 | 0.115000 | 3.08e-01 |
| Collagen biosynthesis and modifying enzymes | 45 | 1.82e-01 | 0.115000 | 3.68e-01 |
| CREB phosphorylation | 7 | 5.99e-01 | 0.115000 | 7.57e-01 |
| Neurotransmitter release cycle | 38 | 2.21e-01 | 0.115000 | 4.14e-01 |
| Downregulation of ERBB2 signaling | 24 | 3.31e-01 | -0.115000 | 5.31e-01 |
| HDR through MMEJ (alt-NHEJ) | 12 | 4.92e-01 | -0.115000 | 6.78e-01 |
| PI Metabolism | 79 | 7.86e-02 | 0.114000 | 2.17e-01 |
| G beta:gamma signalling through PI3Kgamma | 22 | 3.55e-01 | 0.114000 | 5.52e-01 |
| MECP2 regulates transcription of neuronal ligands | 5 | 6.61e-01 | -0.113000 | 7.92e-01 |
| Gene Silencing by RNA | 87 | 6.83e-02 | -0.113000 | 1.98e-01 |
| SUMOylation of intracellular receptors | 26 | 3.20e-01 | 0.113000 | 5.21e-01 |
| Interleukin-1 signaling | 99 | 5.28e-02 | 0.113000 | 1.69e-01 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | 9 | 5.59e-01 | -0.113000 | 7.29e-01 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 183 | 8.66e-03 | 0.113000 | 4.98e-02 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | 40 | 2.18e-01 | 0.112000 | 4.12e-01 |
| Signaling by RAS mutants | 40 | 2.18e-01 | 0.112000 | 4.12e-01 |
| Signaling by moderate kinase activity BRAF mutants | 40 | 2.18e-01 | 0.112000 | 4.12e-01 |
| Signaling downstream of RAS mutants | 40 | 2.18e-01 | 0.112000 | 4.12e-01 |
| TBC/RABGAPs | 45 | 1.92e-01 | 0.112000 | 3.83e-01 |
| PIP3 activates AKT signaling | 232 | 3.28e-03 | 0.112000 | 2.54e-02 |
| Regulation of RAS by GAPs | 55 | 1.52e-01 | 0.112000 | 3.32e-01 |
| Sensing of DNA Double Strand Breaks | 6 | 6.36e-01 | -0.112000 | 7.76e-01 |
| Apoptotic execution phase | 46 | 1.91e-01 | 0.112000 | 3.80e-01 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 32 | 2.75e-01 | 0.111000 | 4.76e-01 |
| Regulation of CDH11 gene transcription | 5 | 6.67e-01 | 0.111000 | 7.95e-01 |
| RND2 GTPase cycle | 36 | 2.49e-01 | 0.111000 | 4.47e-01 |
| Signaling by FGFR4 | 32 | 2.77e-01 | 0.111000 | 4.76e-01 |
| Impaired BRCA2 binding to RAD51 | 35 | 2.57e-01 | -0.111000 | 4.57e-01 |
| IRS-mediated signalling | 35 | 2.57e-01 | 0.111000 | 4.57e-01 |
| PI-3K cascade:FGFR1 | 13 | 4.90e-01 | 0.111000 | 6.76e-01 |
| Translation of Replicase and Assembly of the Replication Transcription Complex 9679504 | 12 | 5.08e-01 | -0.110000 | 6.91e-01 |
| Assembly and cell surface presentation of NMDA receptors | 30 | 2.96e-01 | 0.110000 | 4.95e-01 |
| Acetylcholine regulates insulin secretion | 9 | 5.67e-01 | 0.110000 | 7.35e-01 |
| PTK6 Regulates Cell Cycle | 6 | 6.41e-01 | 0.110000 | 7.80e-01 |
| MITF-M-regulated melanocyte development | 110 | 4.64e-02 | 0.110000 | 1.56e-01 |
| Metabolism of nucleotides | 86 | 7.84e-02 | -0.110000 | 2.17e-01 |
| Signaling by Non-Receptor Tyrosine Kinases | 47 | 1.94e-01 | 0.110000 | 3.84e-01 |
| Signaling by PTK6 | 47 | 1.94e-01 | 0.110000 | 3.84e-01 |
| Ovarian tumor domain proteases | 37 | 2.49e-01 | 0.109000 | 4.47e-01 |
| SHC-mediated cascade:FGFR2 | 13 | 4.95e-01 | 0.109000 | 6.79e-01 |
| Signaling by TGF-beta Receptor Complex | 90 | 7.38e-02 | 0.109000 | 2.08e-01 |
| Toll Like Receptor 2 (TLR2) Cascade | 109 | 4.94e-02 | 0.109000 | 1.62e-01 |
| Toll Like Receptor TLR1:TLR2 Cascade | 109 | 4.94e-02 | 0.109000 | 1.62e-01 |
| MHC class II antigen presentation | 113 | 4.56e-02 | 0.109000 | 1.56e-01 |
| Cytosolic tRNA aminoacylation | 24 | 3.57e-01 | -0.109000 | 5.54e-01 |
| RSK activation | 7 | 6.20e-01 | 0.108000 | 7.67e-01 |
| Signaling by NOTCH1 | 66 | 1.28e-01 | 0.108000 | 3.03e-01 |
| Diseases associated with the TLR signaling cascade | 29 | 3.13e-01 | 0.108000 | 5.15e-01 |
| Diseases of Immune System | 29 | 3.13e-01 | 0.108000 | 5.15e-01 |
| Glutamate Neurotransmitter Release Cycle | 20 | 4.03e-01 | 0.108000 | 5.97e-01 |
| Cellular response to hypoxia | 59 | 1.51e-01 | 0.108000 | 3.31e-01 |
| Golgi Associated Vesicle Biogenesis | 55 | 1.66e-01 | 0.108000 | 3.48e-01 |
| Intraflagellar transport | 47 | 2.01e-01 | -0.108000 | 3.96e-01 |
| TRP channels | 21 | 3.96e-01 | 0.107000 | 5.89e-01 |
| CLEC7A (Dectin-1) induces NFAT activation | 11 | 5.39e-01 | 0.107000 | 7.15e-01 |
| Signaling by Retinoic Acid | 29 | 3.25e-01 | -0.106000 | 5.26e-01 |
| Activation of BH3-only proteins | 29 | 3.25e-01 | -0.106000 | 5.26e-01 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 18 | 4.38e-01 | 0.106000 | 6.30e-01 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | 18 | 4.38e-01 | 0.106000 | 6.30e-01 |
| Miscellaneous transport and binding events | 20 | 4.15e-01 | 0.105000 | 6.11e-01 |
| SLC15A4:TASL-dependent IRF5 activation | 6 | 6.56e-01 | -0.105000 | 7.90e-01 |
| Aggrephagy | 34 | 2.89e-01 | 0.105000 | 4.88e-01 |
| Cargo trafficking to the periciliary membrane | 48 | 2.11e-01 | -0.104000 | 4.04e-01 |
| Nuclear signaling by ERBB4 | 24 | 3.77e-01 | 0.104000 | 5.73e-01 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | 117 | 5.18e-02 | 0.104000 | 1.68e-01 |
| RHOBTB1 GTPase cycle | 23 | 3.89e-01 | 0.104000 | 5.84e-01 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | 23 | 3.90e-01 | 0.104000 | 5.85e-01 |
| Late endosomal microautophagy | 30 | 3.26e-01 | 0.104000 | 5.27e-01 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 13 | 5.18e-01 | -0.103000 | 7.00e-01 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 108 | 6.49e-02 | 0.103000 | 1.91e-01 |
| Toll Like Receptor TLR6:TLR2 Cascade | 108 | 6.49e-02 | 0.103000 | 1.91e-01 |
| Activation of the phototransduction cascade | 8 | 6.16e-01 | 0.102000 | 7.66e-01 |
| Chaperonin-mediated protein folding | 77 | 1.21e-01 | 0.102000 | 2.90e-01 |
| RAF-independent MAPK1/3 activation | 21 | 4.17e-01 | 0.102000 | 6.13e-01 |
| Clathrin-mediated endocytosis | 127 | 4.72e-02 | 0.102000 | 1.58e-01 |
| Biosynthesis of DHA-derived SPMs | 13 | 5.25e-01 | 0.102000 | 7.06e-01 |
| Trafficking and processing of endosomal TLR | 13 | 5.27e-01 | 0.101000 | 7.07e-01 |
| Mitochondrial RNA degradation | 25 | 3.81e-01 | -0.101000 | 5.77e-01 |
| Synthesis of PG | 8 | 6.21e-01 | -0.101000 | 7.67e-01 |
| Immune System | 1828 | 9.26e-13 | 0.101000 | 4.34e-11 |
| HIV Infection | 213 | 1.18e-02 | -0.100000 | 6.23e-02 |
| Resolution of Sister Chromatid Cohesion | 115 | 6.37e-02 | 0.100000 | 1.89e-01 |
| Nitric oxide stimulates guanylate cyclase | 15 | 5.02e-01 | 0.100000 | 6.85e-01 |
| Role of second messengers in netrin-1 signaling | 6 | 6.72e-01 | 0.100000 | 7.99e-01 |
| Sensory processing of sound | 57 | 1.92e-01 | 0.099800 | 3.83e-01 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | 14 | 5.18e-01 | -0.099800 | 7.00e-01 |
| Adipogenesis | 95 | 9.35e-02 | 0.099600 | 2.46e-01 |
| Interleukin-17 signaling | 68 | 1.56e-01 | 0.099400 | 3.37e-01 |
| RUNX2 regulates genes involved in cell migration | 6 | 6.73e-01 | -0.099400 | 8.00e-01 |
| OAS antiviral response | 8 | 6.27e-01 | -0.099400 | 7.71e-01 |
| Intrinsic Pathway for Apoptosis | 53 | 2.12e-01 | -0.099100 | 4.05e-01 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | 8 | 6.28e-01 | -0.099000 | 7.71e-01 |
| Synthesis of IP3 and IP4 in the cytosol | 22 | 4.23e-01 | 0.098800 | 6.17e-01 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 21 | 4.33e-01 | 0.098700 | 6.29e-01 |
| Neurodegenerative Diseases | 21 | 4.33e-01 | 0.098700 | 6.29e-01 |
| AKT phosphorylates targets in the nucleus | 9 | 6.08e-01 | -0.098600 | 7.60e-01 |
| Amine ligand-binding receptors | 10 | 5.90e-01 | 0.098500 | 7.51e-01 |
| SCF(Skp2)-mediated degradation of p27/p21 | 50 | 2.28e-01 | 0.098500 | 4.21e-01 |
| Regulation of MITF-M-dependent genes involved in pigmentation | 35 | 3.17e-01 | 0.097800 | 5.18e-01 |
| Mismatch Repair | 15 | 5.13e-01 | -0.097700 | 6.96e-01 |
| Synthesis of DNA | 108 | 7.96e-02 | -0.097600 | 2.18e-01 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 16 | 5.02e-01 | -0.097000 | 6.85e-01 |
| Inflammasomes | 21 | 4.42e-01 | 0.096900 | 6.34e-01 |
| Negative feedback regulation of MAPK pathway | 6 | 6.81e-01 | 0.096800 | 8.06e-01 |
| RHOH GTPase cycle | 33 | 3.37e-01 | 0.096600 | 5.35e-01 |
| Dopamine Neurotransmitter Release Cycle | 20 | 4.55e-01 | 0.096500 | 6.45e-01 |
| Transport of small molecules | 548 | 1.15e-04 | 0.096400 | 1.72e-03 |
| FasL/ CD95L signaling | 5 | 7.10e-01 | -0.096100 | 8.26e-01 |
| NOTCH1 Intracellular Domain Regulates Transcription | 44 | 2.73e-01 | 0.095600 | 4.73e-01 |
| Cellular Senescence | 142 | 4.96e-02 | 0.095400 | 1.63e-01 |
| Sensory processing of sound by inner hair cells of the cochlea | 54 | 2.25e-01 | 0.095400 | 4.18e-01 |
| FRS-mediated FGFR1 signaling | 15 | 5.23e-01 | 0.095200 | 7.04e-01 |
| PCP/CE pathway | 74 | 1.59e-01 | 0.094700 | 3.41e-01 |
| Regulation of ornithine decarboxylase (ODC) | 38 | 3.13e-01 | 0.094500 | 5.15e-01 |
| Ribavirin ADME | 11 | 5.88e-01 | 0.094400 | 7.50e-01 |
| Membrane binding and targetting of GAG proteins | 13 | 5.56e-01 | -0.094200 | 7.29e-01 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | 13 | 5.56e-01 | -0.094200 | 7.29e-01 |
| Macroautophagy | 128 | 6.58e-02 | -0.094200 | 1.92e-01 |
| TNFR1-induced proapoptotic signaling | 24 | 4.25e-01 | 0.094000 | 6.20e-01 |
| RHOBTB2 GTPase cycle | 23 | 4.36e-01 | 0.093800 | 6.29e-01 |
| Transcriptional regulation by RUNX3 | 80 | 1.49e-01 | 0.093300 | 3.28e-01 |
| MAP kinase activation | 63 | 2.00e-01 | 0.093300 | 3.94e-01 |
| Carboxyterminal post-translational modifications of tubulin | 33 | 3.55e-01 | 0.093100 | 5.52e-01 |
| p75 NTR receptor-mediated signalling | 89 | 1.29e-01 | 0.093000 | 3.05e-01 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 13 | 5.62e-01 | 0.092800 | 7.32e-01 |
| Deubiquitination | 225 | 1.66e-02 | 0.092700 | 7.79e-02 |
| Chaperone Mediated Autophagy | 20 | 4.76e-01 | 0.092100 | 6.62e-01 |
| HDACs deacetylate histones | 45 | 2.86e-01 | 0.092000 | 4.84e-01 |
| Metal ion SLC transporters | 19 | 4.88e-01 | 0.091800 | 6.75e-01 |
| PI3K Cascade | 31 | 3.77e-01 | 0.091700 | 5.73e-01 |
| Other interleukin signaling | 18 | 5.01e-01 | 0.091700 | 6.85e-01 |
| Asparagine N-linked glycosylation | 284 | 7.90e-03 | 0.091600 | 4.68e-02 |
| Toll Like Receptor 3 (TLR3) Cascade | 104 | 1.07e-01 | 0.091600 | 2.68e-01 |
| Cyclin D associated events in G1 | 47 | 2.78e-01 | 0.091500 | 4.76e-01 |
| G1 Phase | 47 | 2.78e-01 | 0.091500 | 4.76e-01 |
| Cytokine Signaling in Immune system | 662 | 6.18e-05 | 0.091300 | 9.73e-04 |
| ABC-family proteins mediated transport | 81 | 1.57e-01 | 0.091000 | 3.38e-01 |
| Activation of NF-kappaB in B cells | 54 | 2.49e-01 | 0.090800 | 4.47e-01 |
| Mitochondrial unfolded protein response (UPRmt) | 17 | 5.19e-01 | -0.090400 | 7.00e-01 |
| Negative epigenetic regulation of rRNA expression | 63 | 2.15e-01 | -0.090300 | 4.09e-01 |
| Inactivation of CSF3 (G-CSF) signaling | 24 | 4.45e-01 | 0.090100 | 6.36e-01 |
| Lewis blood group biosynthesis | 13 | 5.74e-01 | -0.090000 | 7.41e-01 |
| Packaging Of Telomere Ends | 18 | 5.09e-01 | 0.089900 | 6.91e-01 |
| Oncogene Induced Senescence | 33 | 3.72e-01 | 0.089900 | 5.69e-01 |
| Retrograde neurotrophin signalling | 12 | 5.91e-01 | 0.089600 | 7.52e-01 |
| RHOBTB3 ATPase cycle | 10 | 6.24e-01 | 0.089500 | 7.68e-01 |
| Downstream signaling events of B Cell Receptor (BCR) | 68 | 2.03e-01 | 0.089400 | 3.97e-01 |
| Vitamin B5 (pantothenate) metabolism | 20 | 4.90e-01 | 0.089200 | 6.76e-01 |
| Sphingolipid de novo biosynthesis | 34 | 3.68e-01 | 0.089200 | 5.65e-01 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 24 | 4.50e-01 | 0.089100 | 6.41e-01 |
| NF-kB is activated and signals survival | 12 | 5.94e-01 | -0.088900 | 7.54e-01 |
| Cytosolic sensors of pathogen-associated DNA | 63 | 2.23e-01 | -0.088800 | 4.15e-01 |
| MyD88 cascade initiated on plasma membrane | 95 | 1.36e-01 | 0.088400 | 3.12e-01 |
| Toll Like Receptor 10 (TLR10) Cascade | 95 | 1.36e-01 | 0.088400 | 3.12e-01 |
| Toll Like Receptor 5 (TLR5) Cascade | 95 | 1.36e-01 | 0.088400 | 3.12e-01 |
| Hedgehog ligand biogenesis | 47 | 2.95e-01 | 0.088200 | 4.95e-01 |
| TRAIL signaling | 8 | 6.66e-01 | -0.088200 | 7.95e-01 |
| Regulation of signaling by NODAL | 6 | 7.09e-01 | -0.088100 | 8.26e-01 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | 5 | 7.33e-01 | -0.088000 | 8.45e-01 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | 10 | 6.30e-01 | 0.087900 | 7.72e-01 |
| Folding of actin by CCT/TriC | 10 | 6.31e-01 | -0.087700 | 7.73e-01 |
| SARS-CoV-2 Infection | 263 | 1.46e-02 | -0.087500 | 7.13e-02 |
| MyD88-independent TLR4 cascade | 108 | 1.16e-01 | 0.087500 | 2.82e-01 |
| TRIF (TICAM1)-mediated TLR4 signaling | 108 | 1.16e-01 | 0.087500 | 2.82e-01 |
| Early SARS-CoV-2 Infection Events | 30 | 4.09e-01 | 0.087100 | 6.05e-01 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 17 | 5.35e-01 | 0.087000 | 7.13e-01 |
| Beta-oxidation of pristanoyl-CoA | 9 | 6.52e-01 | -0.086900 | 7.88e-01 |
| Caspase activation via extrinsic apoptotic signalling pathway | 25 | 4.53e-01 | 0.086700 | 6.43e-01 |
| Zinc transporters | 12 | 6.03e-01 | 0.086700 | 7.60e-01 |
| Death Receptor Signaling | 145 | 7.33e-02 | 0.086200 | 2.07e-01 |
| Incretin synthesis, secretion, and inactivation | 14 | 5.78e-01 | 0.086000 | 7.42e-01 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 14 | 5.78e-01 | 0.086000 | 7.42e-01 |
| VEGFR2 mediated vascular permeability | 26 | 4.48e-01 | 0.085900 | 6.39e-01 |
| Reversal of alkylation damage by DNA dioxygenases | 7 | 6.94e-01 | -0.085800 | 8.17e-01 |
| Synthesis of PIPs at the late endosome membrane | 11 | 6.24e-01 | -0.085400 | 7.68e-01 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 28 | 4.35e-01 | 0.085300 | 6.29e-01 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 73 | 2.09e-01 | -0.085100 | 4.02e-01 |
| Visual phototransduction | 58 | 2.63e-01 | 0.085000 | 4.62e-01 |
| Drug ADME | 55 | 2.76e-01 | 0.085000 | 4.76e-01 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | 107 | 1.30e-01 | -0.084800 | 3.05e-01 |
| Spry regulation of FGF signaling | 16 | 5.59e-01 | 0.084400 | 7.29e-01 |
| Formyl peptide receptors bind formyl peptides and many other ligands | 7 | 6.99e-01 | 0.084300 | 8.20e-01 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | 14 | 5.86e-01 | 0.084000 | 7.48e-01 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | 14 | 5.86e-01 | 0.084000 | 7.48e-01 |
| Glycogen storage diseases | 13 | 6.00e-01 | -0.084000 | 7.58e-01 |
| Constitutive Signaling by AKT1 E17K in Cancer | 25 | 4.70e-01 | 0.083500 | 6.59e-01 |
| Cyclin E associated events during G1/S transition | 73 | 2.18e-01 | 0.083300 | 4.12e-01 |
| Senescence-Associated Secretory Phenotype (SASP) | 64 | 2.49e-01 | 0.083300 | 4.47e-01 |
| Ketone body metabolism | 8 | 6.85e-01 | -0.083000 | 8.08e-01 |
| Signaling by Activin | 13 | 6.05e-01 | -0.082900 | 7.60e-01 |
| LTC4-CYSLTR mediated IL4 production | 5 | 7.49e-01 | -0.082700 | 8.54e-01 |
| Signaling by NOTCH4 | 68 | 2.40e-01 | 0.082400 | 4.38e-01 |
| Defective CFTR causes cystic fibrosis | 47 | 3.30e-01 | 0.082100 | 5.30e-01 |
| RHOV GTPase cycle | 36 | 3.94e-01 | 0.082100 | 5.88e-01 |
| LDL clearance | 18 | 5.47e-01 | 0.081900 | 7.23e-01 |
| RUNX3 Regulates Immune Response and Cell Migration | 5 | 7.52e-01 | 0.081700 | 8.56e-01 |
| Activated NOTCH1 Transmits Signal to the Nucleus | 27 | 4.65e-01 | 0.081300 | 6.53e-01 |
| Costimulation by the CD28 family | 74 | 2.27e-01 | -0.081200 | 4.20e-01 |
| Inactivation, recovery and regulation of the phototransduction cascade | 25 | 4.82e-01 | -0.081200 | 6.69e-01 |
| Urea cycle | 6 | 7.31e-01 | 0.081200 | 8.43e-01 |
| IRAK2 mediated activation of TAK1 complex | 10 | 6.57e-01 | -0.081000 | 7.90e-01 |
| Pregnenolone biosynthesis | 10 | 6.59e-01 | -0.080700 | 7.91e-01 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | 18 | 5.55e-01 | -0.080400 | 7.29e-01 |
| Hh mutants are degraded by ERAD | 42 | 3.68e-01 | 0.080200 | 5.65e-01 |
| Cardiogenesis | 13 | 6.17e-01 | -0.080200 | 7.67e-01 |
| Metabolism of proteins | 1761 | 2.81e-08 | -0.079800 | 8.99e-07 |
| Bile acid and bile salt metabolism | 28 | 4.67e-01 | 0.079400 | 6.56e-01 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 66 | 2.65e-01 | -0.079400 | 4.64e-01 |
| CASP8 activity is inhibited | 11 | 6.49e-01 | -0.079400 | 7.85e-01 |
| Dimerization of procaspase-8 | 11 | 6.49e-01 | -0.079400 | 7.85e-01 |
| Regulation by c-FLIP | 11 | 6.49e-01 | -0.079400 | 7.85e-01 |
| TRAF6 mediated IRF7 activation | 15 | 5.95e-01 | 0.079300 | 7.54e-01 |
| Transcriptional Regulation by VENTX | 38 | 3.98e-01 | -0.079200 | 5.91e-01 |
| Mitotic G1 phase and G1/S transition | 138 | 1.10e-01 | 0.078800 | 2.73e-01 |
| Neddylation | 215 | 4.70e-02 | -0.078600 | 1.58e-01 |
| Degradation of GLI1 by the proteasome | 46 | 3.58e-01 | 0.078400 | 5.54e-01 |
| Small interfering RNA (siRNA) biogenesis | 9 | 6.84e-01 | -0.078300 | 8.08e-01 |
| Formation of definitive endoderm | 8 | 7.02e-01 | 0.078100 | 8.22e-01 |
| Proteasome assembly | 50 | 3.40e-01 | -0.078100 | 5.37e-01 |
| IFNG signaling activates MAPKs | 8 | 7.02e-01 | 0.078100 | 8.22e-01 |
| Diseases associated with glycosylation precursor biosynthesis | 15 | 6.03e-01 | -0.077700 | 7.60e-01 |
| Fertilization | 12 | 6.42e-01 | 0.077600 | 7.80e-01 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | 13 | 6.30e-01 | -0.077300 | 7.72e-01 |
| Ras activation upon Ca2+ influx through NMDA receptor | 15 | 6.05e-01 | 0.077200 | 7.60e-01 |
| Inositol phosphate metabolism | 42 | 3.87e-01 | 0.077200 | 5.82e-01 |
| RHO GTPases Activate Formins | 127 | 1.34e-01 | 0.077100 | 3.11e-01 |
| Protein folding | 83 | 2.25e-01 | 0.077000 | 4.18e-01 |
| Pyrimidine salvage | 10 | 6.74e-01 | 0.076900 | 8.01e-01 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 52 | 3.40e-01 | 0.076400 | 5.38e-01 |
| Regulation of localization of FOXO transcription factors | 11 | 6.61e-01 | 0.076200 | 7.92e-01 |
| Degradation of GLI2 by the proteasome | 45 | 3.76e-01 | 0.076200 | 5.73e-01 |
| GLI3 is processed to GLI3R by the proteasome | 45 | 3.76e-01 | 0.076200 | 5.73e-01 |
| UCH proteinases | 73 | 2.61e-01 | 0.076100 | 4.60e-01 |
| Signaling by Hedgehog | 120 | 1.51e-01 | 0.075900 | 3.31e-01 |
| Signaling by KIT in disease | 20 | 5.59e-01 | 0.075600 | 7.29e-01 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 20 | 5.59e-01 | 0.075600 | 7.29e-01 |
| Regulation of PTEN stability and activity | 55 | 3.33e-01 | 0.075500 | 5.32e-01 |
| Carnitine shuttle | 12 | 6.53e-01 | -0.074900 | 7.89e-01 |
| Response of Mtb to phagocytosis | 22 | 5.43e-01 | 0.074900 | 7.19e-01 |
| SUMOylation of immune response proteins | 12 | 6.55e-01 | 0.074500 | 7.90e-01 |
| Notch-HLH transcription pathway | 28 | 4.95e-01 | 0.074500 | 6.79e-01 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 6.19e-01 | -0.074200 | 7.67e-01 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | 6 | 7.53e-01 | -0.074100 | 8.57e-01 |
| Regulation of FZD by ubiquitination | 15 | 6.20e-01 | 0.074000 | 7.67e-01 |
| Viral Infection Pathways | 770 | 4.94e-04 | -0.073800 | 5.85e-03 |
| Caspase activation via Death Receptors in the presence of ligand | 16 | 6.11e-01 | -0.073500 | 7.61e-01 |
| Suppression of phagosomal maturation | 12 | 6.60e-01 | -0.073500 | 7.91e-01 |
| Phase 3 - rapid repolarisation | 7 | 7.39e-01 | 0.072800 | 8.49e-01 |
| Prefoldin mediated transfer of substrate to CCT/TriC | 25 | 5.29e-01 | 0.072700 | 7.08e-01 |
| Regulation of TP53 Degradation | 35 | 4.59e-01 | -0.072400 | 6.49e-01 |
| Negative regulation of FGFR3 signaling | 21 | 5.67e-01 | 0.072200 | 7.35e-01 |
| Cilium Assembly | 187 | 8.89e-02 | -0.072100 | 2.39e-01 |
| Sphingolipid metabolism | 92 | 2.32e-01 | 0.072100 | 4.26e-01 |
| Interferon gamma signaling | 87 | 2.45e-01 | -0.072100 | 4.45e-01 |
| NoRC negatively regulates rRNA expression | 60 | 3.37e-01 | -0.071600 | 5.35e-01 |
| SLC transporter disorders | 75 | 2.84e-01 | -0.071500 | 4.83e-01 |
| Activation of RAC1 | 11 | 6.82e-01 | 0.071400 | 8.06e-01 |
| Transcriptional regulation of testis differentiation | 5 | 7.82e-01 | -0.071300 | 8.74e-01 |
| Interferon Signaling | 237 | 5.95e-02 | -0.071100 | 1.82e-01 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | 16 | 6.23e-01 | 0.071100 | 7.68e-01 |
| Negative regulation of FGFR4 signaling | 22 | 5.65e-01 | 0.070800 | 7.34e-01 |
| Signaling by TGFBR3 | 39 | 4.46e-01 | 0.070600 | 6.37e-01 |
| Telomere Extension By Telomerase | 23 | 5.58e-01 | 0.070500 | 7.29e-01 |
| FOXO-mediated transcription of cell cycle genes | 14 | 6.48e-01 | 0.070500 | 7.85e-01 |
| mRNA decay by 5’ to 3’ exoribonuclease | 15 | 6.37e-01 | -0.070300 | 7.77e-01 |
| Transport of inorganic cations/anions and amino acids/oligopeptides | 78 | 2.83e-01 | 0.070200 | 4.82e-01 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 18 | 6.06e-01 | -0.070200 | 7.60e-01 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | 11 | 6.88e-01 | 0.070000 | 8.10e-01 |
| Hedgehog ‘on’ state | 65 | 3.30e-01 | 0.069800 | 5.30e-01 |
| RAF activation | 32 | 4.95e-01 | 0.069700 | 6.79e-01 |
| Meiotic synapsis | 43 | 4.30e-01 | 0.069600 | 6.25e-01 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 23 | 5.65e-01 | -0.069200 | 7.34e-01 |
| EML4 and NUDC in mitotic spindle formation | 106 | 2.18e-01 | 0.069200 | 4.12e-01 |
| Organelle biogenesis and maintenance | 278 | 4.73e-02 | -0.069100 | 1.58e-01 |
| MyD88 dependent cascade initiated on endosome | 101 | 2.30e-01 | 0.069100 | 4.24e-01 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 12 | 6.79e-01 | 0.069000 | 8.05e-01 |
| Downregulation of TGF-beta receptor signaling | 26 | 5.44e-01 | 0.068800 | 7.20e-01 |
| Autophagy | 142 | 1.60e-01 | -0.068300 | 3.41e-01 |
| Maturation of nucleoprotein 9694631 | 15 | 6.47e-01 | 0.068300 | 7.85e-01 |
| Aspartate and asparagine metabolism | 8 | 7.39e-01 | -0.068100 | 8.49e-01 |
| Selective autophagy | 77 | 3.05e-01 | -0.067700 | 5.05e-01 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 49 | 4.13e-01 | 0.067600 | 6.09e-01 |
| RNA polymerase II transcribes snRNA genes | 71 | 3.25e-01 | -0.067600 | 5.26e-01 |
| Antiviral mechanism by IFN-stimulated genes | 140 | 1.69e-01 | -0.067300 | 3.52e-01 |
| Nuclear Envelope Breakdown | 53 | 3.98e-01 | -0.067100 | 5.91e-01 |
| Hedgehog ‘off’ state | 91 | 2.68e-01 | 0.067100 | 4.68e-01 |
| Regulation of HSF1-mediated heat shock response | 78 | 3.06e-01 | -0.067000 | 5.07e-01 |
| Post NMDA receptor activation events | 60 | 3.70e-01 | 0.066900 | 5.67e-01 |
| Hh mutants abrogate ligand secretion | 43 | 4.48e-01 | 0.066900 | 6.39e-01 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 23 | 5.79e-01 | 0.066900 | 7.43e-01 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 105 | 2.37e-01 | 0.066800 | 4.33e-01 |
| Pyruvate metabolism | 44 | 4.43e-01 | -0.066800 | 6.35e-01 |
| SLC-mediated transmembrane transport | 171 | 1.32e-01 | 0.066700 | 3.08e-01 |
| Cyclin A:Cdk2-associated events at S phase entry | 75 | 3.19e-01 | 0.066500 | 5.21e-01 |
| Assembly Of The HIV Virion | 15 | 6.56e-01 | -0.066500 | 7.90e-01 |
| Inhibition of DNA recombination at telomere | 33 | 5.09e-01 | -0.066400 | 6.91e-01 |
| DNA Double-Strand Break Repair | 137 | 1.81e-01 | -0.066200 | 3.67e-01 |
| Activation of NMDA receptors and postsynaptic events | 70 | 3.39e-01 | 0.066100 | 5.37e-01 |
| trans-Golgi Network Vesicle Budding | 69 | 3.43e-01 | 0.066000 | 5.40e-01 |
| Activation of C3 and C5 | 7 | 7.62e-01 | -0.066000 | 8.62e-01 |
| HSF1 activation | 25 | 5.68e-01 | 0.065900 | 7.36e-01 |
| Acyl chain remodeling of CL | 5 | 7.99e-01 | 0.065700 | 8.84e-01 |
| Autodegradation of Cdh1 by Cdh1:APC/C | 54 | 4.04e-01 | -0.065600 | 5.98e-01 |
| Receptor-type tyrosine-protein phosphatases | 11 | 7.07e-01 | 0.065600 | 8.26e-01 |
| Signaling by FGFR1 | 42 | 4.63e-01 | 0.065400 | 6.52e-01 |
| MTOR signalling | 39 | 4.80e-01 | -0.065300 | 6.67e-01 |
| Positive epigenetic regulation of rRNA expression | 60 | 3.82e-01 | -0.065200 | 5.77e-01 |
| G2/M Checkpoints | 126 | 2.07e-01 | 0.065200 | 3.99e-01 |
| Wax and plasmalogen biosynthesis | 5 | 8.01e-01 | 0.065100 | 8.85e-01 |
| Sensory processing of sound by outer hair cells of the cochlea | 40 | 4.77e-01 | 0.065000 | 6.63e-01 |
| Defects in cobalamin (B12) metabolism | 13 | 6.85e-01 | -0.064900 | 8.09e-01 |
| Negative regulation of MAPK pathway | 42 | 4.67e-01 | 0.064800 | 6.56e-01 |
| Degradation of DVL | 43 | 4.64e-01 | 0.064600 | 6.53e-01 |
| Metabolism | 1808 | 5.48e-06 | -0.064500 | 1.20e-04 |
| Infection with Mycobacterium tuberculosis | 26 | 5.70e-01 | 0.064300 | 7.37e-01 |
| Signaling by FGFR2 in disease | 33 | 5.23e-01 | -0.064200 | 7.04e-01 |
| Transcriptional regulation by RUNX2 | 87 | 3.02e-01 | 0.064100 | 5.01e-01 |
| E2F mediated regulation of DNA replication | 22 | 6.03e-01 | -0.064000 | 7.60e-01 |
| Regulation of TP53 Activity through Acetylation | 29 | 5.51e-01 | -0.063900 | 7.27e-01 |
| RSV-host interactions | 76 | 3.36e-01 | -0.063800 | 5.35e-01 |
| C-type lectin receptors (CLRs) | 116 | 2.36e-01 | 0.063700 | 4.32e-01 |
| CDH11 homotypic and heterotypic interactions | 5 | 8.07e-01 | 0.063100 | 8.90e-01 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 100 | 2.76e-01 | 0.063000 | 4.76e-01 |
| Cell-cell junction organization | 56 | 4.19e-01 | 0.062400 | 6.15e-01 |
| DNA Replication Pre-Initiation | 103 | 2.76e-01 | -0.062100 | 4.76e-01 |
| G2/M Transition | 177 | 1.55e-01 | 0.061900 | 3.36e-01 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 20 | 6.32e-01 | -0.061900 | 7.73e-01 |
| Formation of RNA Pol II elongation complex | 56 | 4.24e-01 | -0.061800 | 6.18e-01 |
| RNA Polymerase II Transcription Elongation | 56 | 4.24e-01 | -0.061800 | 6.18e-01 |
| Mitochondrial biogenesis | 91 | 3.09e-01 | -0.061800 | 5.10e-01 |
| Calnexin/calreticulin cycle | 26 | 5.86e-01 | 0.061700 | 7.48e-01 |
| Mitotic G2-G2/M phases | 179 | 1.57e-01 | 0.061300 | 3.38e-01 |
| Negative regulation of FGFR2 signaling | 24 | 6.04e-01 | 0.061200 | 7.60e-01 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 56 | 4.34e-01 | 0.060400 | 6.29e-01 |
| Base-Excision Repair, AP Site Formation | 28 | 5.80e-01 | -0.060400 | 7.43e-01 |
| Regulation of TLR by endogenous ligand | 15 | 6.87e-01 | 0.060100 | 8.10e-01 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | 16 | 6.78e-01 | 0.059900 | 8.04e-01 |
| Beta-oxidation of very long chain fatty acids | 11 | 7.31e-01 | 0.059800 | 8.43e-01 |
| Triglyceride biosynthesis | 9 | 7.56e-01 | 0.059800 | 8.59e-01 |
| Developmental Biology | 906 | 2.35e-03 | 0.059600 | 1.96e-02 |
| Acetylcholine Neurotransmitter Release Cycle | 11 | 7.32e-01 | -0.059600 | 8.44e-01 |
| Metabolism of lipids | 632 | 1.06e-02 | 0.059600 | 5.80e-02 |
| Nuclear Events (kinase and transcription factor activation) | 54 | 4.54e-01 | 0.058900 | 6.44e-01 |
| Regulation of TP53 Activity | 151 | 2.13e-01 | -0.058800 | 4.06e-01 |
| A tetrasaccharide linker sequence is required for GAG synthesis | 16 | 6.85e-01 | 0.058700 | 8.08e-01 |
| AURKA Activation by TPX2 | 72 | 3.91e-01 | 0.058500 | 5.85e-01 |
| NGF-stimulated transcription | 32 | 5.67e-01 | 0.058500 | 7.35e-01 |
| DNA Replication | 128 | 2.57e-01 | -0.058000 | 4.57e-01 |
| RNA Polymerase II Pre-transcription Events | 77 | 3.79e-01 | -0.058000 | 5.74e-01 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | 15 | 6.98e-01 | 0.057900 | 8.19e-01 |
| Maturation of hRSV A proteins | 13 | 7.19e-01 | 0.057600 | 8.35e-01 |
| IRAK1 recruits IKK complex | 14 | 7.10e-01 | -0.057500 | 8.26e-01 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 14 | 7.10e-01 | -0.057500 | 8.26e-01 |
| RMTs methylate histone arginines | 35 | 5.57e-01 | -0.057400 | 7.29e-01 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 39 | 5.37e-01 | 0.057100 | 7.14e-01 |
| p53-Independent DNA Damage Response | 39 | 5.37e-01 | 0.057100 | 7.14e-01 |
| p53-Independent G1/S DNA damage checkpoint | 39 | 5.37e-01 | 0.057100 | 7.14e-01 |
| Oncogenic MAPK signaling | 75 | 3.94e-01 | 0.057000 | 5.88e-01 |
| Deactivation of the beta-catenin transactivating complex | 36 | 5.56e-01 | 0.056800 | 7.29e-01 |
| Vitamin B2 (riboflavin) metabolism | 6 | 8.10e-01 | -0.056600 | 8.91e-01 |
| Toll Like Receptor 9 (TLR9) Cascade | 108 | 3.10e-01 | 0.056500 | 5.12e-01 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 10 | 7.57e-01 | 0.056400 | 8.59e-01 |
| Lipophagy | 7 | 7.96e-01 | -0.056400 | 8.83e-01 |
| Adaptive Immune System | 765 | 8.32e-03 | 0.056100 | 4.86e-02 |
| Heparan sulfate/heparin (HS-GAG) metabolism | 39 | 5.46e-01 | -0.055800 | 7.22e-01 |
| The role of Nef in HIV-1 replication and disease pathogenesis | 28 | 6.10e-01 | 0.055700 | 7.61e-01 |
| E2F-enabled inhibition of pre-replication complex formation | 9 | 7.73e-01 | 0.055600 | 8.68e-01 |
| Nucleotide salvage | 21 | 6.60e-01 | 0.055500 | 7.91e-01 |
| Paracetamol ADME | 19 | 6.78e-01 | 0.055100 | 8.04e-01 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 37 | 5.66e-01 | 0.054600 | 7.34e-01 |
| Alpha-protein kinase 1 signaling pathway | 11 | 7.54e-01 | 0.054500 | 8.58e-01 |
| Ub-specific processing proteases | 153 | 2.45e-01 | 0.054500 | 4.44e-01 |
| SARS-CoV-1 activates/modulates innate immune responses | 40 | 5.51e-01 | -0.054500 | 7.27e-01 |
| IL-6-type cytokine receptor ligand interactions | 12 | 7.46e-01 | 0.054100 | 8.53e-01 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | 11 | 7.56e-01 | -0.054000 | 8.59e-01 |
| Xenobiotics | 9 | 7.79e-01 | 0.053900 | 8.72e-01 |
| Signaling by BRAF and RAF1 fusions | 59 | 4.75e-01 | 0.053800 | 6.62e-01 |
| Phospholipid metabolism | 182 | 2.13e-01 | 0.053500 | 4.06e-01 |
| RND1 GTPase cycle | 36 | 5.80e-01 | 0.053200 | 7.43e-01 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | 7 | 8.08e-01 | 0.053200 | 8.90e-01 |
| Cellular response to heat stress | 92 | 3.79e-01 | -0.053100 | 5.74e-01 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | 42 | 5.55e-01 | 0.052700 | 7.29e-01 |
| Regulation of TP53 Activity through Phosphorylation | 88 | 3.94e-01 | -0.052600 | 5.88e-01 |
| Cell death signalling via NRAGE, NRIF and NADE | 69 | 4.52e-01 | 0.052300 | 6.43e-01 |
| Nicotinate metabolism | 26 | 6.44e-01 | 0.052300 | 7.82e-01 |
| NCAM signaling for neurite out-growth | 47 | 5.38e-01 | 0.052000 | 7.14e-01 |
| Regulation of pyruvate metabolism | 32 | 6.11e-01 | 0.052000 | 7.61e-01 |
| Nicotinamide salvaging | 15 | 7.29e-01 | 0.051700 | 8.42e-01 |
| cGMP effects | 12 | 7.57e-01 | 0.051600 | 8.59e-01 |
| G2/M DNA damage checkpoint | 66 | 4.69e-01 | 0.051600 | 6.57e-01 |
| CDC6 association with the ORC:origin complex | 8 | 8.01e-01 | -0.051500 | 8.85e-01 |
| NADE modulates death signalling | 5 | 8.45e-01 | 0.050500 | 9.13e-01 |
| Regulation of TNFR1 signaling | 47 | 5.50e-01 | 0.050500 | 7.25e-01 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | 34 | 6.12e-01 | -0.050200 | 7.62e-01 |
| FGFRL1 modulation of FGFR1 signaling | 7 | 8.21e-01 | 0.049300 | 8.98e-01 |
| PKMTs methylate histone lysines | 42 | 5.80e-01 | 0.049300 | 7.43e-01 |
| Negative regulation of NOTCH4 signaling | 44 | 5.75e-01 | 0.048800 | 7.42e-01 |
| Caspase-mediated cleavage of cytoskeletal proteins | 12 | 7.70e-01 | 0.048800 | 8.67e-01 |
| Chondroitin sulfate/dermatan sulfate metabolism | 37 | 6.10e-01 | 0.048400 | 7.61e-01 |
| Signaling by FGFR2 | 61 | 5.19e-01 | -0.047800 | 7.00e-01 |
| Homology Directed Repair | 110 | 3.90e-01 | -0.047400 | 5.85e-01 |
| Signaling by NOTCH2 | 33 | 6.40e-01 | 0.047000 | 7.79e-01 |
| Metabolic disorders of biological oxidation enzymes | 23 | 6.97e-01 | 0.046900 | 8.18e-01 |
| TICAM1-dependent activation of IRF3/IRF7 | 13 | 7.70e-01 | -0.046900 | 8.67e-01 |
| SCF-beta-TrCP mediated degradation of Emi1 | 42 | 6.00e-01 | 0.046800 | 7.58e-01 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 30 | 6.58e-01 | 0.046700 | 7.91e-01 |
| Apoptosis induced DNA fragmentation | 10 | 7.99e-01 | -0.046500 | 8.84e-01 |
| IKK complex recruitment mediated by RIP1 | 23 | 7.01e-01 | 0.046200 | 8.22e-01 |
| Protein ubiquitination | 71 | 5.05e-01 | 0.045700 | 6.88e-01 |
| Regulation of TP53 Expression and Degradation | 36 | 6.36e-01 | -0.045600 | 7.76e-01 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | 9 | 8.14e-01 | 0.045400 | 8.94e-01 |
| Estrogen-stimulated signaling through PRKCZ | 6 | 8.47e-01 | 0.045400 | 9.13e-01 |
| The canonical retinoid cycle in rods (twilight vision) | 9 | 8.14e-01 | 0.045200 | 8.94e-01 |
| Basigin interactions | 21 | 7.21e-01 | 0.045100 | 8.35e-01 |
| CLEC7A (Dectin-1) signaling | 85 | 4.74e-01 | 0.045000 | 6.61e-01 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 64 | 5.35e-01 | 0.044800 | 7.13e-01 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | 41 | 6.21e-01 | 0.044700 | 7.67e-01 |
| Synthesis of GDP-mannose | 6 | 8.51e-01 | -0.044400 | 9.14e-01 |
| Cellular hexose transport | 14 | 7.74e-01 | 0.044400 | 8.69e-01 |
| Nef Mediated CD4 Down-regulation | 9 | 8.18e-01 | 0.044300 | 8.95e-01 |
| Asymmetric localization of PCP proteins | 49 | 5.92e-01 | 0.044300 | 7.52e-01 |
| HCMV Early Events | 84 | 4.84e-01 | -0.044100 | 6.72e-01 |
| Metabolism of porphyrins | 22 | 7.20e-01 | 0.044100 | 8.35e-01 |
| ABC transporters in lipid homeostasis | 14 | 7.78e-01 | -0.043600 | 8.71e-01 |
| Diseases associated with glycosaminoglycan metabolism | 24 | 7.14e-01 | 0.043200 | 8.30e-01 |
| Androgen biosynthesis | 5 | 8.67e-01 | 0.043100 | 9.26e-01 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | 11 | 8.04e-01 | -0.043100 | 8.88e-01 |
| Programmed Cell Death | 186 | 3.17e-01 | 0.042500 | 5.18e-01 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 41 | 6.38e-01 | 0.042400 | 7.78e-01 |
| NCAM1 interactions | 26 | 7.08e-01 | -0.042400 | 8.26e-01 |
| Separation of Sister Chromatids | 167 | 3.47e-01 | 0.042200 | 5.44e-01 |
| Mitotic Prometaphase | 192 | 3.14e-01 | 0.042100 | 5.15e-01 |
| Intra-Golgi traffic | 43 | 6.34e-01 | 0.041900 | 7.76e-01 |
| RUNX2 regulates osteoblast differentiation | 16 | 7.72e-01 | 0.041900 | 8.68e-01 |
| Ubiquitin-dependent degradation of Cyclin D | 39 | 6.53e-01 | 0.041500 | 7.89e-01 |
| PTEN Regulation | 126 | 4.21e-01 | 0.041500 | 6.17e-01 |
| APC/C:Cdc20 mediated degradation of Securin | 55 | 5.96e-01 | -0.041300 | 7.55e-01 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | 17 | 7.70e-01 | 0.040900 | 8.67e-01 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 53 | 6.08e-01 | 0.040700 | 7.60e-01 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | 53 | 6.08e-01 | 0.040700 | 7.60e-01 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 53 | 6.08e-01 | 0.040700 | 7.60e-01 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | 53 | 6.08e-01 | 0.040700 | 7.60e-01 |
| Signaling by NOTCH1 in Cancer | 53 | 6.08e-01 | 0.040700 | 7.60e-01 |
| TGFBR3 PTM regulation | 10 | 8.24e-01 | 0.040700 | 8.99e-01 |
| Killing mechanisms | 9 | 8.33e-01 | 0.040500 | 9.06e-01 |
| WNT5:FZD7-mediated leishmania damping | 9 | 8.33e-01 | 0.040500 | 9.06e-01 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | 16 | 7.79e-01 | 0.040500 | 8.72e-01 |
| FASTK family proteins regulate processing and stability of mitochondrial RNAs | 19 | 7.61e-01 | -0.040300 | 8.61e-01 |
| Cell Cycle, Mitotic | 487 | 1.33e-01 | 0.039800 | 3.08e-01 |
| TNF signaling | 56 | 6.06e-01 | 0.039800 | 7.60e-01 |
| Signaling by activated point mutants of FGFR1 | 5 | 8.78e-01 | -0.039500 | 9.35e-01 |
| Glutathione conjugation | 26 | 7.30e-01 | 0.039100 | 8.43e-01 |
| Switching of origins to a post-replicative state | 79 | 5.48e-01 | -0.039100 | 7.24e-01 |
| Glycogen metabolism | 21 | 7.57e-01 | 0.039000 | 8.59e-01 |
| Chromatin modifying enzymes | 213 | 3.27e-01 | 0.039000 | 5.27e-01 |
| Chromatin organization | 213 | 3.27e-01 | 0.039000 | 5.27e-01 |
| Unwinding of DNA | 12 | 8.16e-01 | -0.038800 | 8.94e-01 |
| Aflatoxin activation and detoxification | 14 | 8.02e-01 | 0.038800 | 8.86e-01 |
| Vitamin D (calciferol) metabolism | 10 | 8.33e-01 | 0.038400 | 9.06e-01 |
| G1/S DNA Damage Checkpoints | 54 | 6.27e-01 | 0.038200 | 7.71e-01 |
| Association of TriC/CCT with target proteins during biosynthesis | 35 | 6.96e-01 | -0.038100 | 8.18e-01 |
| HCMV Late Events | 67 | 5.92e-01 | -0.037900 | 7.52e-01 |
| Regulation of Apoptosis | 40 | 6.79e-01 | 0.037800 | 8.05e-01 |
| Amino acid transport across the plasma membrane | 24 | 7.49e-01 | -0.037800 | 8.54e-01 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | 76 | 5.72e-01 | -0.037500 | 7.39e-01 |
| Mitotic Anaphase | 210 | 3.49e-01 | 0.037500 | 5.46e-01 |
| Plasma lipoprotein clearance | 33 | 7.10e-01 | 0.037500 | 8.26e-01 |
| Glycogen synthesis | 11 | 8.30e-01 | -0.037500 | 9.03e-01 |
| Signaling by Hippo | 18 | 7.84e-01 | 0.037400 | 8.74e-01 |
| Negative regulation of FGFR1 signaling | 25 | 7.47e-01 | 0.037200 | 8.53e-01 |
| CTLA4 inhibitory signaling | 21 | 7.68e-01 | -0.037200 | 8.67e-01 |
| Glyoxylate metabolism and glycine degradation | 13 | 8.17e-01 | -0.037100 | 8.94e-01 |
| Transcriptional activation of mitochondrial biogenesis | 52 | 6.44e-01 | 0.037000 | 7.82e-01 |
| Nef mediated downregulation of MHC class I complex cell surface expression | 10 | 8.40e-01 | -0.037000 | 9.10e-01 |
| Metabolism of water-soluble vitamins and cofactors | 114 | 4.96e-01 | -0.037000 | 6.79e-01 |
| Mitotic Metaphase and Anaphase | 211 | 3.60e-01 | 0.036500 | 5.56e-01 |
| Metabolism of polyamines | 46 | 6.68e-01 | 0.036500 | 7.97e-01 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | 63 | 6.20e-01 | 0.036100 | 7.67e-01 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | 9 | 8.51e-01 | -0.036100 | 9.14e-01 |
| Energy dependent regulation of mTOR by LKB1-AMPK | 27 | 7.46e-01 | -0.036000 | 8.53e-01 |
| MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 7.29e-01 | 0.035900 | 8.42e-01 |
| Prevention of phagosomal-lysosomal fusion | 9 | 8.52e-01 | -0.035800 | 9.14e-01 |
| Retrograde transport at the Trans-Golgi-Network | 49 | 6.65e-01 | -0.035800 | 7.95e-01 |
| M Phase | 345 | 2.61e-01 | 0.035200 | 4.61e-01 |
| G1/S Transition | 120 | 5.07e-01 | 0.035100 | 6.90e-01 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 35 | 7.20e-01 | -0.035000 | 8.35e-01 |
| Metabolism of carbohydrates | 236 | 3.56e-01 | 0.034900 | 5.53e-01 |
| G-protein beta:gamma signalling | 29 | 7.46e-01 | 0.034800 | 8.53e-01 |
| Loss of Nlp from mitotic centrosomes | 69 | 6.21e-01 | 0.034400 | 7.67e-01 |
| Loss of proteins required for interphase microtubule organization from the centrosome | 69 | 6.21e-01 | 0.034400 | 7.67e-01 |
| Glucose metabolism | 76 | 6.06e-01 | 0.034200 | 7.60e-01 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 27 | 7.60e-01 | 0.034000 | 8.60e-01 |
| Nuclear Envelope (NE) Reassembly | 68 | 6.30e-01 | 0.033800 | 7.72e-01 |
| Meiotic recombination | 36 | 7.26e-01 | -0.033700 | 8.40e-01 |
| Azathioprine ADME | 20 | 7.95e-01 | 0.033600 | 8.82e-01 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | 42 | 7.07e-01 | 0.033600 | 8.26e-01 |
| TRAF3-dependent IRF activation pathway | 13 | 8.35e-01 | 0.033300 | 9.06e-01 |
| TRAF6 mediated NF-kB activation | 23 | 7.83e-01 | -0.033100 | 8.74e-01 |
| Diseases of metabolism | 198 | 4.27e-01 | -0.032700 | 6.21e-01 |
| Translation of Structural Proteins 9683701 | 29 | 7.61e-01 | 0.032700 | 8.61e-01 |
| Assembly of the ORC complex at the origin of replication | 23 | 7.87e-01 | 0.032600 | 8.75e-01 |
| HCMV Infection | 106 | 5.64e-01 | -0.032500 | 7.33e-01 |
| Synthesis of substrates in N-glycan biosythesis | 58 | 6.71e-01 | -0.032300 | 7.99e-01 |
| Fatty acid metabolism | 152 | 4.93e-01 | -0.032200 | 6.78e-01 |
| LGI-ADAM interactions | 9 | 8.68e-01 | -0.032100 | 9.26e-01 |
| S Phase | 150 | 4.98e-01 | -0.032100 | 6.82e-01 |
| Bicarbonate transporters | 9 | 8.70e-01 | -0.031500 | 9.27e-01 |
| Maturation of nucleoprotein 9683610 | 11 | 8.57e-01 | 0.031500 | 9.18e-01 |
| PRC2 methylates histones and DNA | 27 | 7.78e-01 | 0.031400 | 8.71e-01 |
| PKR-mediated signaling | 67 | 6.57e-01 | 0.031400 | 7.90e-01 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 12 | 8.52e-01 | -0.031200 | 9.14e-01 |
| Antigen processing: Ubiquitination & Proteasome degradation | 275 | 3.74e-01 | -0.031100 | 5.71e-01 |
| Signaling by FGFR | 73 | 6.49e-01 | -0.030800 | 7.85e-01 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 46 | 7.19e-01 | 0.030600 | 8.35e-01 |
| Assembly of the pre-replicative complex | 87 | 6.25e-01 | -0.030400 | 7.69e-01 |
| mTORC1-mediated signalling | 24 | 7.99e-01 | -0.030100 | 8.84e-01 |
| ER-Phagosome pathway | 74 | 6.56e-01 | -0.029900 | 7.90e-01 |
| Mitotic Spindle Checkpoint | 107 | 5.93e-01 | -0.029900 | 7.53e-01 |
| Phospholipase C-mediated cascade; FGFR4 | 6 | 9.00e-01 | 0.029700 | 9.50e-01 |
| Glutamate and glutamine metabolism | 12 | 8.59e-01 | -0.029700 | 9.19e-01 |
| Glycosphingolipid metabolism | 47 | 7.25e-01 | 0.029700 | 8.39e-01 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 30 | 7.78e-01 | 0.029700 | 8.71e-01 |
| Lysosphingolipid and LPA receptors | 11 | 8.66e-01 | 0.029500 | 9.25e-01 |
| Acyl chain remodelling of PE | 19 | 8.25e-01 | -0.029300 | 9.00e-01 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 61 | 6.94e-01 | -0.029100 | 8.17e-01 |
| Reproduction | 84 | 6.45e-01 | 0.029100 | 7.82e-01 |
| Apoptosis | 157 | 5.29e-01 | 0.029100 | 7.08e-01 |
| Downstream TCR signaling | 89 | 6.35e-01 | -0.029100 | 7.76e-01 |
| Nucleotide catabolism | 29 | 7.89e-01 | -0.028800 | 8.77e-01 |
| Sperm Motility And Taxes | 6 | 9.03e-01 | -0.028700 | 9.51e-01 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | 36 | 7.68e-01 | -0.028400 | 8.67e-01 |
| APC/C-mediated degradation of cell cycle proteins | 75 | 6.72e-01 | 0.028300 | 7.99e-01 |
| Regulation of mitotic cell cycle | 75 | 6.72e-01 | 0.028300 | 7.99e-01 |
| Metabolism of folate and pterines | 16 | 8.47e-01 | -0.027800 | 9.13e-01 |
| Diseases of programmed cell death | 58 | 7.20e-01 | -0.027300 | 8.35e-01 |
| Phospholipase C-mediated cascade; FGFR3 | 5 | 9.17e-01 | 0.027100 | 9.59e-01 |
| p53-Dependent G1 DNA Damage Response | 52 | 7.37e-01 | 0.026900 | 8.48e-01 |
| p53-Dependent G1/S DNA damage checkpoint | 52 | 7.37e-01 | 0.026900 | 8.48e-01 |
| Biological oxidations | 135 | 5.89e-01 | -0.026900 | 7.51e-01 |
| Effects of PIP2 hydrolysis | 24 | 8.20e-01 | -0.026900 | 8.97e-01 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 104 | 6.39e-01 | -0.026700 | 7.78e-01 |
| Endogenous sterols | 17 | 8.49e-01 | 0.026600 | 9.13e-01 |
| Regulation of endogenous retroelements | 92 | 6.59e-01 | 0.026600 | 7.91e-01 |
| E3 ubiquitin ligases ubiquitinate target proteins | 51 | 7.45e-01 | 0.026300 | 8.53e-01 |
| Receptor Mediated Mitophagy | 11 | 8.80e-01 | 0.026300 | 9.35e-01 |
| Cleavage of the damaged purine | 21 | 8.35e-01 | -0.026200 | 9.06e-01 |
| Depurination | 21 | 8.35e-01 | -0.026200 | 9.06e-01 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 21 | 8.35e-01 | -0.026200 | 9.06e-01 |
| HATs acetylate histones | 92 | 6.66e-01 | -0.026000 | 7.95e-01 |
| Cellular responses to stress | 694 | 2.44e-01 | -0.026000 | 4.44e-01 |
| TP53 Regulates Metabolic Genes | 77 | 6.94e-01 | 0.025900 | 8.17e-01 |
| Synthesis of bile acids and bile salts | 25 | 8.23e-01 | 0.025900 | 8.99e-01 |
| Deposition of new CENPA-containing nucleosomes at the centromere | 37 | 7.85e-01 | -0.025900 | 8.74e-01 |
| Nucleosome assembly | 37 | 7.85e-01 | -0.025900 | 8.74e-01 |
| Transcriptional Regulation by TP53 | 343 | 4.15e-01 | -0.025600 | 6.11e-01 |
| Amino acids regulate mTORC1 | 48 | 7.60e-01 | 0.025500 | 8.60e-01 |
| Evasion by RSV of host interferon responses | 20 | 8.44e-01 | -0.025400 | 9.12e-01 |
| Resolution of D-Loop Structures | 35 | 7.95e-01 | -0.025400 | 8.82e-01 |
| DNA Double Strand Break Response | 47 | 7.64e-01 | 0.025300 | 8.63e-01 |
| Respiratory Syncytial Virus Infection Pathway | 97 | 6.66e-01 | -0.025300 | 7.95e-01 |
| Protein-protein interactions at synapses | 54 | 7.51e-01 | 0.025000 | 8.55e-01 |
| Noncanonical activation of NOTCH3 | 8 | 9.03e-01 | 0.024900 | 9.51e-01 |
| Anchoring of the basal body to the plasma membrane | 97 | 6.75e-01 | -0.024700 | 8.01e-01 |
| Gene expression (Transcription) | 1391 | 1.27e-01 | -0.024400 | 3.02e-01 |
| RIPK1-mediated regulated necrosis | 31 | 8.16e-01 | 0.024100 | 8.94e-01 |
| Regulation of necroptotic cell death | 31 | 8.16e-01 | 0.024100 | 8.94e-01 |
| Antigen processing-Cross presentation | 88 | 6.97e-01 | 0.024000 | 8.18e-01 |
| TAK1-dependent IKK and NF-kappa-B activation | 43 | 7.86e-01 | 0.024000 | 8.74e-01 |
| Transcriptional regulation of brown and beige adipocyte differentiation | 23 | 8.42e-01 | 0.023900 | 9.11e-01 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | 23 | 8.42e-01 | 0.023900 | 9.11e-01 |
| Autodegradation of the E3 ubiquitin ligase COP1 | 38 | 7.99e-01 | 0.023900 | 8.84e-01 |
| Synaptic adhesion-like molecules | 14 | 8.79e-01 | 0.023500 | 9.35e-01 |
| Passive transport by Aquaporins | 6 | 9.21e-01 | -0.023500 | 9.61e-01 |
| EPH-ephrin mediated repulsion of cells | 42 | 7.93e-01 | 0.023400 | 8.81e-01 |
| Norepinephrine Neurotransmitter Release Cycle | 14 | 8.80e-01 | 0.023200 | 9.35e-01 |
| TNFs bind their physiological receptors | 25 | 8.41e-01 | 0.023200 | 9.10e-01 |
| Interleukin-23 signaling | 7 | 9.16e-01 | -0.023100 | 9.59e-01 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | 7 | 9.16e-01 | -0.023000 | 9.59e-01 |
| Regulation of APC/C activators between G1/S and early anaphase | 68 | 7.44e-01 | 0.022900 | 8.53e-01 |
| Recruitment of NuMA to mitotic centrosomes | 88 | 7.10e-01 | 0.022900 | 8.26e-01 |
| SHC-mediated cascade:FGFR1 | 13 | 8.87e-01 | 0.022800 | 9.41e-01 |
| Glycolysis | 68 | 7.47e-01 | 0.022600 | 8.53e-01 |
| Pyroptosis | 24 | 8.50e-01 | -0.022300 | 9.14e-01 |
| RAS processing | 23 | 8.54e-01 | -0.022100 | 9.16e-01 |
| SARS-CoV Infections | 428 | 4.36e-01 | -0.022000 | 6.29e-01 |
| GABA synthesis, release, reuptake and degradation | 12 | 8.96e-01 | -0.021800 | 9.48e-01 |
| SUMOylation | 167 | 6.28e-01 | -0.021700 | 7.71e-01 |
| Cell Cycle Checkpoints | 245 | 5.59e-01 | 0.021700 | 7.29e-01 |
| Regulation of PTEN gene transcription | 59 | 7.74e-01 | -0.021600 | 8.69e-01 |
| Diseases of glycosylation | 104 | 7.08e-01 | 0.021300 | 8.26e-01 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 11 | 9.03e-01 | 0.021200 | 9.51e-01 |
| Activation of PUMA and translocation to mitochondria | 8 | 9.18e-01 | -0.021000 | 9.59e-01 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | 9 | 9.15e-01 | -0.020500 | 9.59e-01 |
| Interleukin-1 processing | 8 | 9.20e-01 | -0.020500 | 9.61e-01 |
| Activation of HOX genes during differentiation | 68 | 7.71e-01 | -0.020400 | 8.67e-01 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | 68 | 7.71e-01 | -0.020400 | 8.67e-01 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 61 | 7.84e-01 | 0.020300 | 8.74e-01 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 90 | 7.42e-01 | 0.020100 | 8.51e-01 |
| Amplification of signal from the kinetochores | 90 | 7.42e-01 | 0.020100 | 8.51e-01 |
| TRIF-mediated programmed cell death | 9 | 9.17e-01 | -0.020100 | 9.59e-01 |
| Regulation of PLK1 Activity at G2/M Transition | 87 | 7.47e-01 | 0.020000 | 8.53e-01 |
| Keratan sulfate degradation | 9 | 9.17e-01 | -0.020000 | 9.59e-01 |
| Lysosome Vesicle Biogenesis | 32 | 8.45e-01 | -0.019900 | 9.13e-01 |
| Nonhomologous End-Joining (NHEJ) | 40 | 8.28e-01 | 0.019800 | 9.02e-01 |
| O-glycosylation of TSR domain-containing proteins | 25 | 8.66e-01 | -0.019400 | 9.26e-01 |
| Iron uptake and transport | 52 | 8.09e-01 | 0.019300 | 8.91e-01 |
| Axon guidance | 455 | 4.80e-01 | 0.019300 | 6.67e-01 |
| Cell recruitment (pro-inflammatory response) | 25 | 8.69e-01 | 0.019100 | 9.26e-01 |
| Purinergic signaling in leishmaniasis infection | 25 | 8.69e-01 | 0.019100 | 9.26e-01 |
| Eicosanoid ligand-binding receptors | 13 | 9.06e-01 | 0.018900 | 9.53e-01 |
| Unfolded Protein Response (UPR) | 84 | 7.65e-01 | 0.018900 | 8.64e-01 |
| Regulation of RUNX3 expression and activity | 45 | 8.28e-01 | 0.018700 | 9.02e-01 |
| Post-translational protein modification | 1232 | 2.70e-01 | 0.018700 | 4.69e-01 |
| Diseases of mitotic cell cycle | 38 | 8.46e-01 | -0.018200 | 9.13e-01 |
| Orc1 removal from chromatin | 58 | 8.12e-01 | 0.018000 | 8.93e-01 |
| Germ layer formation at gastrulation | 9 | 9.26e-01 | 0.018000 | 9.64e-01 |
| Class I MHC mediated antigen processing & presentation | 343 | 5.80e-01 | -0.017400 | 7.43e-01 |
| CD28 co-stimulation | 33 | 8.64e-01 | -0.017300 | 9.24e-01 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 8.58e-01 | -0.017200 | 9.19e-01 |
| Metabolism of vitamins and cofactors | 163 | 7.05e-01 | -0.017200 | 8.24e-01 |
| HuR (ELAVL1) binds and stabilizes mRNA | 10 | 9.26e-01 | -0.017100 | 9.64e-01 |
| Degradation of AXIN | 42 | 8.49e-01 | 0.017000 | 9.13e-01 |
| SUMOylation of DNA methylation proteins | 16 | 9.07e-01 | -0.016900 | 9.53e-01 |
| Mitotic Prophase | 96 | 7.77e-01 | 0.016700 | 8.71e-01 |
| B-WICH complex positively regulates rRNA expression | 45 | 8.49e-01 | -0.016500 | 9.13e-01 |
| Purine salvage | 12 | 9.22e-01 | 0.016300 | 9.62e-01 |
| Disorders of transmembrane transporters | 134 | 7.46e-01 | 0.016200 | 8.53e-01 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | 20 | 9.01e-01 | 0.016100 | 9.51e-01 |
| Infectious disease | 951 | 4.02e-01 | -0.016000 | 5.97e-01 |
| VLDLR internalisation and degradation | 16 | 9.12e-01 | -0.016000 | 9.57e-01 |
| Centrosome maturation | 81 | 8.07e-01 | -0.015700 | 8.90e-01 |
| Recruitment of mitotic centrosome proteins and complexes | 81 | 8.07e-01 | -0.015700 | 8.90e-01 |
| Cleavage of the damaged pyrimidine | 26 | 8.91e-01 | -0.015600 | 9.43e-01 |
| Depyrimidination | 26 | 8.91e-01 | -0.015600 | 9.43e-01 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 26 | 8.91e-01 | -0.015600 | 9.43e-01 |
| Signaling by FGFR in disease | 52 | 8.47e-01 | 0.015500 | 9.13e-01 |
| Nervous system development | 473 | 5.77e-01 | 0.015000 | 7.42e-01 |
| Metabolism of steroid hormones | 21 | 9.06e-01 | 0.014900 | 9.53e-01 |
| CD28 dependent Vav1 pathway | 12 | 9.29e-01 | 0.014800 | 9.66e-01 |
| Histidine catabolism | 7 | 9.48e-01 | 0.014300 | 9.79e-01 |
| Defective pyroptosis | 27 | 8.98e-01 | -0.014200 | 9.49e-01 |
| TNFR1-induced NF-kappa-B signaling pathway | 32 | 8.89e-01 | -0.014200 | 9.43e-01 |
| Stabilization of p53 | 43 | 8.78e-01 | -0.013500 | 9.35e-01 |
| Neurexins and neuroligins | 35 | 8.98e-01 | -0.012500 | 9.49e-01 |
| Signaling by NODAL | 15 | 9.33e-01 | -0.012400 | 9.70e-01 |
| Synthesis of PA | 31 | 9.05e-01 | -0.012400 | 9.52e-01 |
| Vif-mediated degradation of APOBEC3G | 41 | 8.91e-01 | 0.012400 | 9.43e-01 |
| TCR signaling | 110 | 8.26e-01 | 0.012200 | 9.00e-01 |
| Cell Cycle | 609 | 6.19e-01 | 0.011800 | 7.67e-01 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | 5 | 9.64e-01 | 0.011800 | 9.88e-01 |
| NOD1/2 Signaling Pathway | 36 | 9.03e-01 | 0.011800 | 9.51e-01 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 10 | 9.50e-01 | 0.011400 | 9.81e-01 |
| Ca2+ activated K+ channels | 6 | 9.62e-01 | -0.011200 | 9.88e-01 |
| Phospholipase C-mediated cascade; FGFR2 | 8 | 9.56e-01 | 0.011200 | 9.85e-01 |
| RNA Polymerase II Transcription | 1185 | 5.22e-01 | -0.011100 | 7.03e-01 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 23 | 9.27e-01 | 0.011000 | 9.65e-01 |
| MECP2 regulates transcription factors | 5 | 9.67e-01 | -0.010800 | 9.88e-01 |
| p75NTR signals via NF-kB | 15 | 9.43e-01 | -0.010600 | 9.77e-01 |
| Activated point mutants of FGFR2 | 7 | 9.62e-01 | -0.010300 | 9.88e-01 |
| WNT ligand biogenesis and trafficking | 20 | 9.37e-01 | -0.010200 | 9.72e-01 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 21 | 9.35e-01 | 0.010200 | 9.71e-01 |
| Signaling by ERBB2 | 44 | 9.13e-01 | 0.009550 | 9.58e-01 |
| Advanced glycosylation endproduct receptor signaling | 12 | 9.54e-01 | -0.009540 | 9.84e-01 |
| Transport and synthesis of PAPS | 6 | 9.68e-01 | -0.009490 | 9.88e-01 |
| Ephrin signaling | 17 | 9.46e-01 | -0.009480 | 9.78e-01 |
| SUMOylation of transcription cofactors | 44 | 9.15e-01 | -0.009340 | 9.59e-01 |
| SIRT1 negatively regulates rRNA expression | 22 | 9.40e-01 | -0.009260 | 9.75e-01 |
| Neurotoxicity of clostridium toxins | 9 | 9.63e-01 | 0.008980 | 9.88e-01 |
| Calcineurin activates NFAT | 9 | 9.64e-01 | -0.008770 | 9.88e-01 |
| Disease | 1606 | 5.59e-01 | 0.008750 | 7.29e-01 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | 7 | 9.69e-01 | 0.008550 | 9.88e-01 |
| Epigenetic regulation of gene expression | 263 | 8.13e-01 | 0.008470 | 8.94e-01 |
| Impaired BRCA2 binding to PALB2 | 24 | 9.45e-01 | -0.008140 | 9.78e-01 |
| Transport of RCbl within the body | 8 | 9.69e-01 | -0.008010 | 9.88e-01 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 29 | 9.41e-01 | -0.008000 | 9.75e-01 |
| Defective B3GALTL causes PpS | 24 | 9.47e-01 | 0.007820 | 9.79e-01 |
| Processing of DNA double-strand break ends | 69 | 9.11e-01 | 0.007820 | 9.56e-01 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 29 | 9.44e-01 | 0.007600 | 9.77e-01 |
| Synthesis of PC | 23 | 9.52e-01 | -0.007310 | 9.82e-01 |
| The NLRP3 inflammasome | 16 | 9.60e-01 | 0.007230 | 9.88e-01 |
| Regulation of pyruvate dehydrogenase (PDH) complex | 14 | 9.63e-01 | 0.007120 | 9.88e-01 |
| Budding and maturation of HIV virion | 26 | 9.52e-01 | -0.006820 | 9.82e-01 |
| SUMO E3 ligases SUMOylate target proteins | 161 | 8.82e-01 | -0.006760 | 9.37e-01 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 60 | 9.30e-01 | 0.006580 | 9.66e-01 |
| Synthesis of PIPs at the early endosome membrane | 16 | 9.64e-01 | -0.006500 | 9.88e-01 |
| Dectin-1 mediated noncanonical NF-kB signaling | 47 | 9.45e-01 | 0.005800 | 9.78e-01 |
| Cargo recognition for clathrin-mediated endocytosis | 88 | 9.25e-01 | 0.005790 | 9.64e-01 |
| Generic Transcription Pathway | 1067 | 7.82e-01 | -0.005030 | 8.73e-01 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 22 | 9.68e-01 | 0.005010 | 9.88e-01 |
| Cellular responses to stimuli | 776 | 8.21e-01 | 0.004770 | 8.98e-01 |
| Listeria monocytogenes entry into host cells | 17 | 9.74e-01 | -0.004490 | 9.90e-01 |
| Cytosolic sulfonation of small molecules | 18 | 9.74e-01 | 0.004430 | 9.90e-01 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | 21 | 9.72e-01 | 0.004370 | 9.90e-01 |
| SMAC (DIABLO) binds to IAPs | 7 | 9.85e-01 | 0.004120 | 9.94e-01 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | 7 | 9.85e-01 | 0.004120 | 9.94e-01 |
| SMAC, XIAP-regulated apoptotic response | 7 | 9.85e-01 | 0.004120 | 9.94e-01 |
| Defective Intrinsic Pathway for Apoptosis | 24 | 9.74e-01 | -0.003890 | 9.90e-01 |
| Regulated Necrosis | 55 | 9.60e-01 | 0.003880 | 9.88e-01 |
| FLT3 signaling through SRC family kinases | 6 | 9.88e-01 | 0.003640 | 9.95e-01 |
| Activation of BAD and translocation to mitochondria | 15 | 9.81e-01 | -0.003570 | 9.94e-01 |
| NIK–>noncanonical NF-kB signaling | 46 | 9.67e-01 | -0.003490 | 9.88e-01 |
| ERKs are inactivated | 13 | 9.83e-01 | -0.003460 | 9.94e-01 |
| FGFR4 ligand binding and activation | 5 | 9.90e-01 | 0.003330 | 9.96e-01 |
| Phase II - Conjugation of compounds | 68 | 9.63e-01 | -0.003270 | 9.88e-01 |
| Josephin domain DUBs | 10 | 9.86e-01 | 0.003130 | 9.95e-01 |
| Regulation of RUNX2 expression and activity | 54 | 9.68e-01 | -0.003120 | 9.88e-01 |
| Meiosis | 66 | 9.66e-01 | -0.003000 | 9.88e-01 |
| Phase I - Functionalization of compounds | 62 | 9.68e-01 | 0.002920 | 9.88e-01 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 35 | 9.77e-01 | 0.002820 | 9.92e-01 |
| Amyloid fiber formation | 51 | 9.74e-01 | 0.002630 | 9.90e-01 |
| Defensins | 8 | 9.90e-01 | 0.002590 | 9.96e-01 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | 7 | 9.91e-01 | 0.002540 | 9.96e-01 |
| CDK-mediated phosphorylation and removal of Cdc6 | 60 | 9.74e-01 | 0.002420 | 9.90e-01 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | 25 | 9.84e-01 | 0.002370 | 9.94e-01 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | 25 | 9.84e-01 | 0.002370 | 9.94e-01 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | 25 | 9.84e-01 | 0.002370 | 9.94e-01 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | 25 | 9.84e-01 | 0.002370 | 9.94e-01 |
| Cobalamin (Cbl) metabolism | 7 | 9.92e-01 | 0.002170 | 9.96e-01 |
| Sensory perception of taste | 23 | 9.87e-01 | -0.002010 | 9.95e-01 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | 61 | 9.80e-01 | -0.001880 | 9.94e-01 |
| CD209 (DC-SIGN) signaling | 20 | 9.90e-01 | 0.001560 | 9.96e-01 |
| TNFR2 non-canonical NF-kB pathway | 84 | 9.81e-01 | -0.001540 | 9.94e-01 |
| Glycerophospholipid biosynthesis | 104 | 9.78e-01 | 0.001530 | 9.93e-01 |
| Diseases of Mismatch Repair (MMR) | 5 | 9.96e-01 | 0.001410 | 9.98e-01 |
| ER Quality Control Compartment (ERQC) | 21 | 9.91e-01 | -0.001380 | 9.96e-01 |
| ERBB2 Regulates Cell Motility | 10 | 9.94e-01 | -0.001370 | 9.97e-01 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | 8 | 9.96e-01 | 0.001120 | 9.98e-01 |
| TP53 Regulates Transcription of Cell Death Genes | 42 | 9.90e-01 | 0.001100 | 9.96e-01 |
| Vpu mediated degradation of CD4 | 39 | 9.93e-01 | 0.000863 | 9.96e-01 |
| Crosslinking of collagen fibrils | 12 | 9.97e-01 | 0.000698 | 9.98e-01 |
| Reactions specific to the complex N-glycan synthesis pathway | 7 | 9.98e-01 | -0.000444 | 9.98e-01 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 30 | 9.97e-01 | 0.000341 | 9.98e-01 |
| ERK/MAPK targets | 22 | 9.98e-01 | -0.000257 | 9.98e-01 |
Detailed Gene set reports
CD163 mediating an anti-inflammatory response
| set | CD163 mediating an anti-inflammatory response |
| setSize | 8 |
| pANOVA | 1.91e-05 |
| s.dist | 0.873 |
| p.adjustANOVA | 0.00035 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAPK14 | 10146 |
| FURIN | 9787 |
| IL10 | 9783 |
| ADAM17 | 9123 |
| CD163 | 8710 |
| MYH9 | 8624 |
| RHBDF2 | 8363 |
| PLK2 | 7307 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MAPK14 | 10146 |
| FURIN | 9787 |
| IL10 | 9783 |
| ADAM17 | 9123 |
| CD163 | 8710 |
| MYH9 | 8624 |
| RHBDF2 | 8363 |
| PLK2 | 7307 |
Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA
| set | Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA |
| setSize | 6 |
| pANOVA | 0.000554 |
| s.dist | 0.814 |
| p.adjustANOVA | 0.00626 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H19 | 9980 |
| IGF2BP3 | 9845 |
| MYC | 8860 |
| CD44 | 8699 |
| ACTB | 7610 |
| IGF2BP2 | 5158 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| H19 | 9980 |
| IGF2BP3 | 9845 |
| MYC | 8860 |
| CD44 | 8699 |
| ACTB | 7610 |
| IGF2BP2 | 5158 |
Response to metal ions
| set | Response to metal ions |
| setSize | 6 |
| pANOVA | 0.00103 |
| s.dist | 0.774 |
| p.adjustANOVA | 0.0103 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MTF1 | 9776 |
| MT1X | 9137 |
| MT2A | 8856 |
| MT1E | 8758 |
| MT1F | 5937 |
| CSRP1 | 5132 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MTF1 | 9776 |
| MT1X | 9137 |
| MT2A | 8856 |
| MT1E | 8758 |
| MT1F | 5937 |
| CSRP1 | 5132 |
Inhibition of Signaling by Overexpressed EGFR
| set | Inhibition of Signaling by Overexpressed EGFR |
| setSize | 5 |
| pANOVA | 0.00354 |
| s.dist | 0.753 |
| p.adjustANOVA | 0.027 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TGFA | 10260 |
| EREG | 9520 |
| AREG | 9309 |
| HBEGF | 8211 |
| EGF | 1257 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TGFA | 10260 |
| EREG | 9520 |
| AREG | 9309 |
| HBEGF | 8211 |
| EGF | 1257 |
Signaling by Overexpressed Wild-Type EGFR in Cancer
| set | Signaling by Overexpressed Wild-Type EGFR in Cancer |
| setSize | 5 |
| pANOVA | 0.00354 |
| s.dist | 0.753 |
| p.adjustANOVA | 0.027 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TGFA | 10260 |
| EREG | 9520 |
| AREG | 9309 |
| HBEGF | 8211 |
| EGF | 1257 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TGFA | 10260 |
| EREG | 9520 |
| AREG | 9309 |
| HBEGF | 8211 |
| EGF | 1257 |
Formation of xylulose-5-phosphate
| set | Formation of xylulose-5-phosphate |
| setSize | 5 |
| pANOVA | 0.00528 |
| s.dist | -0.72 |
| p.adjustANOVA | 0.0359 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| XYLB | -10123 |
| CRYL1 | -9133 |
| AKR1A1 | -7217 |
| SORD | -7095 |
| DCXR | -6143 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| XYLB | -10123 |
| CRYL1 | -9133 |
| AKR1A1 | -7217 |
| SORD | -7095 |
| DCXR | -6143 |
NFE2L2 regulates pentose phosphate pathway genes
| set | NFE2L2 regulates pentose phosphate pathway genes |
| setSize | 8 |
| pANOVA | 0.000594 |
| s.dist | 0.701 |
| p.adjustANOVA | 0.0066 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PGD | 10160 |
| MAFG | 9975 |
| CREBBP | 9117 |
| G6PD | 8982 |
| EP300 | 8092 |
| TKT | 4470 |
| NFE2L2 | 3414 |
| TALDO1 | 3056 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PGD | 10160 |
| MAFG | 9975 |
| CREBBP | 9117 |
| G6PD | 8982 |
| EP300 | 8092 |
| TKT | 4470 |
| NFE2L2 | 3414 |
| TALDO1 | 3056 |
G2/M DNA replication checkpoint
| set | G2/M DNA replication checkpoint |
| setSize | 5 |
| pANOVA | 0.0074 |
| s.dist | 0.692 |
| p.adjustANOVA | 0.0449 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CDK1 | 8897 |
| CCNB1 | 7371 |
| WEE1 | 7202 |
| PKMYT1 | 6506 |
| CCNB2 | 5317 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CDK1 | 8897 |
| CCNB1 | 7371 |
| WEE1 | 7202 |
| PKMYT1 | 6506 |
| CCNB2 | 5317 |
Formation of a pool of free 40S subunits
| set | Formation of a pool of free 40S subunits |
| setSize | 100 |
| pANOVA | 1.71e-32 |
| s.dist | -0.686 |
| p.adjustANOVA | 5.47e-30 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
| RPL7A | -9040 |
| RPL6 | -8995 |
| RPL12 | -8971 |
| EIF3F | -8955 |
| RPL11 | -8932 |
| EIF3G | -8914 |
| RPL8 | -8894 |
| EIF3K | -8872 |
| RPL15 | -8846 |
| RPS11 | -8836 |
| UBA52 | -8729 |
| RPL3 | -8725 |
| RPS27A | -8697 |
| RPL23A | -8695 |
| RPL30 | -8665 |
| EIF3D | -8646 |
| RPL36A | -8635 |
| RPL13A | -8632 |
| RPS10 | -8578 |
| RPL21 | -8575 |
| EIF3H | -8454 |
| RPL31 | -8380 |
| RPL17 | -8359 |
| RPS14 | -8301 |
| RPL19 | -8300 |
| RPL14 | -8257 |
| RPL3L | -8254 |
| RPL18A | -8223 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| RPL10A | -8093 |
| RPL39 | -8078 |
| RPL24 | -8009 |
| EIF3B | -7939 |
| RPS27L | -7877 |
| RPL23 | -7851 |
| FAU | -7843 |
| RPL32 | -7813 |
| EIF3C | -7727 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPL38 | -7530 |
| RPS12 | -7527 |
| RPL27 | -7255 |
| RPS15A | -7215 |
| RPL27A | -7212 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPLP2 | -6981 |
| RPL41 | -6731 |
| RPL37 | -6639 |
| RPSA | -6608 |
| RPL28 | -6550 |
| RPL37A | -6495 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| EIF3J | -6194 |
| RPS27 | -6034 |
| EIF3I | -5939 |
| RPL36 | -5842 |
| RPLP0 | -5840 |
| RPL13 | -5801 |
| RPS5 | -5787 |
| EIF3A | -5698 |
| RPL35 | -5324 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| RPLP1 | -4244 |
| EIF1AX | -4224 |
| RPS29 | -2896 |
| RPL36AL | 321 |
| RPL9 | 460 |
| RPL26L1 | 1524 |
| RPS26 | 6287 |
Peptide chain elongation
| set | Peptide chain elongation |
| setSize | 88 |
| pANOVA | 1.39e-28 |
| s.dist | -0.683 |
| p.adjustANOVA | 2.22e-26 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EEF1A1 | -10245 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| EEF2 | -9782 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| EEF1A1 | -10245 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| EEF2 | -9782 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
| RPL7A | -9040 |
| RPL6 | -8995 |
| RPL12 | -8971 |
| RPL11 | -8932 |
| RPL8 | -8894 |
| RPL15 | -8846 |
| RPS11 | -8836 |
| UBA52 | -8729 |
| RPL3 | -8725 |
| RPS27A | -8697 |
| RPL23A | -8695 |
| RPL30 | -8665 |
| RPL36A | -8635 |
| RPL13A | -8632 |
| RPS10 | -8578 |
| RPL21 | -8575 |
| RPL31 | -8380 |
| RPL17 | -8359 |
| RPS14 | -8301 |
| RPL19 | -8300 |
| RPL14 | -8257 |
| RPL3L | -8254 |
| RPL18A | -8223 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| RPL10A | -8093 |
| RPL39 | -8078 |
| RPL24 | -8009 |
| RPS27L | -7877 |
| RPL23 | -7851 |
| FAU | -7843 |
| RPL32 | -7813 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPL38 | -7530 |
| RPS12 | -7527 |
| RPL27 | -7255 |
| RPS15A | -7215 |
| RPL27A | -7212 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPLP2 | -6981 |
| RPL41 | -6731 |
| RPL37 | -6639 |
| RPSA | -6608 |
| RPL28 | -6550 |
| RPL37A | -6495 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| RPS27 | -6034 |
| RPL36 | -5842 |
| RPLP0 | -5840 |
| RPL13 | -5801 |
| RPS5 | -5787 |
| RPL35 | -5324 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| RPLP1 | -4244 |
| RPS29 | -2896 |
| RPL36AL | 321 |
| RPL9 | 460 |
| RPL26L1 | 1524 |
| RPS26 | 6287 |
Eukaryotic Translation Elongation
| set | Eukaryotic Translation Elongation |
| setSize | 93 |
| pANOVA | 3.95e-29 |
| s.dist | -0.671 |
| p.adjustANOVA | 6.89e-27 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EEF1A1 | -10245 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| EEF2 | -9782 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| EEF1A1P5 | -9368 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| EEF1A1 | -10245 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| EEF2 | -9782 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| EEF1A1P5 | -9368 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
| RPL7A | -9040 |
| RPL6 | -8995 |
| RPL12 | -8971 |
| RPL11 | -8932 |
| RPL8 | -8894 |
| RPL15 | -8846 |
| RPS11 | -8836 |
| UBA52 | -8729 |
| RPL3 | -8725 |
| RPS27A | -8697 |
| RPL23A | -8695 |
| RPL30 | -8665 |
| RPL36A | -8635 |
| RPL13A | -8632 |
| RPS10 | -8578 |
| RPL21 | -8575 |
| RPL31 | -8380 |
| RPL17 | -8359 |
| RPS14 | -8301 |
| RPL19 | -8300 |
| RPL14 | -8257 |
| RPL3L | -8254 |
| RPL18A | -8223 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| RPL10A | -8093 |
| RPL39 | -8078 |
| EEF1B2 | -8023 |
| RPL24 | -8009 |
| RPS27L | -7877 |
| RPL23 | -7851 |
| FAU | -7843 |
| RPL32 | -7813 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPL38 | -7530 |
| RPS12 | -7527 |
| RPL27 | -7255 |
| RPS15A | -7215 |
| RPL27A | -7212 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPLP2 | -6981 |
| RPL41 | -6731 |
| EEF1G | -6690 |
| RPL37 | -6639 |
| RPSA | -6608 |
| RPL28 | -6550 |
| RPL37A | -6495 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| EEF1D | -6126 |
| RPS27 | -6034 |
| RPL36 | -5842 |
| RPLP0 | -5840 |
| RPL13 | -5801 |
| RPS5 | -5787 |
| RPL35 | -5324 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| RPLP1 | -4244 |
| RPS29 | -2896 |
| RPL36AL | 321 |
| RPL9 | 460 |
| RPL26L1 | 1524 |
| EEF1A2 | 4434 |
| RPS26 | 6287 |
Selenocysteine synthesis
| set | Selenocysteine synthesis |
| setSize | 92 |
| pANOVA | 2.01e-28 |
| s.dist | -0.666 |
| p.adjustANOVA | 2.98e-26 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS4X | -10154 |
| RPS13 | -10047 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| SECISBP2 | -9328 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPS4X | -10154 |
| RPS13 | -10047 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| SECISBP2 | -9328 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
| RPL7A | -9040 |
| SEPSECS | -9022 |
| RPL6 | -8995 |
| RPL12 | -8971 |
| RPL11 | -8932 |
| RPL8 | -8894 |
| RPL15 | -8846 |
| RPS11 | -8836 |
| UBA52 | -8729 |
| RPL3 | -8725 |
| RPS27A | -8697 |
| RPL23A | -8695 |
| RPL30 | -8665 |
| RPL36A | -8635 |
| RPL13A | -8632 |
| RPS10 | -8578 |
| RPL21 | -8575 |
| RPL31 | -8380 |
| RPL17 | -8359 |
| RPS14 | -8301 |
| RPL19 | -8300 |
| RPL14 | -8257 |
| RPL3L | -8254 |
| RPL18A | -8223 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| RPL10A | -8093 |
| RPL39 | -8078 |
| RPL24 | -8009 |
| RPS27L | -7877 |
| RPL23 | -7851 |
| FAU | -7843 |
| RPL32 | -7813 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPL38 | -7530 |
| RPS12 | -7527 |
| RPL27 | -7255 |
| RPS15A | -7215 |
| RPL27A | -7212 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPLP2 | -6981 |
| PSTK | -6973 |
| RPL41 | -6731 |
| RPL37 | -6639 |
| RPSA | -6608 |
| RPL28 | -6550 |
| RPL37A | -6495 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| SARS1 | -6275 |
| RPS27 | -6034 |
| EEFSEC | -5940 |
| RPL36 | -5842 |
| RPLP0 | -5840 |
| RPL13 | -5801 |
| RPS5 | -5787 |
| RPL35 | -5324 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| RPLP1 | -4244 |
| RPS29 | -2896 |
| RPL36AL | 321 |
| RPL9 | 460 |
| RPL26L1 | 1524 |
| SEPHS2 | 4069 |
| RPS26 | 6287 |
Viral mRNA Translation
| set | Viral mRNA Translation |
| setSize | 88 |
| pANOVA | 1.31e-26 |
| s.dist | -0.658 |
| p.adjustANOVA | 1.48e-24 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS4X | -10154 |
| RPS13 | -10047 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
| RPL7A | -9040 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPS4X | -10154 |
| RPS13 | -10047 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
| RPL7A | -9040 |
| RPL6 | -8995 |
| RPL12 | -8971 |
| RPL11 | -8932 |
| RPL8 | -8894 |
| RPL15 | -8846 |
| RPS11 | -8836 |
| UBA52 | -8729 |
| RPL3 | -8725 |
| RPS27A | -8697 |
| RPL23A | -8695 |
| RPL30 | -8665 |
| RPL36A | -8635 |
| RPL13A | -8632 |
| RPS10 | -8578 |
| RPL21 | -8575 |
| RPL31 | -8380 |
| RPL17 | -8359 |
| RPS14 | -8301 |
| RPL19 | -8300 |
| RPL14 | -8257 |
| RPL3L | -8254 |
| RPL18A | -8223 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| RPL10A | -8093 |
| RPL39 | -8078 |
| RPL24 | -8009 |
| RPS27L | -7877 |
| RPL23 | -7851 |
| FAU | -7843 |
| RPL32 | -7813 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPL38 | -7530 |
| RPS12 | -7527 |
| RPL27 | -7255 |
| RPS15A | -7215 |
| RPL27A | -7212 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPLP2 | -6981 |
| RPL41 | -6731 |
| RPL37 | -6639 |
| RPSA | -6608 |
| RPL28 | -6550 |
| RPL37A | -6495 |
| RPS19 | -6357 |
| GRSF1 | -6338 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| RPS27 | -6034 |
| RPL36 | -5842 |
| RPLP0 | -5840 |
| RPL13 | -5801 |
| RPS5 | -5787 |
| RPL35 | -5324 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| RPLP1 | -4244 |
| RPS29 | -2896 |
| RPL36AL | 321 |
| RPL9 | 460 |
| RPL26L1 | 1524 |
| RPS26 | 6287 |
| DNAJC3 | 10014 |
SARS-CoV-1 modulates host translation machinery
| set | SARS-CoV-1 modulates host translation machinery |
| setSize | 36 |
| pANOVA | 9.12e-12 |
| s.dist | -0.656 |
| p.adjustANOVA | 3.73e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EEF1A1 | -10245 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPS11 | -8836 |
| RPS27A | -8697 |
| RPS10 | -8578 |
| RPS14 | -8301 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| RPS27L | -7877 |
| FAU | -7843 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| EEF1A1 | -10245 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPS11 | -8836 |
| RPS27A | -8697 |
| RPS10 | -8578 |
| RPS14 | -8301 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| RPS27L | -7877 |
| FAU | -7843 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPS12 | -7527 |
| RPS15A | -7215 |
| HNRNPA1 | -7206 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPSA | -6608 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| RPS27 | -6034 |
| RPS5 | -5787 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| RPS29 | -2896 |
| RPS26 | 6287 |
EGFR interacts with phospholipase C-gamma
| set | EGFR interacts with phospholipase C-gamma |
| setSize | 6 |
| pANOVA | 0.00549 |
| s.dist | 0.655 |
| p.adjustANOVA | 0.0364 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TGFA | 10260 |
| EREG | 9520 |
| AREG | 9309 |
| HBEGF | 8211 |
| PLCG1 | 1429 |
| EGF | 1257 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TGFA | 10260 |
| EREG | 9520 |
| AREG | 9309 |
| HBEGF | 8211 |
| PLCG1 | 1429 |
| EGF | 1257 |
Eukaryotic Translation Termination
| set | Eukaryotic Translation Termination |
| setSize | 92 |
| pANOVA | 1.7e-27 |
| s.dist | -0.655 |
| p.adjustANOVA | 2.34e-25 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS4X | -10154 |
| RPS13 | -10047 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| N6AMT1 | -9592 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPS4X | -10154 |
| RPS13 | -10047 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| N6AMT1 | -9592 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
| RPL7A | -9040 |
| RPL6 | -8995 |
| RPL12 | -8971 |
| RPL11 | -8932 |
| RPL8 | -8894 |
| RPL15 | -8846 |
| RPS11 | -8836 |
| UBA52 | -8729 |
| RPL3 | -8725 |
| RPS27A | -8697 |
| RPL23A | -8695 |
| RPL30 | -8665 |
| RPL36A | -8635 |
| RPL13A | -8632 |
| RPS10 | -8578 |
| RPL21 | -8575 |
| RPL31 | -8380 |
| RPL17 | -8359 |
| RPS14 | -8301 |
| RPL19 | -8300 |
| RPL14 | -8257 |
| RPL3L | -8254 |
| RPL18A | -8223 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| RPL10A | -8093 |
| RPL39 | -8078 |
| RPL24 | -8009 |
| RPS27L | -7877 |
| RPL23 | -7851 |
| FAU | -7843 |
| RPL32 | -7813 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPL38 | -7530 |
| RPS12 | -7527 |
| RPL27 | -7255 |
| RPS15A | -7215 |
| RPL27A | -7212 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPLP2 | -6981 |
| TRMT112 | -6824 |
| RPL41 | -6731 |
| RPL37 | -6639 |
| RPSA | -6608 |
| RPL28 | -6550 |
| RPL37A | -6495 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| RPS27 | -6034 |
| APEH | -5934 |
| RPL36 | -5842 |
| RPLP0 | -5840 |
| RPL13 | -5801 |
| RPS5 | -5787 |
| RPL35 | -5324 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| RPLP1 | -4244 |
| GSPT2 | -4177 |
| RPS29 | -2896 |
| RPL36AL | 321 |
| RPL9 | 460 |
| RPL26L1 | 1524 |
| ETF1 | 1864 |
| GSPT1 | 2489 |
| RPS26 | 6287 |
Formation of the ternary complex, and subsequently, the 43S complex
| set | Formation of the ternary complex, and subsequently, the 43S complex |
| setSize | 51 |
| pANOVA | 1.77e-15 |
| s.dist | -0.644 |
| p.adjustANOVA | 1.03e-13 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| EIF3F | -8955 |
| EIF3G | -8914 |
| EIF3K | -8872 |
| RPS11 | -8836 |
| RPS27A | -8697 |
| EIF3D | -8646 |
| RPS10 | -8578 |
| EIF3H | -8454 |
| EIF2S3 | -8440 |
| RPS14 | -8301 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| EIF3F | -8955 |
| EIF3G | -8914 |
| EIF3K | -8872 |
| RPS11 | -8836 |
| RPS27A | -8697 |
| EIF3D | -8646 |
| RPS10 | -8578 |
| EIF3H | -8454 |
| EIF2S3 | -8440 |
| RPS14 | -8301 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| EIF3B | -7939 |
| RPS27L | -7877 |
| FAU | -7843 |
| EIF3C | -7727 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPS12 | -7527 |
| RPS15A | -7215 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPSA | -6608 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| EIF3J | -6194 |
| RPS27 | -6034 |
| EIF3I | -5939 |
| RPS5 | -5787 |
| EIF3A | -5698 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| EIF1AX | -4224 |
| RPS29 | -2896 |
| EIF2S2 | 1009 |
| EIF2S1 | 1134 |
| RPS26 | 6287 |
L13a-mediated translational silencing of Ceruloplasmin expression
| set | L13a-mediated translational silencing of Ceruloplasmin expression |
| setSize | 110 |
| pANOVA | 2.14e-31 |
| s.dist | -0.642 |
| p.adjustANOVA | 4.56e-29 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| EIF4B | -10332 |
| PABPC1 | -10239 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| EIF4B | -10332 |
| PABPC1 | -10239 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
| RPL7A | -9040 |
| RPL6 | -8995 |
| RPL12 | -8971 |
| EIF3F | -8955 |
| RPL11 | -8932 |
| EIF3G | -8914 |
| RPL8 | -8894 |
| EIF3K | -8872 |
| RPL15 | -8846 |
| RPS11 | -8836 |
| UBA52 | -8729 |
| RPL3 | -8725 |
| RPS27A | -8697 |
| RPL23A | -8695 |
| RPL30 | -8665 |
| EIF3D | -8646 |
| RPL36A | -8635 |
| RPL13A | -8632 |
| RPS10 | -8578 |
| RPL21 | -8575 |
| EIF3H | -8454 |
| EIF2S3 | -8440 |
| RPL31 | -8380 |
| RPL17 | -8359 |
| RPS14 | -8301 |
| RPL19 | -8300 |
| RPL14 | -8257 |
| RPL3L | -8254 |
| RPL18A | -8223 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| RPL10A | -8093 |
| RPL39 | -8078 |
| RPL24 | -8009 |
| EIF3B | -7939 |
| RPS27L | -7877 |
| RPL23 | -7851 |
| FAU | -7843 |
| RPL32 | -7813 |
| EIF3C | -7727 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPL38 | -7530 |
| RPS12 | -7527 |
| RPL27 | -7255 |
| RPS15A | -7215 |
| RPL27A | -7212 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPLP2 | -6981 |
| RPL41 | -6731 |
| RPL37 | -6639 |
| RPSA | -6608 |
| RPL28 | -6550 |
| RPL37A | -6495 |
| EIF4A1 | -6442 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| EIF3J | -6194 |
| EIF4A2 | -6158 |
| RPS27 | -6034 |
| EIF3I | -5939 |
| RPL36 | -5842 |
| RPLP0 | -5840 |
| RPL13 | -5801 |
| RPS5 | -5787 |
| EIF3A | -5698 |
| RPL35 | -5324 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| RPLP1 | -4244 |
| EIF1AX | -4224 |
| RPS29 | -2896 |
| EIF4H | -1997 |
| RPL36AL | 321 |
| RPL9 | 460 |
| EIF2S2 | 1009 |
| EIF2S1 | 1134 |
| RPL26L1 | 1524 |
| RPS26 | 6287 |
| EIF4E | 7774 |
| EIF4G1 | 9201 |
Acetylcholine binding and downstream events
| set | Acetylcholine binding and downstream events |
| setSize | 5 |
| pANOVA | 0.0132 |
| s.dist | 0.64 |
| p.adjustANOVA | 0.0664 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CHRNA2 | 8983 |
| CHRNB2 | 8794 |
| CHRNA5 | 5115 |
| CHRNA7 | 4920 |
| CHRNE | 4721 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CHRNA2 | 8983 |
| CHRNB2 | 8794 |
| CHRNA5 | 5115 |
| CHRNA7 | 4920 |
| CHRNE | 4721 |
Postsynaptic nicotinic acetylcholine receptors
| set | Postsynaptic nicotinic acetylcholine receptors |
| setSize | 5 |
| pANOVA | 0.0132 |
| s.dist | 0.64 |
| p.adjustANOVA | 0.0664 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CHRNA2 | 8983 |
| CHRNB2 | 8794 |
| CHRNA5 | 5115 |
| CHRNA7 | 4920 |
| CHRNE | 4721 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CHRNA2 | 8983 |
| CHRNB2 | 8794 |
| CHRNA5 | 5115 |
| CHRNA7 | 4920 |
| CHRNE | 4721 |
rRNA modification in the mitochondrion
| set | rRNA modification in the mitochondrion |
| setSize | 8 |
| pANOVA | 0.00174 |
| s.dist | -0.639 |
| p.adjustANOVA | 0.0156 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MRM2 | -10081 |
| NSUN4 | -10010 |
| MRM3 | -8393 |
| TFB1M | -6984 |
| MTERF4 | -6945 |
| MRM1 | -5690 |
| MT-RNR1 | -4979 |
| MT-RNR2 | -3550 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MRM2 | -10081 |
| NSUN4 | -10010 |
| MRM3 | -8393 |
| TFB1M | -6984 |
| MTERF4 | -6945 |
| MRM1 | -5690 |
| MT-RNR1 | -4979 |
| MT-RNR2 | -3550 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
| set | Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) |
| setSize | 94 |
| pANOVA | 1.16e-26 |
| s.dist | -0.637 |
| p.adjustANOVA | 1.4e-24 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NCBP2 | -10422 |
| PABPC1 | -10239 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| NCBP2 | -10422 |
| PABPC1 | -10239 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
| RPL7A | -9040 |
| RPL6 | -8995 |
| RPL12 | -8971 |
| RPL11 | -8932 |
| RPL8 | -8894 |
| RPL15 | -8846 |
| RPS11 | -8836 |
| UBA52 | -8729 |
| RPL3 | -8725 |
| RPS27A | -8697 |
| RPL23A | -8695 |
| RPL30 | -8665 |
| RPL36A | -8635 |
| RPL13A | -8632 |
| RPS10 | -8578 |
| RPL21 | -8575 |
| RPL31 | -8380 |
| RPL17 | -8359 |
| RPS14 | -8301 |
| RPL19 | -8300 |
| RPL14 | -8257 |
| RPL3L | -8254 |
| RPL18A | -8223 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| RPL10A | -8093 |
| RPL39 | -8078 |
| RPL24 | -8009 |
| RPS27L | -7877 |
| RPL23 | -7851 |
| FAU | -7843 |
| RPL32 | -7813 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPL38 | -7530 |
| RPS12 | -7527 |
| RPL27 | -7255 |
| RPS15A | -7215 |
| RPL27A | -7212 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPLP2 | -6981 |
| RPL41 | -6731 |
| RPL37 | -6639 |
| RPSA | -6608 |
| RPL28 | -6550 |
| RPL37A | -6495 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| NCBP1 | -6313 |
| RPS27 | -6034 |
| RPL36 | -5842 |
| RPLP0 | -5840 |
| RPL13 | -5801 |
| RPS5 | -5787 |
| RPL35 | -5324 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| RPLP1 | -4244 |
| GSPT2 | -4177 |
| RPS29 | -2896 |
| UPF1 | -1566 |
| RPL36AL | 321 |
| RPL9 | 460 |
| RPL26L1 | 1524 |
| ETF1 | 1864 |
| GSPT1 | 2489 |
| RPS26 | 6287 |
| EIF4G1 | 9201 |
Synthesis of diphthamide-EEF2
| set | Synthesis of diphthamide-EEF2 |
| setSize | 8 |
| pANOVA | 0.00181 |
| s.dist | -0.637 |
| p.adjustANOVA | 0.0159 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| DPH6 | -10840 |
| DNAJC24 | -10560 |
| EEF2 | -9782 |
| DPH7 | -9744 |
| DPH1 | -8654 |
| DPH2 | -8411 |
| DPH5 | -3684 |
| DPH3 | 5248 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| DPH6 | -10840 |
| DNAJC24 | -10560 |
| EEF2 | -9782 |
| DPH7 | -9744 |
| DPH1 | -8654 |
| DPH2 | -8411 |
| DPH5 | -3684 |
| DPH3 | 5248 |
GTP hydrolysis and joining of the 60S ribosomal subunit
| set | GTP hydrolysis and joining of the 60S ribosomal subunit |
| setSize | 111 |
| pANOVA | 1.55e-30 |
| s.dist | -0.63 |
| p.adjustANOVA | 2.97e-28 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| EIF4B | -10332 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| EIF4B | -10332 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
| RPL7A | -9040 |
| RPL6 | -8995 |
| RPL12 | -8971 |
| EIF3F | -8955 |
| RPL11 | -8932 |
| EIF3G | -8914 |
| RPL8 | -8894 |
| EIF3K | -8872 |
| RPL15 | -8846 |
| RPS11 | -8836 |
| UBA52 | -8729 |
| RPL3 | -8725 |
| RPS27A | -8697 |
| RPL23A | -8695 |
| RPL30 | -8665 |
| EIF3D | -8646 |
| RPL36A | -8635 |
| RPL13A | -8632 |
| RPS10 | -8578 |
| RPL21 | -8575 |
| EIF3H | -8454 |
| EIF2S3 | -8440 |
| RPL31 | -8380 |
| RPL17 | -8359 |
| RPS14 | -8301 |
| RPL19 | -8300 |
| RPL14 | -8257 |
| RPL3L | -8254 |
| RPL18A | -8223 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| RPL10A | -8093 |
| RPL39 | -8078 |
| RPL24 | -8009 |
| EIF3B | -7939 |
| RPS27L | -7877 |
| RPL23 | -7851 |
| FAU | -7843 |
| RPL32 | -7813 |
| EIF3C | -7727 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPL38 | -7530 |
| RPS12 | -7527 |
| RPL27 | -7255 |
| RPS15A | -7215 |
| RPL27A | -7212 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPLP2 | -6981 |
| RPL41 | -6731 |
| RPL37 | -6639 |
| RPSA | -6608 |
| RPL28 | -6550 |
| RPL37A | -6495 |
| EIF4A1 | -6442 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| EIF3J | -6194 |
| EIF4A2 | -6158 |
| RPS27 | -6034 |
| EIF3I | -5939 |
| RPL36 | -5842 |
| RPLP0 | -5840 |
| RPL13 | -5801 |
| RPS5 | -5787 |
| EIF3A | -5698 |
| RPL35 | -5324 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| RPLP1 | -4244 |
| EIF1AX | -4224 |
| RPS29 | -2896 |
| EIF4H | -1997 |
| EIF5 | -1825 |
| EIF5B | -1182 |
| RPL36AL | 321 |
| RPL9 | 460 |
| EIF2S2 | 1009 |
| EIF2S1 | 1134 |
| RPL26L1 | 1524 |
| RPS26 | 6287 |
| EIF4E | 7774 |
| EIF4G1 | 9201 |
Cap-dependent Translation Initiation
| set | Cap-dependent Translation Initiation |
| setSize | 118 |
| pANOVA | 5.65e-32 |
| s.dist | -0.626 |
| p.adjustANOVA | 1.36e-29 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| EIF4B | -10332 |
| PABPC1 | -10239 |
| EIF2B1 | -10174 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| EIF4EBP1 | -9923 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| EIF4B | -10332 |
| PABPC1 | -10239 |
| EIF2B1 | -10174 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| EIF4EBP1 | -9923 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
| RPL7A | -9040 |
| RPL6 | -8995 |
| RPL12 | -8971 |
| EIF3F | -8955 |
| RPL11 | -8932 |
| EIF3G | -8914 |
| RPL8 | -8894 |
| EIF3K | -8872 |
| RPL15 | -8846 |
| RPS11 | -8836 |
| UBA52 | -8729 |
| RPL3 | -8725 |
| RPS27A | -8697 |
| RPL23A | -8695 |
| RPL30 | -8665 |
| EIF3D | -8646 |
| RPL36A | -8635 |
| RPL13A | -8632 |
| RPS10 | -8578 |
| RPL21 | -8575 |
| EIF3H | -8454 |
| EIF2S3 | -8440 |
| RPL31 | -8380 |
| RPL17 | -8359 |
| RPS14 | -8301 |
| RPL19 | -8300 |
| RPL14 | -8257 |
| RPL3L | -8254 |
| RPL18A | -8223 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| RPL10A | -8093 |
| RPL39 | -8078 |
| RPL24 | -8009 |
| EIF3B | -7939 |
| RPS27L | -7877 |
| RPL23 | -7851 |
| FAU | -7843 |
| RPL32 | -7813 |
| EIF3C | -7727 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPL38 | -7530 |
| RPS12 | -7527 |
| RPL27 | -7255 |
| RPS15A | -7215 |
| RPL27A | -7212 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPLP2 | -6981 |
| RPL41 | -6731 |
| RPL37 | -6639 |
| RPSA | -6608 |
| RPL28 | -6550 |
| RPL37A | -6495 |
| EIF4A1 | -6442 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| EIF2B4 | -6196 |
| EIF3J | -6194 |
| EIF4A2 | -6158 |
| RPS27 | -6034 |
| EIF3I | -5939 |
| RPL36 | -5842 |
| RPLP0 | -5840 |
| RPL13 | -5801 |
| RPS5 | -5787 |
| EIF3A | -5698 |
| RPL35 | -5324 |
| EIF2B5 | -5246 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| EIF2B3 | -4327 |
| RPLP1 | -4244 |
| EIF1AX | -4224 |
| RPS29 | -2896 |
| EIF4H | -1997 |
| EIF5 | -1825 |
| EIF5B | -1182 |
| RPL36AL | 321 |
| RPL9 | 460 |
| EIF2S2 | 1009 |
| EIF2S1 | 1134 |
| RPL26L1 | 1524 |
| EIF2B2 | 2557 |
| RPS26 | 6287 |
| EIF4E | 7774 |
| EIF4G1 | 9201 |
Eukaryotic Translation Initiation
| set | Eukaryotic Translation Initiation |
| setSize | 118 |
| pANOVA | 5.65e-32 |
| s.dist | -0.626 |
| p.adjustANOVA | 1.36e-29 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| EIF4B | -10332 |
| PABPC1 | -10239 |
| EIF2B1 | -10174 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| EIF4EBP1 | -9923 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| EIF4B | -10332 |
| PABPC1 | -10239 |
| EIF2B1 | -10174 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| EIF4EBP1 | -9923 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
| RPL7A | -9040 |
| RPL6 | -8995 |
| RPL12 | -8971 |
| EIF3F | -8955 |
| RPL11 | -8932 |
| EIF3G | -8914 |
| RPL8 | -8894 |
| EIF3K | -8872 |
| RPL15 | -8846 |
| RPS11 | -8836 |
| UBA52 | -8729 |
| RPL3 | -8725 |
| RPS27A | -8697 |
| RPL23A | -8695 |
| RPL30 | -8665 |
| EIF3D | -8646 |
| RPL36A | -8635 |
| RPL13A | -8632 |
| RPS10 | -8578 |
| RPL21 | -8575 |
| EIF3H | -8454 |
| EIF2S3 | -8440 |
| RPL31 | -8380 |
| RPL17 | -8359 |
| RPS14 | -8301 |
| RPL19 | -8300 |
| RPL14 | -8257 |
| RPL3L | -8254 |
| RPL18A | -8223 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| RPL10A | -8093 |
| RPL39 | -8078 |
| RPL24 | -8009 |
| EIF3B | -7939 |
| RPS27L | -7877 |
| RPL23 | -7851 |
| FAU | -7843 |
| RPL32 | -7813 |
| EIF3C | -7727 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPL38 | -7530 |
| RPS12 | -7527 |
| RPL27 | -7255 |
| RPS15A | -7215 |
| RPL27A | -7212 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPLP2 | -6981 |
| RPL41 | -6731 |
| RPL37 | -6639 |
| RPSA | -6608 |
| RPL28 | -6550 |
| RPL37A | -6495 |
| EIF4A1 | -6442 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| EIF2B4 | -6196 |
| EIF3J | -6194 |
| EIF4A2 | -6158 |
| RPS27 | -6034 |
| EIF3I | -5939 |
| RPL36 | -5842 |
| RPLP0 | -5840 |
| RPL13 | -5801 |
| RPS5 | -5787 |
| EIF3A | -5698 |
| RPL35 | -5324 |
| EIF2B5 | -5246 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| EIF2B3 | -4327 |
| RPLP1 | -4244 |
| EIF1AX | -4224 |
| RPS29 | -2896 |
| EIF4H | -1997 |
| EIF5 | -1825 |
| EIF5B | -1182 |
| RPL36AL | 321 |
| RPL9 | 460 |
| EIF2S2 | 1009 |
| EIF2S1 | 1134 |
| RPL26L1 | 1524 |
| EIF2B2 | 2557 |
| RPS26 | 6287 |
| EIF4E | 7774 |
| EIF4G1 | 9201 |
Erythrocytes take up oxygen and release carbon dioxide
| set | Erythrocytes take up oxygen and release carbon dioxide |
| setSize | 7 |
| pANOVA | 0.00492 |
| s.dist | 0.614 |
| p.adjustANOVA | 0.0348 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CA4 | 9426 |
| SLC4A1 | 8635 |
| CA1 | 8021 |
| HBA1 | 7846 |
| HBB | 7497 |
| AQP1 | 2322 |
| CA2 | -133 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CA4 | 9426 |
| SLC4A1 | 8635 |
| CA1 | 8021 |
| HBA1 | 7846 |
| HBB | 7497 |
| AQP1 | 2322 |
| CA2 | -133 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
| set | Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S |
| setSize | 59 |
| pANOVA | 1.91e-15 |
| s.dist | -0.598 |
| p.adjustANOVA | 1.08e-13 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| EIF4B | -10332 |
| PABPC1 | -10239 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| EIF4EBP1 | -9923 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| EIF3F | -8955 |
| EIF3G | -8914 |
| EIF3K | -8872 |
| RPS11 | -8836 |
| RPS27A | -8697 |
| EIF3D | -8646 |
| RPS10 | -8578 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| EIF4B | -10332 |
| PABPC1 | -10239 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| EIF4EBP1 | -9923 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| EIF3F | -8955 |
| EIF3G | -8914 |
| EIF3K | -8872 |
| RPS11 | -8836 |
| RPS27A | -8697 |
| EIF3D | -8646 |
| RPS10 | -8578 |
| EIF3H | -8454 |
| EIF2S3 | -8440 |
| RPS14 | -8301 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| EIF3B | -7939 |
| RPS27L | -7877 |
| FAU | -7843 |
| EIF3C | -7727 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPS12 | -7527 |
| RPS15A | -7215 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPSA | -6608 |
| EIF4A1 | -6442 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| EIF3J | -6194 |
| EIF4A2 | -6158 |
| RPS27 | -6034 |
| EIF3I | -5939 |
| RPS5 | -5787 |
| EIF3A | -5698 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| EIF1AX | -4224 |
| RPS29 | -2896 |
| EIF4H | -1997 |
| EIF2S2 | 1009 |
| EIF2S1 | 1134 |
| RPS26 | 6287 |
| EIF4E | 7774 |
| EIF4G1 | 9201 |
Translation initiation complex formation
| set | Translation initiation complex formation |
| setSize | 58 |
| pANOVA | 5.79e-15 |
| s.dist | -0.592 |
| p.adjustANOVA | 3.18e-13 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| EIF4B | -10332 |
| PABPC1 | -10239 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| EIF3F | -8955 |
| EIF3G | -8914 |
| EIF3K | -8872 |
| RPS11 | -8836 |
| RPS27A | -8697 |
| EIF3D | -8646 |
| RPS10 | -8578 |
| EIF3H | -8454 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| EIF4B | -10332 |
| PABPC1 | -10239 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| EIF3F | -8955 |
| EIF3G | -8914 |
| EIF3K | -8872 |
| RPS11 | -8836 |
| RPS27A | -8697 |
| EIF3D | -8646 |
| RPS10 | -8578 |
| EIF3H | -8454 |
| EIF2S3 | -8440 |
| RPS14 | -8301 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| EIF3B | -7939 |
| RPS27L | -7877 |
| FAU | -7843 |
| EIF3C | -7727 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPS12 | -7527 |
| RPS15A | -7215 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPSA | -6608 |
| EIF4A1 | -6442 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| EIF3J | -6194 |
| EIF4A2 | -6158 |
| RPS27 | -6034 |
| EIF3I | -5939 |
| RPS5 | -5787 |
| EIF3A | -5698 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| EIF1AX | -4224 |
| RPS29 | -2896 |
| EIF4H | -1997 |
| EIF2S2 | 1009 |
| EIF2S1 | 1134 |
| RPS26 | 6287 |
| EIF4E | 7774 |
| EIF4G1 | 9201 |
Relaxin receptors
| set | Relaxin receptors |
| setSize | 5 |
| pANOVA | 0.022 |
| s.dist | 0.591 |
| p.adjustANOVA | 0.0921 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| INSL3 | 9238 |
| RLN3 | 8466 |
| RXFP4 | 7153 |
| RLN2 | 5327 |
| RXFP2 | -216 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| INSL3 | 9238 |
| RLN3 | 8466 |
| RXFP4 | 7153 |
| RLN2 | 5327 |
| RXFP2 | -216 |
Regulation of NFE2L2 gene expression
| set | Regulation of NFE2L2 gene expression |
| setSize | 8 |
| pANOVA | 0.00385 |
| s.dist | 0.59 |
| p.adjustANOVA | 0.0287 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NOTCH1 | 9269 |
| CREBBP | 9117 |
| MYC | 8860 |
| EP300 | 8092 |
| NFKB1 | 4876 |
| RELA | 4301 |
| NFE2L2 | 3414 |
| MAFK | -92 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| NOTCH1 | 9269 |
| CREBBP | 9117 |
| MYC | 8860 |
| EP300 | 8092 |
| NFKB1 | 4876 |
| RELA | 4301 |
| NFE2L2 | 3414 |
| MAFK | -92 |
STAT5 activation downstream of FLT3 ITD mutants
| set | STAT5 activation downstream of FLT3 ITD mutants |
| setSize | 9 |
| pANOVA | 0.00217 |
| s.dist | 0.59 |
| p.adjustANOVA | 0.0181 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PIM1 | 10319 |
| PTPN11 | 8724 |
| BCL2L1 | 8277 |
| GAB2 | 6886 |
| CDKN1A | 6185 |
| GRB2 | 6102 |
| STAT5B | 3275 |
| FLT3 | 2330 |
| STAT5A | 1714 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PIM1 | 10319 |
| PTPN11 | 8724 |
| BCL2L1 | 8277 |
| GAB2 | 6886 |
| CDKN1A | 6185 |
| GRB2 | 6102 |
| STAT5B | 3275 |
| FLT3 | 2330 |
| STAT5A | 1714 |
RUNX1 regulates transcription of genes involved in BCR signaling
| set | RUNX1 regulates transcription of genes involved in BCR signaling |
| setSize | 6 |
| pANOVA | 0.0123 |
| s.dist | 0.59 |
| p.adjustANOVA | 0.0642 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RUNX1 | 10315 |
| BLK | 7828 |
| PAX5 | 7274 |
| CBFB | 4971 |
| ELF2 | 4102 |
| ELF1 | 1383 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RUNX1 | 10315 |
| BLK | 7828 |
| PAX5 | 7274 |
| CBFB | 4971 |
| ELF2 | 4102 |
| ELF1 | 1383 |
Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA
| set | Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA |
| setSize | 5 |
| pANOVA | 0.0228 |
| s.dist | -0.588 |
| p.adjustANOVA | 0.0939 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ECHS1 | -10384 |
| HADH | -8416 |
| HADHA | -7197 |
| ACADL | -3778 |
| HADHB | -2895 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ECHS1 | -10384 |
| HADH | -8416 |
| HADHA | -7197 |
| ACADL | -3778 |
| HADHB | -2895 |
Response of EIF2AK4 (GCN2) to amino acid deficiency
| set | Response of EIF2AK4 (GCN2) to amino acid deficiency |
| setSize | 100 |
| pANOVA | 3.25e-24 |
| s.dist | -0.587 |
| p.adjustANOVA | 2.83e-22 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS4X | -10154 |
| RPS13 | -10047 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
| RPL7A | -9040 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPS4X | -10154 |
| RPS13 | -10047 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
| RPL7A | -9040 |
| RPL6 | -8995 |
| RPL12 | -8971 |
| RPL11 | -8932 |
| RPL8 | -8894 |
| RPL15 | -8846 |
| RPS11 | -8836 |
| UBA52 | -8729 |
| RPL3 | -8725 |
| RPS27A | -8697 |
| RPL23A | -8695 |
| RPL30 | -8665 |
| RPL36A | -8635 |
| RPL13A | -8632 |
| RPS10 | -8578 |
| RPL21 | -8575 |
| EIF2S3 | -8440 |
| RPL31 | -8380 |
| RPL17 | -8359 |
| RPS14 | -8301 |
| RPL19 | -8300 |
| RPL14 | -8257 |
| RPL3L | -8254 |
| RPL18A | -8223 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| RPL10A | -8093 |
| RPL39 | -8078 |
| RPL24 | -8009 |
| RPS27L | -7877 |
| RPL23 | -7851 |
| FAU | -7843 |
| RPL32 | -7813 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| ATF4 | -7601 |
| EIF2AK4 | -7596 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPL38 | -7530 |
| RPS12 | -7527 |
| RPL27 | -7255 |
| RPS15A | -7215 |
| RPL27A | -7212 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPLP2 | -6981 |
| RPL41 | -6731 |
| RPL37 | -6639 |
| RPSA | -6608 |
| RPL28 | -6550 |
| RPL37A | -6495 |
| IMPACT | -6465 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| RPS27 | -6034 |
| RPL36 | -5842 |
| RPLP0 | -5840 |
| RPL13 | -5801 |
| RPS5 | -5787 |
| RPL35 | -5324 |
| CEBPG | -5066 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| RPLP1 | -4244 |
| RPS29 | -2896 |
| ASNS | -1428 |
| ATF2 | 233 |
| RPL36AL | 321 |
| RPL9 | 460 |
| DDIT3 | 942 |
| EIF2S2 | 1009 |
| EIF2S1 | 1134 |
| RPL26L1 | 1524 |
| GCN1 | 3532 |
| TRIB3 | 4555 |
| RPS26 | 6287 |
| CEBPB | 8069 |
| ATF3 | 9077 |
Defective GALNT3 causes HFTC
| set | Defective GALNT3 causes HFTC |
| setSize | 8 |
| pANOVA | 0.0043 |
| s.dist | 0.583 |
| p.adjustANOVA | 0.0317 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MUC1 | 9749 |
| GALNT3 | 9496 |
| MUC6 | 8985 |
| MUC16 | 7555 |
| MUC5B | 6749 |
| MUC12 | 6698 |
| MUC4 | 5096 |
| MUC20 | -7100 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MUC1 | 9749 |
| GALNT3 | 9496 |
| MUC6 | 8985 |
| MUC16 | 7555 |
| MUC5B | 6749 |
| MUC12 | 6698 |
| MUC4 | 5096 |
| MUC20 | -7100 |
Fructose metabolism
| set | Fructose metabolism |
| setSize | 7 |
| pANOVA | 0.00778 |
| s.dist | -0.581 |
| p.adjustANOVA | 0.0463 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ALDH1A1 | -10915 |
| AKR1B1 | -10849 |
| TKFC | -10688 |
| KHK | -10573 |
| SORD | -7095 |
| ALDOB | 2371 |
| GLYCTK | 2531 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ALDH1A1 | -10915 |
| AKR1B1 | -10849 |
| TKFC | -10688 |
| KHK | -10573 |
| SORD | -7095 |
| ALDOB | 2371 |
| GLYCTK | 2531 |
Ribosomal scanning and start codon recognition
| set | Ribosomal scanning and start codon recognition |
| setSize | 58 |
| pANOVA | 2.39e-14 |
| s.dist | -0.579 |
| p.adjustANOVA | 1.28e-12 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| EIF4B | -10332 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| EIF3F | -8955 |
| EIF3G | -8914 |
| EIF3K | -8872 |
| RPS11 | -8836 |
| RPS27A | -8697 |
| EIF3D | -8646 |
| RPS10 | -8578 |
| EIF3H | -8454 |
| EIF2S3 | -8440 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| EIF3M | -10593 |
| EIF3L | -10568 |
| EIF4B | -10332 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| EIF3E | -9990 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| EIF3F | -8955 |
| EIF3G | -8914 |
| EIF3K | -8872 |
| RPS11 | -8836 |
| RPS27A | -8697 |
| EIF3D | -8646 |
| RPS10 | -8578 |
| EIF3H | -8454 |
| EIF2S3 | -8440 |
| RPS14 | -8301 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| EIF3B | -7939 |
| RPS27L | -7877 |
| FAU | -7843 |
| EIF3C | -7727 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPS12 | -7527 |
| RPS15A | -7215 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPSA | -6608 |
| EIF4A1 | -6442 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| EIF3J | -6194 |
| EIF4A2 | -6158 |
| RPS27 | -6034 |
| EIF3I | -5939 |
| RPS5 | -5787 |
| EIF3A | -5698 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| EIF1AX | -4224 |
| RPS29 | -2896 |
| EIF4H | -1997 |
| EIF5 | -1825 |
| EIF2S2 | 1009 |
| EIF2S1 | 1134 |
| RPS26 | 6287 |
| EIF4E | 7774 |
| EIF4G1 | 9201 |
Synthesis of Leukotrienes (LT) and Eoxins (EX)
| set | Synthesis of Leukotrienes (LT) and Eoxins (EX) |
| setSize | 15 |
| pANOVA | 0.000105 |
| s.dist | 0.578 |
| p.adjustANOVA | 0.00161 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PTGR1 | 10266 |
| GGT5 | 9839 |
| CYP4F22 | 9836 |
| GGT1 | 9627 |
| ABCC1 | 9424 |
| ALOX5 | 9294 |
| ALOX5AP | 9258 |
| MAPKAPK2 | 8302 |
| CYP4F8 | 8058 |
| CYP4F3 | 6197 |
| CYP4F2 | 4838 |
| LTA4H | 4589 |
| ALOX15 | 3193 |
| LTC4S | -4117 |
| DPEP2 | -10835 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PTGR1 | 10266 |
| GGT5 | 9839 |
| CYP4F22 | 9836 |
| GGT1 | 9627 |
| ABCC1 | 9424 |
| ALOX5 | 9294 |
| ALOX5AP | 9258 |
| MAPKAPK2 | 8302 |
| CYP4F8 | 8058 |
| CYP4F3 | 6197 |
| CYP4F2 | 4838 |
| LTA4H | 4589 |
| ALOX15 | 3193 |
| LTC4S | -4117 |
| DPEP2 | -10835 |
Beta oxidation of hexanoyl-CoA to butanoyl-CoA
| set | Beta oxidation of hexanoyl-CoA to butanoyl-CoA |
| setSize | 5 |
| pANOVA | 0.0255 |
| s.dist | -0.577 |
| p.adjustANOVA | 0.101 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ECHS1 | -10384 |
| HADH | -8416 |
| HADHA | -7197 |
| ACADS | -3194 |
| HADHB | -2895 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ECHS1 | -10384 |
| HADH | -8416 |
| HADHA | -7197 |
| ACADS | -3194 |
| HADHB | -2895 |
Butyrophilin (BTN) family interactions
| set | Butyrophilin (BTN) family interactions |
| setSize | 10 |
| pANOVA | 0.00164 |
| s.dist | -0.575 |
| p.adjustANOVA | 0.015 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| BTN2A2 | -10892 |
| BTN3A1 | -10808 |
| BTN2A1 | -10543 |
| CD209 | -10416 |
| BTN3A2 | -7555 |
| BTN1A1 | -7516 |
| BTN3A3 | -7390 |
| BTNL9 | -5641 |
| BTNL8 | 2440 |
| PPL | 4345 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| BTN2A2 | -10892 |
| BTN3A1 | -10808 |
| BTN2A1 | -10543 |
| CD209 | -10416 |
| BTN3A2 | -7555 |
| BTN1A1 | -7516 |
| BTN3A3 | -7390 |
| BTNL9 | -5641 |
| BTNL8 | 2440 |
| PPL | 4345 |
POLB-Dependent Long Patch Base Excision Repair
| set | POLB-Dependent Long Patch Base Excision Repair |
| setSize | 8 |
| pANOVA | 0.00505 |
| s.dist | -0.572 |
| p.adjustANOVA | 0.0351 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PARP2 | -10798 |
| APEX1 | -10723 |
| FEN1 | -8581 |
| LIG1 | -8330 |
| POLB | -7924 |
| ADPRS | -6688 |
| PARP1 | -2222 |
| PARG | 4314 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PARP2 | -10798 |
| APEX1 | -10723 |
| FEN1 | -8581 |
| LIG1 | -8330 |
| POLB | -7924 |
| ADPRS | -6688 |
| PARP1 | -2222 |
| PARG | 4314 |
Mitochondrial translation initiation
| set | Mitochondrial translation initiation |
| setSize | 90 |
| pANOVA | 1.09e-20 |
| s.dist | -0.568 |
| p.adjustANOVA | 8.24e-19 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MRPS25 | -10846 |
| MRPL32 | -10514 |
| MRPL45 | -10364 |
| MRPS21 | -10131 |
| MRPL10 | -10028 |
| MTIF2 | -9813 |
| MRPS14 | -9761 |
| MRPS18B | -9566 |
| MRPL34 | -9468 |
| MRPL55 | -9467 |
| MRPL2 | -9462 |
| DAP3 | -9377 |
| OXA1L | -9351 |
| MTFMT | -9285 |
| MRPL37 | -9165 |
| MRPL39 | -9077 |
| MRPS7 | -9074 |
| MRPL20 | -9015 |
| MRPL57 | -8985 |
| MRPS2 | -8956 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MRPS25 | -10846 |
| MRPL32 | -10514 |
| MRPL45 | -10364 |
| MRPS21 | -10131 |
| MRPL10 | -10028 |
| MTIF2 | -9813 |
| MRPS14 | -9761 |
| MRPS18B | -9566 |
| MRPL34 | -9468 |
| MRPL55 | -9467 |
| MRPL2 | -9462 |
| DAP3 | -9377 |
| OXA1L | -9351 |
| MTFMT | -9285 |
| MRPL37 | -9165 |
| MRPL39 | -9077 |
| MRPS7 | -9074 |
| MRPL20 | -9015 |
| MRPL57 | -8985 |
| MRPS2 | -8956 |
| MRPS27 | -8897 |
| MRPL14 | -8883 |
| MRPL15 | -8847 |
| MRPS30 | -8636 |
| MRPL27 | -8477 |
| MRPS9 | -8473 |
| MRPL40 | -8138 |
| MRPL48 | -8110 |
| MRPL43 | -8022 |
| MRPS6 | -7926 |
| MRPL46 | -7913 |
| PTCD3 | -7856 |
| MRPL11 | -7736 |
| MRPL16 | -7668 |
| ERAL1 | -7627 |
| MRPL9 | -7528 |
| RPS12 | -7527 |
| MRPL54 | -7471 |
| MRPL17 | -7450 |
| MRPS17 | -7182 |
| MRPL3 | -7157 |
| MRPS22 | -7099 |
| MRPL35 | -7050 |
| MRPL41 | -6997 |
| MRPL49 | -6748 |
| MRPS16 | -6740 |
| MRPS24 | -6737 |
| MRPL30 | -6732 |
| AURKAIP1 | -6388 |
| MRPL4 | -6379 |
| MRPL42 | -6349 |
| MRPS26 | -6323 |
| MRPS33 | -6273 |
| MRPS35 | -6101 |
| MRPS18A | -5955 |
| MRPL1 | -5947 |
| MRPS18C | -5886 |
| MRPL22 | -5742 |
| MRPS34 | -5581 |
| MRPL50 | -5553 |
| MRPL12 | -5535 |
| MRPL44 | -5512 |
| MRPL24 | -5442 |
| MRPS28 | -5327 |
| MT-RNR1 | -4979 |
| CHCHD1 | -4589 |
| MRPL13 | -4504 |
| MRPL58 | -4408 |
| MRPL19 | -4166 |
| MRPS10 | -4111 |
| MRPL21 | -3940 |
| MRPL38 | -3918 |
| MRPL33 | -3846 |
| MRPS15 | -3791 |
| MT-RNR2 | -3550 |
| MRPS23 | -3339 |
| MRPL47 | -3309 |
| MTIF3 | -3193 |
| MRPL51 | -2987 |
| MRPL53 | -2834 |
| MRPS5 | -2562 |
| GADD45GIP1 | -2308 |
| MRPS36 | -2167 |
| MRPL36 | -1870 |
| MRPL23 | -981 |
| MRPL52 | -569 |
| MRPS31 | 370 |
| MRPL28 | 452 |
| MRPL18 | 2193 |
| MRPS11 | 3352 |
Ethanol oxidation
| set | Ethanol oxidation |
| setSize | 6 |
| pANOVA | 0.016 |
| s.dist | -0.568 |
| p.adjustANOVA | 0.0765 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ALDH1A1 | -10915 |
| ACSS1 | -10346 |
| ADH5 | -10292 |
| ALDH1B1 | -7209 |
| ALDH2 | -7135 |
| ACSS2 | 7954 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ALDH1A1 | -10915 |
| ACSS1 | -10346 |
| ADH5 | -10292 |
| ALDH1B1 | -7209 |
| ALDH2 | -7135 |
| ACSS2 | 7954 |
Type I hemidesmosome assembly
| set | Type I hemidesmosome assembly |
| setSize | 8 |
| pANOVA | 0.0056 |
| s.dist | 0.566 |
| p.adjustANOVA | 0.0367 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| LAMB3 | 10197 |
| ITGA6 | 9799 |
| COL17A1 | 9113 |
| PLEC | 8552 |
| KRT5 | 8074 |
| CD151 | 3763 |
| ITGB4 | 62 |
| DST | -3812 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| LAMB3 | 10197 |
| ITGA6 | 9799 |
| COL17A1 | 9113 |
| PLEC | 8552 |
| KRT5 | 8074 |
| CD151 | 3763 |
| ITGB4 | 62 |
| DST | -3812 |
SRP-dependent cotranslational protein targeting to membrane
| set | SRP-dependent cotranslational protein targeting to membrane |
| setSize | 111 |
| pANOVA | 7.74e-25 |
| s.dist | -0.565 |
| p.adjustANOVA | 7.08e-23 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SEC11A | -10463 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| SSR2 | -9913 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| SEC11A | -10463 |
| RPS4X | -10154 |
| RPS13 | -10047 |
| SSR2 | -9913 |
| RPL29 | -9905 |
| RPL39L | -9834 |
| RPL4 | -9637 |
| RPL26 | -9580 |
| RPL7 | -9553 |
| RPS3A | -9507 |
| RPS4Y1 | -9472 |
| RPL34 | -9464 |
| RPL35A | -9421 |
| RPL22L1 | -9402 |
| RPL18 | -9365 |
| RPL5 | -9353 |
| RPS7 | -9302 |
| RPS3 | -9260 |
| RPS20 | -9205 |
| RPL10 | -9193 |
| RPL22 | -9058 |
| RPL7A | -9040 |
| RPL6 | -8995 |
| RPL12 | -8971 |
| RPL11 | -8932 |
| RPL8 | -8894 |
| RPL15 | -8846 |
| RPS11 | -8836 |
| UBA52 | -8729 |
| RPL3 | -8725 |
| RPS27A | -8697 |
| RPL23A | -8695 |
| RPL30 | -8665 |
| RPL36A | -8635 |
| RPL13A | -8632 |
| RPS10 | -8578 |
| RPL21 | -8575 |
| RPL31 | -8380 |
| RPL17 | -8359 |
| RPS14 | -8301 |
| RPL19 | -8300 |
| RPL14 | -8257 |
| RPL3L | -8254 |
| RPL18A | -8223 |
| RPS25 | -8214 |
| RPS24 | -8168 |
| RPL10A | -8093 |
| RPL39 | -8078 |
| RPL24 | -8009 |
| RPS27L | -7877 |
| RPL23 | -7851 |
| FAU | -7843 |
| RPL32 | -7813 |
| RPS2 | -7645 |
| RPS6 | -7638 |
| SRP9 | -7599 |
| RPS15 | -7592 |
| RPS8 | -7537 |
| RPL38 | -7530 |
| RPS12 | -7527 |
| RPL27 | -7255 |
| RPS15A | -7215 |
| RPL27A | -7212 |
| SEC11C | -7188 |
| RPS23 | -7122 |
| RPS28 | -7102 |
| RPS16 | -7012 |
| RPLP2 | -6981 |
| RPL41 | -6731 |
| RPL37 | -6639 |
| SRPRB | -6633 |
| SEC61A2 | -6613 |
| RPSA | -6608 |
| RPL28 | -6550 |
| RPL37A | -6495 |
| SPCS1 | -6363 |
| RPS19 | -6357 |
| RPS21 | -6334 |
| RPS18 | -6316 |
| RPS27 | -6034 |
| RPL36 | -5842 |
| RPLP0 | -5840 |
| RPL13 | -5801 |
| RPS5 | -5787 |
| RPL35 | -5324 |
| SSR3 | -4941 |
| RPS17 | -4935 |
| RPS9 | -4833 |
| SRP72 | -4418 |
| RPLP1 | -4244 |
| SSR4 | -4031 |
| SSR1 | -3984 |
| SEC61G | -3448 |
| SRP68 | -3133 |
| SEC61B | -3122 |
| RPS29 | -2896 |
| DDOST | -1151 |
| SEC61A1 | -639 |
| RPL36AL | 321 |
| RPL9 | 460 |
| TRAM1 | 1133 |
| SPCS3 | 1189 |
| SRP14 | 1497 |
| RPL26L1 | 1524 |
| SRPRA | 2028 |
| SRP19 | 2354 |
| SPCS2 | 3557 |
| RPN1 | 4374 |
| RPS26 | 6287 |
| SRP54 | 6890 |
| RPN2 | 7391 |
RHOT1 GTPase cycle
| set | RHOT1 GTPase cycle |
| setSize | 5 |
| pANOVA | 0.0298 |
| s.dist | 0.561 |
| p.adjustANOVA | 0.114 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TRAK1 | 7904 |
| RHOT1 | 7537 |
| TRAK2 | 5104 |
| RAP1GDS1 | 4390 |
| MYO19 | 3418 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TRAK1 | 7904 |
| RHOT1 | 7537 |
| TRAK2 | 5104 |
| RAP1GDS1 | 4390 |
| MYO19 | 3418 |
Mitochondrial translation elongation
| set | Mitochondrial translation elongation |
| setSize | 90 |
| pANOVA | 4.25e-20 |
| s.dist | -0.559 |
| p.adjustANOVA | 3.02e-18 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MRPS25 | -10846 |
| MRPL32 | -10514 |
| MRPL45 | -10364 |
| MRPS21 | -10131 |
| MRPL10 | -10028 |
| MRPS14 | -9761 |
| MRPS18B | -9566 |
| MRPL34 | -9468 |
| MRPL55 | -9467 |
| MRPL2 | -9462 |
| DAP3 | -9377 |
| OXA1L | -9351 |
| MRPL37 | -9165 |
| MRPL39 | -9077 |
| MRPS7 | -9074 |
| MRPL20 | -9015 |
| MRPL57 | -8985 |
| MRPS2 | -8956 |
| MRPS27 | -8897 |
| MRPL14 | -8883 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MRPS25 | -10846 |
| MRPL32 | -10514 |
| MRPL45 | -10364 |
| MRPS21 | -10131 |
| MRPL10 | -10028 |
| MRPS14 | -9761 |
| MRPS18B | -9566 |
| MRPL34 | -9468 |
| MRPL55 | -9467 |
| MRPL2 | -9462 |
| DAP3 | -9377 |
| OXA1L | -9351 |
| MRPL37 | -9165 |
| MRPL39 | -9077 |
| MRPS7 | -9074 |
| MRPL20 | -9015 |
| MRPL57 | -8985 |
| MRPS2 | -8956 |
| MRPS27 | -8897 |
| MRPL14 | -8883 |
| MRPL15 | -8847 |
| MRPS30 | -8636 |
| MRPL27 | -8477 |
| MRPS9 | -8473 |
| TSFM | -8360 |
| MRPL40 | -8138 |
| MRPL48 | -8110 |
| MRPL43 | -8022 |
| MRPS6 | -7926 |
| MRPL46 | -7913 |
| PTCD3 | -7856 |
| MRPL11 | -7736 |
| MRPL16 | -7668 |
| ERAL1 | -7627 |
| MRPL9 | -7528 |
| RPS12 | -7527 |
| MRPL54 | -7471 |
| MRPL17 | -7450 |
| MRPS17 | -7182 |
| MRPL3 | -7157 |
| MRPS22 | -7099 |
| MRPL35 | -7050 |
| MRPL41 | -6997 |
| MRPL49 | -6748 |
| MRPS16 | -6740 |
| MRPS24 | -6737 |
| MRPL30 | -6732 |
| AURKAIP1 | -6388 |
| MRPL4 | -6379 |
| MRPL42 | -6349 |
| MRPS26 | -6323 |
| MRPS33 | -6273 |
| MRPS35 | -6101 |
| MRPS18A | -5955 |
| MRPL1 | -5947 |
| MRPS18C | -5886 |
| MRPL22 | -5742 |
| MRPS34 | -5581 |
| MRPL50 | -5553 |
| MRPL12 | -5535 |
| MRPL44 | -5512 |
| MRPL24 | -5442 |
| MRPS28 | -5327 |
| MT-RNR1 | -4979 |
| CHCHD1 | -4589 |
| MRPL13 | -4504 |
| MRPL58 | -4408 |
| MRPL19 | -4166 |
| MRPS10 | -4111 |
| MRPL21 | -3940 |
| MRPL38 | -3918 |
| MRPL33 | -3846 |
| TUFM | -3809 |
| MRPS15 | -3791 |
| MT-RNR2 | -3550 |
| MRPS23 | -3339 |
| MRPL47 | -3309 |
| MRPL51 | -2987 |
| MRPL53 | -2834 |
| MRPS5 | -2562 |
| GADD45GIP1 | -2308 |
| MRPS36 | -2167 |
| MRPL36 | -1870 |
| GFM1 | -1721 |
| MRPL23 | -981 |
| MRPL52 | -569 |
| MRPS31 | 370 |
| MRPL28 | 452 |
| MRPL18 | 2193 |
| MRPS11 | 3352 |
Synthesis of wybutosine at G37 of tRNA(Phe)
| set | Synthesis of wybutosine at G37 of tRNA(Phe) |
| setSize | 6 |
| pANOVA | 0.0183 |
| s.dist | -0.556 |
| p.adjustANOVA | 0.0817 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TYW1 | -8244 |
| TRMT5 | -6630 |
| TYW5 | -6498 |
| TRMT12 | -5891 |
| TYW3 | -5612 |
| LCMT2 | -4320 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TYW1 | -8244 |
| TRMT5 | -6630 |
| TYW5 | -6498 |
| TRMT12 | -5891 |
| TYW3 | -5612 |
| LCMT2 | -4320 |
GAB1 signalosome
| set | GAB1 signalosome |
| setSize | 14 |
| pANOVA | 0.000315 |
| s.dist | 0.556 |
| p.adjustANOVA | 0.00404 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TGFA | 10260 |
| PAG1 | 9781 |
| EREG | 9520 |
| AREG | 9309 |
| PTPN11 | 8724 |
| HBEGF | 8211 |
| PXN | 7077 |
| GRB2 | 6102 |
| PIK3CA | 5469 |
| PIK3R1 | 5072 |
| CSK | 4744 |
| EGF | 1257 |
| GAB1 | -877 |
| SRC | -6033 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TGFA | 10260 |
| PAG1 | 9781 |
| EREG | 9520 |
| AREG | 9309 |
| PTPN11 | 8724 |
| HBEGF | 8211 |
| PXN | 7077 |
| GRB2 | 6102 |
| PIK3CA | 5469 |
| PIK3R1 | 5072 |
| CSK | 4744 |
| EGF | 1257 |
| GAB1 | -877 |
| SRC | -6033 |
Here is the session info with all the versions of packages used.
sessionInfo()## R version 4.4.1 (2024-06-14)
## Platform: x86_64-pc-linux-gnu
## Running under: Ubuntu 22.04.5 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.10.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.10.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=en_US.UTF-8
## [9] LC_ADDRESS=en_US.UTF-8 LC_TELEPHONE=en_US.UTF-8
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=en_US.UTF-8
##
## time zone: Australia/Melbourne
## tzcode source: system (glibc)
##
## attached base packages:
## [1] stats4 stats graphics grDevices utils datasets methods
## [8] base
##
## other attached packages:
## [1] pkgload_1.4.0 GGally_2.2.1
## [3] beeswarm_0.4.0 gtools_3.9.5
## [5] tibble_3.2.1 echarts4r_0.4.5
## [7] xlsx_0.6.5 DT_0.33
## [9] eulerr_7.0.2 ggplot2_3.5.1
## [11] kableExtra_1.4.0 MASS_7.3-61
## [13] mitch_1.17.4 DESeq2_1.44.0
## [15] SummarizedExperiment_1.34.0 Biobase_2.64.0
## [17] MatrixGenerics_1.16.0 matrixStats_1.4.1
## [19] GenomicRanges_1.56.1 GenomeInfoDb_1.40.1
## [21] IRanges_2.38.1 S4Vectors_0.42.1
## [23] BiocGenerics_0.50.0 dplyr_1.1.4
## [25] WGCNA_1.73 fastcluster_1.2.6
## [27] dynamicTreeCut_1.63-1 reshape2_1.4.4
## [29] gplots_3.2.0
##
## loaded via a namespace (and not attached):
## [1] RColorBrewer_1.1-3 rstudioapi_0.17.1 jsonlite_1.8.9
## [4] magrittr_2.0.3 rmarkdown_2.28 zlibbioc_1.50.0
## [7] vctrs_0.6.5 memoise_2.0.1.9000 base64enc_0.1-3
## [10] htmltools_0.5.8.1 S4Arrays_1.4.1 SparseArray_1.4.8
## [13] Formula_1.2-5 sass_0.4.9 KernSmooth_2.23-24
## [16] bslib_0.8.0 htmlwidgets_1.6.4 plyr_1.8.9
## [19] impute_1.78.0 cachem_1.1.0 mime_0.12
## [22] lifecycle_1.0.4 iterators_1.0.14 pkgconfig_2.0.3
## [25] Matrix_1.7-0 R6_2.5.1 fastmap_1.2.0
## [28] GenomeInfoDbData_1.2.12 shiny_1.9.1 digest_0.6.37
## [31] colorspace_2.1-1 AnnotationDbi_1.66.0 Hmisc_5.1-3
## [34] RSQLite_2.3.7 fansi_1.0.6 httr_1.4.7
## [37] abind_1.4-8 compiler_4.4.1 bit64_4.5.2
## [40] withr_3.0.1 doParallel_1.0.17 htmlTable_2.4.3
## [43] backports_1.5.0 BiocParallel_1.38.0 DBI_1.2.3
## [46] ggstats_0.7.0 highr_0.11 DelayedArray_0.30.1
## [49] caTools_1.18.3 tools_4.4.1 foreign_0.8-87
## [52] httpuv_1.6.15 nnet_7.3-19 glue_1.8.0
## [55] promises_1.3.0 grid_4.4.1 checkmate_2.3.2
## [58] cluster_2.1.6 generics_0.1.3 gtable_0.3.5
## [61] preprocessCore_1.66.0 tidyr_1.3.1 data.table_1.16.0
## [64] xml2_1.3.6 utf8_1.2.4 XVector_0.44.0
## [67] foreach_1.5.2 pillar_1.9.0 stringr_1.5.1
## [70] later_1.3.2 rJava_1.0-11 splines_4.4.1
## [73] lattice_0.22-6 survival_3.7-0 bit_4.5.0
## [76] tidyselect_1.2.1 GO.db_3.19.1 locfit_1.5-9.10
## [79] Biostrings_2.72.1 knitr_1.48 gridExtra_2.3
## [82] svglite_2.1.3 xfun_0.48 stringi_1.8.4
## [85] UCSC.utils_1.0.0 yaml_2.3.10 xlsxjars_0.6.1
## [88] evaluate_1.0.1 codetools_0.2-20 cli_3.6.3
## [91] rpart_4.1.23 xtable_1.8-4 systemfonts_1.1.0
## [94] munsell_0.5.1 jquerylib_0.1.4 Rcpp_1.0.13
## [97] png_0.1-8 parallel_4.4.1 blob_1.2.4
## [100] bitops_1.0-9 viridisLite_0.4.2 scales_1.3.0
## [103] purrr_1.0.2 crayon_1.5.3 rlang_1.1.4
## [106] KEGGREST_1.44.1END of report